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ABSTRACT 
A series of 88 novel tetrahydroisoquinoline (TIQ) compounds have been synthesised for 
applications in asymmetric catalysis.  Several chiral TIQ ligands, possessing N,O and N,N 
donor atoms, have been prepared and evaluated for the catalytic asymmetric transfer 
hydrogenation (ATH) of pro-chiral ketones.  The highest selectivity obtained for the 
asymmetric transfer hydrogenation of acetophenone with the N,O donor atom ligands was 
>99 % ee at low temperatures in iso-propanol with [Ru(p-cymene)Cl2]2 as a pre-catalyst.  The 
observed enantioselectivity was supported by theoretical calculations using the Jaguar 
interphase program (Paper I).  An enantioselectivity of 70 % was obtained with the ligands 
possessing the N,N donor atoms with the observation that water played a significant role in 
the enantioselectivity of the ATH reaction of acetophenone (Paper II). 
An investigation into the usefulness of the TIQ scaffold with other donor atoms was also 
undertaken.  A series of novel P,N oxazoline ligands were synthesised and coordinated to 
Iridium BArF.  These complexes were screened as chiral catalysts for the high pressure 
asymmetric hydrogenation of unsymmetrical olefins.  The reactions proceeded readily at 
ambient temperature and provided selectivities of up to >91 % ee with excellent conversion 
rates (>99 %) for the benchmark reactions.  Based upon these favorable results, the ligands 
providing the best results were further screened on a variety of functionalized and un-
functionalised olefins (Paper III). 
The success of the TIQ backbone in ATH reactions prompted an investigation into its 
applications in carbon-carbon (C-C) bond forming reactions.  The Henry (nitroaldol) reaction 
is an important C-C bond forming reaction with the chiral oxazoline class of ligands being 
widely utilised.  A series of novel, chiral TIQ oxazoline ligands were synthesised and 
complexed to various metals (Cu, Sc, Co, Zn, Ni and Mn).  These complexes were screened 
as chiral catalysts in the asymmetric Henry reaction.  The highest enantioselectivity (>77 %) 
was obtained when Cu(OAc)2was employed as a pre-catalyst and iso-propanol as a solvent 
(Paper IV). 
The final chapter deals with carbon-sulphur bond formations facilitated by the conjugate 
addition of thioglycolate to various chalcones.  A series of novel, chiral TIQ N-oxide ligands 
were synthesised and complexed to lanthanum.  The complexes were screened for activity 
against the benchmark reaction and an enantioselectivity of 81 % was obtained. 
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1.1 HISTORY OF STEREOCHEMISTRY AND CHIRALITY 
Stereochemistry describes the orientation in space of atoms in a molecule.  Louis Pasteur 
could rightly be described as the first to discover chirality, a stereochemical property he 
observed in the salts of tartaric acid collected during wine production.
1
  He observed that 
some of the crystals rotated polarised light in one direction while other crystals rotated the 
light in the opposite direction.  This unique property, in which the two types of tartrate salt 
stereo isomers differed, is due to optical isomerism.  
The term chiral is derived from the greek name kheir meaning "hand" and was coined by 
Lord Kelvin in 1904.
2
  Chirality is a fundamental property of certain three-dimensional 
objects.  It is of prime significance, as biological macromolecules exist exclusively in one 
enantiomeric form.
2
  Enantiomers are defined as non-superimposable mirror images (Figure 
1) and they have identical physical and chemical properties except in two important respects:  
1. They rotate plane-polarized light in opposite directions, though in equal amounts.  
The isomer that rotates the plane to the left (counterclockwise) is called the levo 
isomer designated (–), while the one that rotates the plane to the right (clockwise) is 
called dextro isomer and is designated (+).
3
 
2. They react at different rates with other chiral compounds.  
 
 
   
 
 
Figure 1. Example of chiral objects
4
 
Following Kekule's recognition in 1858 that carbon has a valence of four, Vant' Hoff and Le 
Bel independently recognized that when four different groups are attached to a carbon atom, 
2 
arrayed at the corners of a tetrahedron, then the arrangements can be in two different forms.  
Cahn, Ingold and Prelog
5
 devised a system based on sequence rules of decreasing atomic 
number (and respective extent of substitution for atoms of the same atomic number) for 
projection formulas.  This method allows for the assignment of a nomenclature based on the 
absolute configuration assignments of R (for rectus, Latin for right) and S (for sinister, Latin 
for left). 
1.2 IMPORTANCE OF CHIRALITY IN DRUGS 
Understanding the phenomenon of chirality is extremely significant in the preparation of 
therapeutic drugs.  For example, one enantiomer of penicillamine is a potent anti-arthritic 
agent
6
 whereas the other enantiomer is highly toxic.
7
  Perhaps the most amazing example of 
the difference in activity between enantiomers is that of Thalidomide.  This drug was seen as 
a panacea for the treatment of morning sickness in pregnant women.  However, the drug was 
marketed as a racemic mixture with only one enantiomer, the (R)- having the desired 
therapeutic effect.  The (S)- enantiomer unfortunately, has been associated with well-






























(S)-Thalidomide (R )-Thalidomide  
Figure 2. The mirror image relationship between chiral molecules 
1.3 ROUTES TO ENATIOMERICALLY PURE COMPOUNDS 
It is important to have sources of enantiomerically pure compounds, especially for the use of 
pharmaceutical drug production.  In general, there are three routes for obtaining enantiopure 
compounds.  They can be obtained from a chiral pool, from prochiral substrates or from a 




Figure 3. Schematic diagram of methods to obtain enantiomerically pure derivatives 
1.3.1 CHIRAL POOL STRATEGY 
The utilization of naturally occurring chiral starting materials, also called the chiral pool 
approach,
9
 plays an important role in the synthesis of enantiomerically enriched compounds.  
Nature provides good chiral species in several varieties of compound classes of which amino 











(carboxylic acid)  
Figure 4. Several examples of naturally occurring chiral compounds. 
Many chiral compounds have been synthesised using the chiral pool strategy.  Synthesis of 
oseltamivir phosphate, Tamiflu
®
, is an example of the chiral pool approach.  This drug is a 
potent antiviral agent and is synthesized from the naturally occurring chiral compound (-)-
shikimic acid (Scheme 1).
10
  The main disadvantage of this strategy is that it suffers from a 
limited number of starting materials and often the availability of only one enantiomer. 
Enantiopure compounds 
Chiral pool Prochiral 
substrates 
Racemates 













(-)-Shikimic acid Tamiflu®  
Scheme 1. Synthesis of Tamiflu
®
 starting from (-)-shikimic acid 
Another example for this synthetic approach would be the preparation of aspartame, an 
artificial sweetener which is a simple dipeptide.  From retro-synthetic methodology, it was 
observed that the two natural amino acids (S)-phenyl alanine methyl ester and (S)-aspartic 
acid can be condensed to form the desired aspartame.
11















(S)-phenyl alanine methyl ester (S)-aspartic acid
 
Scheme 2. Retro-synthetic approach for the aspartame 
1.3.2 RESOLUTION OF RACEMATES 
The separation of a racemate into its two optically pure compounds is called resolution.
12
  It 
is a classic approach to obtain enantiopure compounds from racemates which were 
temporarily converted into diastereomers.  The reagents used to form the diastereomers are 
often from a natural source, eg. tartaric acid, brucine, quinidine and lactic acid.  The main 
drawback of this strategy is efficiency and low yields of the enantiomerically pure 
compounds (the maximum theoretical yield is 50 %).  On further development of this 
technique, researchers developed kinetic resolution and dynamic kinetic resolution. 
1. In kinetic resolution two enantiomers show different reaction rates in a chemical 
reaction thereby creating an excess of the less reactive enantiomer.  The excess goes 
through a maximum and disappears on full completion of the reaction. 
2. Dynamic kinetic resolution (DKR) is an extension of kinetic resolution.  By using this 
technique, the less reactive isomer is racemized in situ and then transformed again 
5 
into the desired enantiomer via resolution.
13
  Due to the increase of entropy, it is a 
completely thermodynamically favoured process.
14
  From the appropriate 
combination of metal catalysts, enzymes, acyl donors and reaction conditions, a broad 
range of secondary alcohols as chiral substrates have been implemented for DKR 
process.  Figure 5 shows the different varieties of secondary carbinols which were 
accessed through this method.  From the approach of dynamic kinetic resolution, a 






































Figure 5. Few varieties of secondary carbinols accessed through dynamic kinetic resolution. 
1.3.3 ASYMMETRIC SYNTHESIS 
The development of new methodologies for the preparation of stereoisomers is amongst the 
most important topics in modern organic synthesis.
15
  There are several methods to obtain 
enantiomerically pure isomers like enzymatic resolution, chromatographic separation and 
resolution of racemates.  Due to the high atom economy of these methods,
16
 asymmetric 
catalysis is the most desirable method for producing enantiomerically pure compounds.  This 
method allows large quantities of the chiral materials to be produced using a small amount of 
a chiral catalyst.
17
  An interest in our research group is the development of novel metal 
6 
complexes as catalysts for stereoselective transformations such as: asymmetric transfer 
hydrogenation of unsymmetrical ketones, high pressure hydrogenation of functionalized, 
non-functionalized olefins and enantioselective C–C bond formation reactions. 
1.3.4 ASYMMETRIC CATALYSIS BY CHIRAL METAL COMPLEXES  
A catalyst is defined as a species that increases the rate of a chemical reaction without itself 
being consumed or changed in the overall reaction.  The first synthetically useful asymmetric 
catalysis was reported in the late 1950s.  During the last few decades, transition-metal-
catalyzed reactions have been extremely useful in organic synthesis.
18-19
  Izumi et al. first 
applied and reported the asymmetric hydrogenation of methyl acetoacetate into methyl β-




The first industrial application employing asymmetric catalysis was Monsanto’s production 
of L-DOPA, an important anti-Parkinson’s drug.
21
  The process involved the asymmetric 
























Scheme 3. Monsanto’s L-DOPA process 
7 
Later, Ryoji Noyori introduced the binapthalene based ligands that coordinated to ruthenium 







Figure 6. Noyori’s BINAP ligand 
1.3.5 IMPORTANCE OF ASYMMETRIC CATALYSIS 
In recent years, there has been considerable effort directed towards the use of chiral metal 
complexes as catalysts for a wide variety of asymmetric transformations.
25-27
  For example, it 
is often possible to transform a pro-chiral substrate into an enantiomerically pure chiral 
product.
28
  These types of conversions are extremely important for the synthesis of drugs and 
natural products, which usually contain at least one chiral center.
29-31
  Currently, one of the 
main focuses of organic synthetic research groups is the development of new chiral metal 
catalysts for stereoselective synthesis.  Some of the most important industrially applied 
asymmetric catalysis include C-C bond formation and reduction reactions.
32-34
 
Enantioselective C-C bond formation reactions are one of the greatest challenges in modern 
synthetic organic chemistry.
35
  Considering the recent survey on the use of C-C bond 
formations in pharmaceutical industry,
36
 Figure 7 shows that the palladium catalysed 























From the recent approaches in the applications of C-C bond reactions, researchers have 





and other palladium catalysed couplings
41-42
 with good turnover rates.  Scheme 4 shows the 















41-66 % yield, 72-86 % ee
Ar = Fu, indolyl, o-, m-, p -(CHO)Ph, etc
 
Scheme 4. Example for Suzuki coupling
37
 
Beginning with Wilkinson’s catalyst for the synthesis of L-DOPA, researchers considered the 
importance of asymmetric hydrogenation reactions by utilizing transition metal complexes.
21
  
Asymmetric reduction reactions involved the hydrogenation of C=C, C=O and C=N to CH-
CH, CH-OH and CH-NH respectively.
43-44
  In many instances, the use of transition metal 
catalysts was found to be the optimum choice for this transformation.
45-46
  A large array of 




  In this respect, asymmetric hydrogenations have progressed significantly over 
the past few decades.  It is now a conventional method by which the manufacture of a wide 
range of chiral compounds in the agrochemical, pharmaceutical, fragrance and fine chemical 
industries is achieved.  Enantiomerically enriched amines, amino acids, esters, alcohols and 
acids are commercially synthesized utilizing chiral catalysts.
49
  Ruthenium, rhodium and 
iridium based metal catalysts have played an important role in the synthesis of bulk scale 





















Scheme 5. Approach for the asymmetric hydrogenation of candoxatril.
50
 
1.4 HISTORY OF TETRAHYDROISOQUINOLINE (TIQ) BACKBONE AND 
APPLICATIONS IN ASYMMETRIC CATALYSIS 
The 1,2,3,4-tetrahydroisoquinoline (TIQ) moiety is commonly found in biologically 
important molecules of either natural or synthetic origin.
51-58
  Several well established 







 reactions have been used to obtain the backbone of TIQ compounds.  










Scheme 6. Pictet-Spengler reaction of phenylalanine 
10 
To date, very little research has been applied to the TIQ backbone as a chiral ligand in 
asymmetric catalysis.  TIQ derivatives as catalytic ligands have yielded limited success with 
poor to moderate enantioselectivities in allylic alkylation
62
 and borane mediated 
hydrogenation reactions.
63-64
  In the alkylation reactions, TIQ oxazoline ligands were 
synthesised and coordinated with palladium and iridium metals and tested for a variety of C-
C bond formation reactions (Figure 8).  Our focus is the design and synthesis of novel TIQ 











































Figure 8. Previously reported TIQ oxazoline ligands and their applications. 
From the previous literature reports various five membered, bicyclic and heterocyclic 
backbones were introduced as ligands for the applications of asymmetric catalysis (Figure 
9).
65















R1 R2 R2 R1  
Figure 9. Some of the examples of chiral ligands with difference backbones  
11 
Andersson et al. were the first to introduce the bicyclic amino alcohol system in asymmetric 
catalysis.  The bicyclic backbone was modified and introduced as amino alcohol ligands for 
Asymmetric Transfer Hydrogenation (ATH) reactions.
66
  The results obtained from this 
system were excellent and further confirmed by computational studies.  Keeping this concept 
in mind we decided to design a six-membered backbone (TIQ backbone), for designing 












Figure 10. Comparison of Bicyclic ligands with TIQ ligands 
Furthermore, they have developed chiral oxazoline ligands for a wide range of substrates.  In 
particular, the bicyclic oxazolines are among the most successful and have produced 







Since asymmetric hydrogenation of unfunctionalized olefins remains a challenge due to 
substrate dependence, we have decided to synthesise TIQ oxazoline ligands for applications 
















Figure 11. Design of TIQ oxazoline ligands from bicyclic oxazoline ligands 
In recent years, the contribution of proline derived ligands to the field of asymmetric catalysis 
was outstanding.  The N-oxide type ligands were introduced by Feng et al for the 
enantioselective Strecker reaction,
70
 C-C bond formation reaction,
71
 and conjugate addition 
to chalcones.
72
  The success of these ligands prompted us to synthesise TIQ N-oxide ligands 
for various applications.  Intial study focused on the conjugate addition of thioglycolate to 






















Figure 12. Examples for Proline N-oxide and TIQ N-oxide ligands 
1.5 RESEARCH PERFORMED IN THIS THESIS 
This thesis contains five papers describing the application catalysts developed from the TIQ 
backbone in asymmetric reductions, C-C bond formation and asymmetric conjugate addition 
of sulphur to chalcones.  The asymmetric reactions involve the reduction of pro-chiral 
ketones into chiral alcohols and olefins into chiral alkanes.  In papers I and II novel 
tetrahydroisoquinoline amino alcohols and TIQ diamine ligands were reported.  These 
ligands have been evaluated in the asymmetric transfer hydrogenation of acetophenone by 
coordination with ruthenium-, rhodium- and iridium metals.  As part of the work, the 
minimum energy transition states of TIQ amino alcohol coordinating with ruthenium and 
acetophenone were calculated (Paper I).  The results obtained thus far prompted a change in 
donor atoms and a series of TIQ P,N oxazoline ligands were synthesised.  These ligands were 
screened in the asymmetric hydrogenation of olefins by complexation with Iridium 
tetrakis[(3,5-trifluoromethyl)phenyl]borate (Ir-BArF) (Paper III).  In paper IV novel C
1
 
substituted TIQ oxazoline ligands were designed and synthesised for the copper catalysed 
Henry reaction.  Paper V describes the design and evaluation of novel TIQ N-oxide ligands 
for carbon-sulfur bond formation. 
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ABSTRACT 
Tetrahydroisoquinoline (TIQ) derivatives exhibit good biological activity.  However, 
utilization of TIQ compounds in asymmetric catalysis is limited.  This paper presents a series 
of TIQ derivatives in asymmetric transfer hydrogenation (ATH) reactions.  Chiral TIQ amino 
alcohol ligands were synthesized and screened for the ATH reaction of aromatic ketones.  
The effect of a cis- and trans-phenyl substitution at the C
1
 position on the ligand backbone 
was investigated both experimentally and computationally.  The results showed that the trans 
orientation on the TIQ scaffold yields higher turnover rates with a selectivity of up to 94 % ee 
obtained at room temperature with an Ru complex.  The cis isomer results in a high turnover 
rate with no selectivity.  The trans isomer gave 99 % ee at lower temperatures.  Furthermore, 
it was observed that substitution at the C
3
-α position results in a drop of the enantioselectivity 
and the reactivity of the catalyst. 




Chiral amino alcohol containing ligands (Figure 1) are among the more successful classes of 
compounds in asymmetric transfer hydrogenation reactions (ATH).
1-3
  In these reactions 
transfer hydrogenation has been applied to ketones and imines.
4-5
  In particular it has been 
very successful for the reduction of a range of unsymmetrical ketones.  Nevertheless, there is 
still significant interest in the development of new chiral scaffolds as potential ligands in 






1 2 3  
Figure 1. Examples of chiral amino alcohol ligands reported with high selectivity in ATH 
reactions 
Since the isolation of naphthyridinomycin in 1974, the biological activity of 
tetrahydroisoquinoline (TIQ) carboxylic acid derivatives have been widely investigated.
6-8
  
Our interest in the development of novel chiral backbones prompted us to investigate the 
application of the TIQ scaffold as a source of chirality in ATH reactions.  Previous reports on 
the use of TIQ derivatives as catalytic ligands have indicated limited success, with poor to 





  Recently, a related study of different TIQ ligands on 
the addition of diethylzinc to benzaldehyde was reported with promising results.
12
 
Given the reports in the literature thus far, we aimed to couple the catalytic success of the 
chiral amino alcohol containing class of ligands, with the innovation of the TIQ scaffold 





substitutions.  The ligands were coordinated to (arene) ruthenium, -rhodium, and -iridium 
precursors, and their efficiency was investigated as ATH catalysts for the reduction of 
prochiral ketones.
13-15
  To the best of our knowledge, this is the first successful application of 
a TIQ ligand to effect high enantioselective transfer hydrogenations yielding high turnover 
rates at reasonable catalyst loading. 
18 
RESULTS AND DISCUSSION 
Mechanistic studies on non-TIQ-related ligands
1,3
 developed by Noyori have demonstrated 
that typically two stereogenic centers, a cyclic secondary amine and a secondary alcohol are 
required for optimal chiral activity.
16-18
  For maximum activity these two metal coordination 
sites are typically within three bonds of each other.  In this paper, we introduce the 
tetrahydroisoquinoline (TIQ) ligands, which have initially a single chiral center, a secondary 
amine in a six-membered ring with a primary alcohol as a side chain.  Our first choice was 
ligand 4, which represents a simple TIQ backbone (Figure 2) from the literature.
19
  The ATH 
reduction of acetophenone proved to be inefficient with this ligand after coordination with a 











Figure 2. Unsubstituted TIQ ligand for ATH reactions 
From our lead molecule we thought conversion of the primary alcohol 4 to a secondary 
alcohol could potentially improve the ligand activity.  However, due to the difficulty in the 
synthesis as will be demonstrated later, we designed and synthesized the amino tertiary 
alcohol 8, introducing phenyl moieties as bulky groups at the C
3
 position.  Ligand 8 was 
synthesized from the TIQ amino ester 5,
19
 and the benzyl protection of the secondary amine 
was carried out with benzyl bromide and K2CO3 in acetonitrile.  Subsequently, a Grignard 
reaction on 6 afforded 7 in less than 20 % yields.  Ultimately, deprotection of 7 resulted in the 























Scheme 1. Reagents for the synthesis of ligand 8: (i) Benzyl bromide, K2CO3, CH3CN, 
reflux, 3hrs; (ii) PhMgBr, dry THF, reflux, 6 hrs; (iii) 10 wt.- % Pd/C, H2 (1 atm), MeOH. 
Disappointingly, phenyl substitution at the C
3
-α position did not improve the catalytic 
activity, in fact, no reactivity was observed with this ligand (Table 1, Entry 2).  To further 
investigate the factors affecting the efficiency of our TIQ backbone, we returned to the 
primary alcohol system and substituted a phenyl group creating a stereogenic center at the C
1
 
position while increasing the pKa of the secondary nitrogen atom and the steric bulk of the 
ligand.  All attempts to achieve substitution at the C
1
 position through a Pictet–Spengler 
reaction between phenylalanine and benzaldehyde were met with limited success.  It was 
essential to employ the activated aromatic group of L-DOPA (9) to facilitate product 
formation. 
Aubry et al reported on the effect of solvent on the stereocontrol of Pictet–Spengler 
reactions.
20
  For ligand 14, L-DOPA (9) was treated with benzaldehyde in the presence of 
K2CO3 and aqueous EtOH to afford the trans-substituted TIQ compound 10 in 20 % yield 
(Scheme 2).
20
  The cis-substituted TIQ compound 11 was obtained from benzaldehyde and 






















Scheme 2. Reagents for the synthesis of TIQ acids 10 and 11: (i) PhCHO, K2CO3, 
EtOH/H2O, 0 
o
C − r.t.; (ii) PhCHO, K2CO3, H2O, 0 
o
C − r.t. 
To obtain compound 12, C
1
-substituted N-Cbz protected methyl ester, an in situ reaction was 
performed on 10 with benzyl chloroformate (Cbz) and monitored with LCMS.  After 
completion of the reaction, the solvent was evaporated under vacuum and the crude product 
was used directly and methylated at the phenolic and carboxylic acid positions.  This was 
achieved by refluxing the compound in acetone in the presence of Me2SO4 and KHCO3.
21
  
The crude product was purified by column chromatography to obtain the desired compound 
12 in 80 % yield.  Deprotection of the Cbz group gave 13, which was reduced to the amino 
alcohol 14 (Scheme 3).  It was observed that partial racemization had occurred during the 
reduction of the ester at elevated temperatures (diastereomers were observed by HPLC and 
TLC).  To afford maximum optical purity, the reduction of 13 was subsequently repeated at 0 




























Scheme 3. Reagents for the synthesis of ligand 14: (i) KHCO3, Cbz-Cl, dioxane/water in situ 
solvent evaporation KHCO3, Me2SO4, acetone, reflux, overnight; (ii) 10 wt.- % Pd/C, H2 (1 
atm), MeOH, r.t.; (iii) LiAlH4, dry THF, 0 
o
C, 2 hrs. 
A similar synthetic route was applied to produce the cis TIQ amino alcohol 17 starting from 



























Scheme 4. Reagents for the synthesis of ligand 17: (i) KHCO3, Cbz-Cl, dioxane/water in situ 
solvent evaporation KHCO3, Me2SO4, acetone, reflux, overnight; (ii) 10 wt.- % Pd/C, H2 (1 
atm), MeOH, r.t.; (iii) LiAlH4, dry THF, 0 
o
C, 2 hrs. 
22 
Interesting results were observed for the ATH reaction of acetophenone utilizing ligands 14 
and 17.  Ligand 14 showed good catalytic activity with 94 % conversion and 94 % ee (R) in 
45 min.  In the case of 17, a racemic mixture was observed with an 80 % conversion (Table 1, 
Entries 3 and 4). 
Table 1. Asymmetric transfer hydrogenation of acetophenone using different ligands 





1 mol % (M/S), L*  





1 4 24.0 28 35 (S) 





3 14 0.75 94 94 (R) 
4 17 0.75 80 Racemic 
a
Determined by chiral GC analysis.  
b
Absolute configuration determined by comparison with reported retention times values 
reported are the average of three runs.  
c
No reaction observed. 
The reason for this difference in catalytic activity is not readily understood.  With the 
encouraging results from ligand 14, however, we decided to modify the ligand by introducing 
phenyl groups at the C
3
-α position to re-investigate the effect of steric bulk.  To obtain this 
ligand, intermediate 13 could be converted into the N-benzyl methyl ester 18.  In order to 
introduce the phenyl groups, the secondary amine was first benzyl-protected, after which a 
Grignard reaction with phenylmagnesium bromide afforded 19.  Deprotection of 19 (Scheme 
5) resulted in the formation of ligand 20.  It was comparable to ligand 8 (Table 2, Entry 1) 
and thus confirmed that bulky groups present on the C
3

























Scheme 5. Reagents for the synthesis of ligand 20: (i) Benzyl Bromide, K2CO3, CH3CN, 
reflux, 3 hrs; (ii) PhMgBr, dry THF, reflux, 6 hrs; (iii) 10 wt.- % Pd/C H2 (1 atm), MeOH. 
From the results of ligand 14 and 20, it was decided to investigate the effect of less bulky 
substitution at the C
3
-α position.  There were two reasons for this: (i) it is known from the 
literature that amino alcohols with a secondary alcohol exhibit excellent reactivity and 
selectivity;
22-23
 (ii) this allows us to introduce another chiral center into our catalytic ligand 
design.  The reduction of ester 18 with LiAlH4 followed by a Swern oxidation afforded the 
aldehyde 22 in 82 % yield.  Subsequently, a Grignard reaction with methylmagnesium iodide 
under reflux conditions afforded two diastereomeric alcohols in a 1:1 mixture.  To improve 
the selectivity, the Grignard reaction was repeated at 0 °C giving the diastereomers in a 9:1 
ratio and in good yields.  These diastereomers were named major 23 and minor 23.  
Separation of the isomers followed by deprotection afforded ligands major 24 and minor 24 





























Scheme 6. Reagents for the synthesis of major 24 and minor 24 ligands: (i) LiAlH4, dry THF, 
r.t.; (ii) DMSO, oxalyl chloride, TEA, CH2Cl2, −78 °C; (iii) CH3MgI, dry THF, 0 °C; (iv) 10 
wt.- % Pd/C, H2 (1 atm), MeOH, r.t. (All experimental details are available in supporting 
information). 
Ligands major 24 and minor 24 were tested for transfer hydrogenation activity under 
identical conditions.  Ligand major 24 gave a 94 % ee (R), and minor 24 gave 70 % ee (S), 
















1 mol % (M/S), L*  










2 Major 24 0.5 33 94 (R) 
3 Minor 24 0.5 30 70 (S) 
a
Determined by chiral GC analysis.   
b
Absolute configuration determined by comparison with reported retention times.  Values 
reported are the average of three runs.   
c
No reaction observed. 
To summarize, a total of seven ligands were prepared and evaluated in the ruthenium-
catalyzed ATH of acetophenone; the results are found in Tables 1 and 2.  Unsubstituted 
amino alcohol 4 reduced acetophenone with low conversion rates and enantiomeric excess 
(Table 1, Entry 1).  Phenyl substitution at the C
3
-α position of ligands 8 (Table 1, Entry 2) 
and 20 (Table 2, Entry 1) deactivated the catalyst.  Similar phenyl substitution at the C
1
 
position gave cis and trans configurations, which enhanced the turnover rates in ATH 
reactions.  In this system, ligand 14 (trans) provided better selectivity than ligand 17 (cis) 
(Table 2, Entry 3, 4).  The TIQ amino alcohols with smaller substituents at the C
3
-α position 
(ligands major 24 and minor 24) showed a decrease in activity compared to ligand 14. 
Having identified an efficient and selective ligand for catalytic purposes, the system was 
varied with the introduction of different metal complexes.  Half-sandwich π complexes such 
as ruthenium, rhodium or iridium complexes are the most important metal sources associated 
with amino alcohol ligands in ATH reactions.
1,3,24
  In this study, we measured the reactivity 
of 14 with various organometallic complexes i.e. [Ru(p-cymene)Cl2]2, [RhCl2Cp*]2 and 
[IrCl2Cp*]2. 
All of the new complexes, catalytic conversions and selectivities are shown in Table 3.  Also 
the reactions at lower temperatures provided improved selectivities.  We repeated the 
hydrogenation of acetophenone at 0 °C using [Ru(p-cymene)Cl2]2, and an excellent 
26 
selectivity was observed with upto 99 % ee but with a low conversion of 35 %.  [RhCl2Cp*]2 
gave a higher reactivity (94 % conversion) than [Ru(p-cymene)Cl2]2, but with a diminished 
enantioselectivity of 90 % ee (Table 3, Entry 4).  The reaction was repeated at different 
temperatures affording respectable selectivities with moderate conversions (Table 3, Entries 
5, 6).  Due to the higher rates when rhodium was used, we attempted the same reaction with a 
low catalyst loading of 0.5 mol- % (metal/substrate).  The reaction rate was reduced 
providing good selectivity and conversion rates (Table 3, Entry 7).  Replacing rhodium with 
iridium gave poorer selectivity and conversion results. 





1 mol % (M/S), 14  





1 [Ru(p-cymene)Cl2]2 RT 0.75 94 94 (R) 
2 [Ru(p-cymene)Cl2]2 0 °C 1.0 35 99 (R) 
3
[c]
 [Ru(p-cymene)Cl2]2 RT 1.25 85 94 (R) 
4 [RhCl2Cp*]2 RT 0.25 94 90 (R) 
5 [RhCl2Cp*]2 0 °C 0.5 86 94 (R) 
6 [RhCl2Cp*]2 −15 °C 0.5 42 99 (R) 
7
[c]
 [RhCl2Cp*]2 RT 0.5 94 91 (R) 
8 [IrCl2Cp*]2 RT 0.5 35 75 (R) 
a
Determined by chiral GC analysis.   
b
Absolute configuration determined by comparison with reported optical rotation.  Values 
reported are the average of three runs.   
c
Reaction was performed using 0.5 mol- % of metal/substrate. 
Having identified the most efficient metal complex in our system we then undertook studies 
on different substrates.  The results are summarized in Table 4.  In general, when compared 
to the reduction of acetophenone, all of the other substrates tested led to decreased 
27 
conversions.  The substrates can be grouped based on their electronic and steric properties.  
Electron-donating (4-methylacetophenone) or electron-withdrawing (4-nitroacetophenone) 
groups decreased the rate of conversion.  Replacing the phenyl ring with a pyridyl species 
completely arrests any reactivity.  This could be due to transient coordination of the sp
2
 
nitrogen atom to the metal center thereby disrupting the active transition state.  An increase in 




















Table 4. ATH of various aryl-alkyl ketones with [Ru(p-cymene)Cl2]2 and 14 as chiral ligand 
at ambient temperature. 














































Determined by chiral GC analysis.   
b
Absolute configuration determined by comparison with reported optical rotation.  Values 
reported are the average of two runs.   
c
No reaction observed. 
The observed enantioselectivity could be explained by the mechanism proposed for Ru-
catalyzed transfer hydrogenations using amino alcohol ligands.
16,25
  According to this 
mechanism, a ruthenium hydride and a proton from the ligand are simultaneously transferred 
from the catalyst to the prochiral carbonyl group.  The structures of the two possible 
29 
diastereomeric transition states were calculated using the Jaguar program.
26
  The transition-
state structures were located using the quadratic synchronous transit (QST) method and the 
B3LYP functional together with the LACVP ECP basis set.  Normal mode analysis revealed 
one imaginary frequency for each structure (Figure 3).  LACVP in Jaguar defines a 
combination of the LANL2DZ basis set for ruthenium
27
 and the 6-31G basis set for other 
atoms.  LACVP implies the use of an effective core potential for 28 core electrons of 
ruthenium and a (5s,6p,4d) primitive basis contracted to [3s,3p,2d].  Final energies were 
retrieved from single-point calculations at B3LYP/LACV3p+**.   
LACV3p+** differs from LACVP by using the 6-311+G** basis set in place of 6-31G. 
 
3.2 Kcal/mol     0.0 Kcal/mol  
Figure 2. The calculated (S) (left) and (R) (right) transition states for the reduction of 
acetophenone using ligand 14. The (S)-transition state showing a close-contact between the 
phenyl of the substrate and the arene ligand, making it less favorable. The Cartesian 
coordinates of the optimized structures are available as supplementary material. 
The energy of the transition state leading to the (S)-alcohol product is significantly higher in 
energy than that of the (R)-alcohol product.  This theoretical result supports the observed 
experimental result for ligand 14 reported in Tables 1, 2, 3, and 4. 
CONCLUSIONS 
We have synthesized and evaluated seven ligands of a new class of N,O TIQ compounds.  
These ligands were coordinated with ruthenium, and they were evaluated in the asymmetric 
transfer hydrogenation of acetophenone.  C
1
-substituted TIQ amino primary alcohol 14 gave 
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rise to a catalyst that induced good enantioselectivity, upto 94 % ee.  The reaction was 
repeated under various conditions, affording 99 % ee at lower temperature as the best result.  
The rhodium complex with amino alcohol ligand 14 showed the fastest rate of all complexes 
evaluated in this study, 94 % conversion in 0.5 h using a 0.5 mol- % ratio of metal/substrate 
with a lower selectivity of 91 % ee.  Considering the good selectivity at ambient temperature, 
we screened different alkyl aryl ketone substrates, rendering moderate to reasonable results.  
Acetophenone as substrate gave the best results. 
EXPERIMENTAL SECTION 
Reagents and solvents were purchased from Aldrich, Merck and Fluka.  All NMR spectra 
were recorded on Bruker AVANCE III 400 MHz or 600 MHz instruments.  Chemical shifts 
are expressed in ppm relative to TMS, and coupling constants are reported in Hz.  NMR 
Spectra were obtained at room temperature, except if stated different.  Thin layer 
chromatography (TLC) was performed using Merck Kieselgel 60 F254.  Crude compounds 
were purified by column chromatography using Silica gel (60–200 mesh except if stated 
different).  All solvents were dried using standard procedures.  All IR spectra were recorded 
on a Perkin Elmer spectrum 100 instrument with a universal ATR attachment.  Optical 
rotations were recorded on a Perkin Elmer Polarimeter (Model 341).  All melting points are 
uncorrected.  All testing reactions were carried out under dry UHP Argon gas.  The results of 
all testing reactions that were analyzed using GC analysis were obtained on an Agilent 
capillary gas chromatograph with a CP-Chirasil-β-Dex column (25 m with 0.25 mm inner 
diameter), nitrogen as carrier gas, and a flame ionization detector.  LC traces were recorded 
on an Agilent 1100 HPLC with reverse phase using 0.1 % formic acid in acetonitrile and 
Millipore water.  High resolution mass spectrometric data was obtained using a Bruker 
microTOF-Q II instrument operating at ambient temperatures, using a sample concentration 
of approximately 1 ppm. 
General procedure for transfer hydrogenation of aromatic ketones 
To an oven-dried Schlenk tube was added [Ru(p-cymene)Cl2]2 (3.0 mg, 4.8 µmol), ligand (4 
equiv.) and the system was evacuated for 10 minutes.  Thereafter, freshly distilled isopropyl 
alcohol (6 mL) was added under a dry argon atmosphere.  The mixture was stirred for 15 
minutes and freshly prepared 0.1 M t-BuOK solution was added to the complex, followed by 
the substrate.  An aliquot of the reaction mixture was tested at different intervals by 
quenching with 5 % acetic acid in isopropyl alcohol and passing through a pad of silica-gel 
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and monitoring by GC with a chiral β-dex column.  The percentage ee values were calculated 
from the integration values of the GC peaks for each enantiomer.  The experiment was 
repeated two or three times and the average values are reported in the tables. 
General procedure for compounds 12 and 15 
To a solution of C
1
 substituted TIQ carboxylic acid (1.0 g, 3.5 mmol) in dioxane (20 mL) and 
water (10 mL) at 0 °C a solution of potassium hydrogen carbonate (2.1 g, 21.1 mmol) in 
water (10 mL) was added dropwise over 15 minutes followed by addition of Cbz-Cl (0.65 g, 
3.8 mmol).  The solution was stirred for 1.5 hours at 0 °C and then at ambient temperature for 
a further 1.5 hours.  The reaction was monitored with LC-MS (by neutralizing the reaction 
mixture with 10 % HCl and extracting with ethyl acetate).  The solvent was evaporated under 
reduced pressure and the residue dried under high vacuum.  The crude residue obtained was 
dissolved in acetone (40 mL) and potassium hydrogen carbonate (7.0 g, 70.1 mmol) was 
added followed by dimethyl sulfate (4.4 g, 35.2 mmol) and stirred for 16 hours (overnight) at 
reflux.  Completion of the reaction was monitored with TLC using hexane/ethyl acetate 
(60/40, Rf 0.6).  The reaction solvent was evaporated under reduced pressure, and ethyl 
acetate (60 mL) was added and the resulting mixture was washed with 20 mL (2 × 10) of 
water followed by 10 mL of brine.  The organic layer was separated and dried over 
anhydrous MgSO4 and the solvent was evaporated under reduced pressure to afford crude 
Cbz-ester, which was purified by column chromatography using 0−40 % ethyl acetate in 
hexane as the eluent to yield approximately 1.3 g (80 % yield) of pure compounds 12 and 15. 
General deprotection procedure for preparation of amino esters 13 and 16 
A solution of the Cbz protected TIQ ester (1.0 g, 2.1 mmol) in THF (20 mL) was added to a 
suspension of activated 10 wt.- % Pd/C (500 mg) in dry MeOH (20 mL).  The mixture was 
supplied with H2 under atmospheric pressure and stirred at room temperature for 1 hour.  The 
reaction was monitored with TLC using hexane/ethyl acetate (40/50, Rf 0.4).  The Pd/C was 
filtered off through a celite pad and washed with methanol (20 mL).  The filtrate was 
evaporated under reduced pressure affording the crude amino ester, which was purified by 
column chromatography using 0−50 % ethyl acetate in hexane as the eluent to yield 
approximately 0.65 g (95 % yield) of the pure compounds 12 and 16. 
General procedure for 14 and 17 
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A solution of amino ester (0.5 g, 1.5 mmol) in dry THF (20 mL) was added dropwise to a 
suspension of LiAlH4 (0.18, 4.5 mmol) in dry THF (20 mL) under N2 atmosphere at 0 °C.  
The mixture was stirred at 0 °C for 2 hours, and the reaction was monitored with TLC using 
hexane/ethyl acetate (50/50, Rf 0.5).  Excess lithium aluminium hydride was quenched with 
saturated sodium sulphate solution at 0 °C.  The reaction mixture was filtered and the solid 
was washed with THF (20 mL).  The organic solution was evaporated to dryness, ethyl 
acetate (20 mL) was added to the residue and the resulting solution was washed with water (2 
× 5 mL), the organic layer was separated and dried over anhydrous MgSO4 to afford the 
crude amino alcohol.  This was purified by gradient column chromatography; Solvent A: 
10:90 saturated ammonia in DCM:DCM and solvent B: 2:98 MeOH:DCM to yield 
approximately 0.33 g (70 % yield) of pure amino alcohols 14 and 17. 
(S)-Diphenyl(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol (8) 





D − 130 (c 0.26 in CHCl3); HRESIMS m/z 316.1774 [M + 1H]
1+
 (calc. for C22H22NO, 
316.1701). 
Spectroscopic data of novel compounds 
(1R,3S)-2-Benzyl 3-methyl 6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-2,3(1H)-
dicarboxylate (12) 
Rf 0.6 (hexane/EtOAc 6:4); White solid: m.p. 127−129 °C (hexane−ethyl acetate); [α]
20
D 
=+9.54 (c 0.26 in CHCl3); 
1
H NMR (600 MHz, DMSO-d6, 100 °C): δ 7.36−7.15 (m, 9H), 
7.09 (s, 1H), 6.76 (s, 1H), 5.16−5.05 (m, 3H), 3.78 (s, 3H), 3.73 (s, 3H), 3.48 (s, 3H), 3.21 
(dd, J = 15.69, 5.97 Hz, 1H), 3.13−3.04 (m, 2H); 13C NMR (150 MHz, DMSO, 100 °C): δ 
172.1, 155.9, 149.0, 148.9, 137.0, 130.3, 128.6, 128.1, 127.7, 126.9, 126.4, 124.2, 113.4, 
113.2, 67.2, 59.6, 56.8, 56.6, 55.9, 55.8, 52.1, 30.9; IR (neat): 2942, 1744, 1714, 1204, 735, 
698 cm
-1
; HRESIMS m/z 462.1896 [M + 1H]
1+
 (calc. for C27H28NO6, 462.1916) and 
484.1720 [M + Na]
23+
(calc. for C27H27NNaO6, 484.1736). 
(1R,3S)-Methyl 6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
(13) 
Rf 0.5 (hexane/EtOAc 6:4); Colorless oil; [α]
20
D =+15.38 (c 0.26 in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 7.35−7.24 (m, 3H), 7.23−7.16 (m, 2H), 6.65 (s, 1H), 6.34 (s, 1H), 5.25 (s, 
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1H), 3.88 (s, 3H), 3.80 (q, J = 8.58, 5.06 Hz, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 3.15 (dd, J = 
16.02, 5.08 Hz, 1H) 3.01 (dd, J = 16.02, 8.68Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ 173.8, 
147.9, 147.4, 144.5, 128.6, 128.4, 127.9, 127.3, 125.6, 111.1, 110.8, 58.8, 55.8, 52.0, 51.3, 
31.0; IR (neat): 2928, 2600, 1746, 1516, 1250, 1123, 727 cm
-1
; HRESIMS m/z 328.1547 [M 
+ 1H]
1+
 (calcd for C19H22NO4, 328.1548). 
[(1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl]-methanol (14) 
Rf 0.4 (CH2Cl2/MeOH/sat.NH3 in CHCl3 9.5:0.5:1); Pale yellow solid; m.p. 115−117 °C 
(CH2Cl2); [α]
20
D =+3.7 (c  0.27 in CHCl3); 
1
H NMR (400 MHz, CDCl3): δ 7.32−7.21 (m, 
3H), 7.18−7.13 (m, 2H), 6.64 (s, 1H), 6.42 (s, 1H), 5.19 (s, 1H), 3.88 (s, 3H), 3.72 (s, 3H), 
3.66−3.60 (dd, J = 10.76, 2.96 Hz, 1H), 3.49−3.41 (dd, J = 10.64, 7.81 Hz, 1H), 3.12−3.02 
(m, 1H), 2.70 (dd, J = 16.38, 4.56 Hz, 1H), 2.57 (dd, J = 16.38, 10.28 Hz, 1H); 
13
C NMR 
(100 MHz, CDCl3): δ 147.9, 147.2, 144.6, 128.7, 128.2, 127.1, 126.7, 111.5, 110.9, 65.7, 
58.9, 55.9, 55.8, 48.8, 30.5; IR (neat): 3264, 2832, 1515, 1222, 1066, 981, 726, 694 cm
-1
; 
HRESIMS m/z 300.1622 [M + 1H]
1+





D =−38.27 (c 0.39 in CHCl3); 
1
H NMR (600 MHz, DMSO-d6, 100 °C): δ 
7.40−7.15 (m, 10H), 7.02 (s, 1H), 6.93 (s, 1H), 5.16 (s, 1H), 4.43 (q, J = 10.81, 5.71 Hz, 1H), 
3.79 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H), 3.02 (dd, J = 15.09, 5.67 Hz, 1H), 2.70 (dd, J = 14.73, 
11.13 Hz, 1H); 
13
C NMR (150 MHz, DMSO-d6, 100 °C): δ 172.1, 156.1, 149.4, 148.8, 
142.0, 136.9, 129.6, 128.7, 128.2, 128.2, 127.9, 127.5, 127.1, 126.2, 113.5, 67.6, 67.6, 58.8, 
56.9, 56.8, 56.7, 56.7, 56.5, 51.9, 30.2, 30.1; IR (neat): 1752, 1693, 1514, 1404, 1295, 1216, 
1102, 697, 596 cm
-1
; HRESIMS m/z 462.1906 [M + 1H]
1+
 (calcd for C27H28NO6, 462.1916) 
and 484.1730 [M + Na]
23+
(calcd for C27H27NO6Na, 484.1736). 
(1S,3S)-Methyl 6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
(16) 
Rf 0.6 (hexane/EtOAc 6:4); Colorless oil; [α]
20
D =−42.0 (c 0.24 in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 7.38−7.28 (m, 5H), 6.64 (s, 1H), 6.17 (s, 1H), 5.09 (s, 1H), 3.91−3.86 (m, 
4H), 3.85−3.74 (m, 4H), 3.56−3.61 (s, 3H), 3.41−3.05 (m, 2H); 13C NMR (100 MHz, 
CDCl3): δ 172.9, 147.7, 147.3, 143.8, 130.2, 129.0, 128.5, 127.8, 126.0, 111.2, 110.5, 62.8, 
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56.5, 55.8, 55.8, 52.1, 32.2; IR (neat): 3020, 1737, 1514, 1244, 1213, 749, 665 cm
-1
; 
HRESIMS m/z 328.1548 [M + 1H]
1+
 (calcd for C19H22NO4, 328.1548). 
((1S,3S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)methanol (17) 
Rf 0.4 (CH2Cl2/MeOH/sat.NH3 in CHCl3 9.5/0.5/1); Off white solid: m.p. 175−177 °C 
(CH2Cl2); [α]
20
D =−24.0 (c 0.25 in CHCl3); 
1
H NMR (600 MHz, CDCl3): δ 7.39−7.27 (m, 
5H), 6.62 (s, 1H), 6.14 (s, 1H), 5.04 (s, 1H), 3.85 (s, 1H), 3.79−3.72 (m, 1H), 3.62−3.53 (m, 
4H), 3.26−3.10 (m, 1H), 3.00−2.52 (m, 2H); 13C NMR (150 MHz, CDCl3): δ 147.0, 143.7, 
130.2, 128.9, 128.5, 127.7, 126.8, 111.4, 110.7, 65.5, 66.5, 62.8, 55.8, 55.7, 55.7, 31.2; IR 
(neat): 3256, 2919, 1511, 1453, 1258, 1215, 1100, 1073, 822, 737, 700, 561 cm
-1
; HRESIMS 
m/z 300.1594 [M + 1H]
1+
 (calcd for C18H22NO3, 300.1600). 
(1R,3S)-Methyl 2-benzyl-6,7-dimethoxy-1-p-tolyl-1,2,3,4-tetrahydroiso-quin-oline-3-
carboxylate (18) 
To a solution of compound 13 (0.5 g, 1.5 mmol) in acetonitrile (20 mL), solid K2CO3 (635 
mg, 4.5 mmol) was added followed by benzyl bromide (286 mg, 1.6 mmol) at ambient 
temperature.  Thereafter the reaction mixture was refluxed for 3 hours.  Completion of the 
reaction was monitored with TLC using hexane/ethyl acetate (60/40, Rf 0.5).  The solvent 
was evaporated, 30 mL of ethyl acetate was added and the mixture washed with 2 × 10 mL of 
water, the organic layer was separated, and dried over anhydrous MgSO4.  The solvent was 
evaporated under reduced pressure to afford crude product, which was purified by column 
chromatography using 0−20 % ethyl acetate/hexane as the eluent to yield 0.44 g (90 % yield) 
pure benzyl ester (18): Rf 0.7 (hexane/EtOAc 6/4);  White solid;  m.p. 146−148 °C 
(hexane/EtOAc);  [α]
20
D =−164.3 (c 0.28 in CHCl3);  
1
H NMR (600 MHz, CDCl3): δ 7.38 (d, 
J=7.26 Hz, 2H), 7.32−7.16 (m, 9H), 6.54 (s, 1H), 6.26 (s, 1H), 5.19 (s, 1H), 3.85−3.72 (m, 
6H), 3.61 (s, 6H), 3.23 (dd, J=5.10, 15.66 Hz, 1H), 2.98 (dd, J=3.00, 15.72, Hz, 1H); 
13
C 
NMR (150 MHz, CDCl3): δ 173.5, 147.4, 147.3, 145.4, 139.3, 129.7, 128.7, 128.3, 128.2, 
127.1, 127.0, 123.8, 111.5, 110.9, 64.7, 55.7, 55.7, 55.3, 54.6, 51.2, 31.5; IR (neat): 2944, 
1729, 1511, 1152, 753, 699 cm
-1
; HRESIMS m/z 418.2012 [M + 1H]
1+





A solution of compound 18 (500 mg, 1.1 mmol) in THF (10 mL) was added to freshly 
prepared Grignard reagent of phenyl magnesium bromide (2.17 g, 11.9 mmol) under dry inert 
atmosphere at ambient temperature for 15 minutes.  Completion of the reaction was 
monitored with TLC, and the reaction mixture was quenched with saturated ammonium 
chloride solution at 0 °C.  The reaction mixture was filtered off and washed with 20 mL of 
ethyl acetate.  The filtrate was evaporated under reduced pressure to yield 0.52 g (80 % yield) 
of the crude C3-α diphenyl tert alcohol: Rf 0.5 (hexane/EtOAc 6/4); White solid: m.p. 
205−207 °C (hexane/EtOAc); [α]20D =+20.37 (c 0.27 in CHCl3); 
1
H NMR (400 MHz, 
CDCl3): δ 7.44 (d, J=1.16 Hz, 2H), 7.32−7.10 (m, 14H), 7.0−6.88 (m, 6H), 6.69 (s, 1H), 6.38 
(s, 1H), 4.74 (s, 1H), 4.21 (d, J=13.60 Hz, 1H), 4.14 (q, J=3.70, 12.74 Hz, 1H), 3.89 (s, 3H), 
3.72 (s, 3H), 3.57 (s, 1H), 3.30−3.18 (m, 2H), 2.60 (dd, J=3.60, 16.48 Hz, 1H); 13C NMR 
(100 MHz, CDCl3): δ 147.8, 147.5, 146.1, 145.5, 143.4, 140.2, 129.8, 129.1, 128.2, 128.1, 
127.7, 127.6, 127.0, 126.7, 126.3, 126.1, 125.5, 112.1, 111.6, 79.4, 64.6, 56.8, 55.8, 55.8, 
51.8, 23.4); IR (neat): 3589, 1509, 1240, 1093, 694 cm
-1
; HRESIMS m/z 542.2698 [M + 
1H]
1+
 (calcd for C37H36NO3, 542.2695). 
[(1R,3S)-6,7-Dimethoxy-1-p-tolyl-1,2,3,4-tetrahydroisoquinolin-3-yl]diphe-nylmethanol 
(20) 
A solution of compound 19 (400 mg, 0.7 mmol) in methanol (10 mL/mmol) was added to a 
suspension of activated Pd/C (200 mg, 10 wt.- %) in dry MeOH under inert atmosphere.  The 
reaction mixture was connected to H2 source at 1 atmosphere and stirred for 6 hours at room 
temperature.  Completion of the reaction was monitored with TLC using hexane/ethyl acetate 
(40/60, Rf 0.5).  The Pd/C was filtered off through a celite pad and washed with methanol (10 
mL).  The filtrate was evaporated under reduced pressure affording the crude amino ester, 
which was purified by column chromatography using 0−2 % methanol in dichloromethane as 
the eluent to yield 0.30 g (92 % yield) of pure compound 20. Rf 0.3 (hexane/EtOAc 5/5); Pale 
yellow solid: mp 77−79 °C (CH2Cl2); [α]
20
D −119.5 (c 0.26 in CHCl3); 
1
H NMR (400 MHz, 
CDCl3): δ 7.42−7.34 (m, 5H), 7.29−7.24 (t, J=15.20 Hz, 1H), 7.05−7.21 (m, 6H), 7.02−6.96 
(m, 2H), 6.56 (s, 1H), 6.43 (s, 1H), 5.23 (s, 1H), 3.89−3.85 (q, J=10.94, 3.86 Hz, 1H), 3.81 (s, 
3H), 3.72 (s, 3H), 3.03−2.92 (dd, J=16.42, 10.94 Hz, 1H), 2.24−2.16 (m, 1H); 13C NMR (100 
MHz, CDCl3): δ 148.0, 147.2, 145.1, 144.6, 144.0, 128.4, 128.0, 127.7, 127.4, 126.9, 126.5, 
126.2, 126.0, 125.4, 111.4, 110.6, 78.3, 60.0, 55.9, 55.8, 51.9, 28.5; IR (neat): 2926, 1512, 
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1447, 1243, 1063, 698 cm
-1
; HRESIMS m/z 452.2220 [M + 1H]
1+




A solution of compound 18 (1.30 g, 3.1 mmol) in dry THF (20 mL) was added dropwise to a 
suspension of LiAlH4 (0.35 g, 9.3 mmol) in 30 mL of dry THF under N2 atmosphere at 0 °C.  
The reaction mixture was stirred at 0 °C for 2 hours.  Completion of the reaction was 
monitored with TLC using hexane/ethyl acetate (80/20, Rf: 0.6).  Excess lithium aluminium 
hydride was quenched with saturated sodium sulphate solution at 0 °C.  The reaction mixture 
was filtered and the solid washed with 20 mL of THF.  The solvent was evaporated to 
dryness under reduced pressure.  Ethyl acetate (20 mL) was added and the resulting solution 
washed with water (2 × 5 mL).  The organic layer was separated and dried over anhydrous 
MgSO4 and concentrated to give crude amino alcohol.  The crude product was purified with 
column chromatography using 0−40 % ethyl acetate in hexane as a mobile phase and silica 
gel as a stationary phase to yield 0.85 g (70 % yield) of pure amino alcohol. Rf 0.3 
(hexane/EtOAc 5/5); Yellow solid: m.p. 108−110 °C; [α]20D =+66.0 (c  0.25 in CHCl3); 
1
H 
NMR (400 MHz, CDCl3): δ 7.43−7.28 (m, 5H), 7.24−7.12 (m, 3H), 6.98 (d, J=6.88 Hz, 2H), 
6.70 (s, 1H), 6.41 (s, 1H), 4.85 (s, 1H), 3.98−3.89 (m, 4H), 3.77−3.69 (m, 4H), 3.58−3.49 (m, 
1H), 3.41−3.29 (m, 2H), 2.69 (dd, J=11.60, 11.56 Hz, 1H), 2.53 (dd, J=4.68, 4.68 Hz, 1H); 
13
C NMR (100 MHz, CDCl3): δ 147.9, 147.5, 143.7, 139.2, 129.2, 129.0, 128.5, 127.9, 127.2, 
126.9, 125.9, 112.3, 111.6, 62.6, 61.2, 55.8, 52.2, 49.0, 25.5; IR (neat): 3511, 2919, 1609, 
1514, 1292, 1127, 1029, 697 cm
-1
;  HRESIMS m/z 390.2060 [M + 1H]
1+




To a solution of oxalyl chloride (0.34 g, 2.6 mmol) in dry CH2Cl2 (12 mL) at −78 °C was 
added a solution of DMSO (0.45 g, 5.8 mmol) in CH2Cl2 (1.2 mL) over 5 minutes, and the 
reaction mixture was stirred for 10 minutes at −78 °C.  Compound 21 (0.95 g, 2.4 mmol) was 
added as a solution in CH2Cl2 (1 mL) over 5 minutes.  The reaction mixture was stirred for 15 
minutes, and an excess of Et3N (0.86 g, 8.5 mmol) was added over 5 minutes.  The cooling 
bath was removed for the temperature to rise to room temperature.  Water (30 mL) was added 
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and the phases were separated.  The aqueous phase was extracted with CH2Cl2 (3 × 10 mL) 
and the combined organic extracts were washed with brine and dried over MgSO4.  Filtration 
and evaporation of the solvent afforded a residue that was purified by column 
chromatography using 0−30 % ethyl acetate in hexane as a mobile phase and silica gel as a 
stationary phase to yield approximately 0.80 g (85 % yield) of the aldehyde 22 as an yellow 
oil: Rf 0.8 (hexane/ethyl acetate 7/3); 
1
H NMR (400 MHz, CDCl3): δ 9.76 (s, 1H), 7.40−7.16 
(m, 10H), 6.68 (s, 1H), 6.33 (s, 1H), 5.0 (s, 1H), 3.87 (s, 3H), 3.77−3.63 (m, 6H), 3.01−2.95 
(m, 2H); 
13
C NMR (100 MHz, CDCl3): δ 204.2, 147.9, 147.6, 144.1, 138.8, 129.1, 129.0, 
127.4, 127.3, 127.2, 124.7, 111.9, 111.3, 63.8, 60.9, 55.8, 55.8, 54.1, 25.2; IR (neat): 2931, 





A solution of compound 22 (0.65 g, 1.6 mmol) in dry THF (10 mL) was added to freshly 
prepared methyl magnesium iodide (1.4 g, 8.4 mmol) under inert atmosphere at 0 °C for 15 
minutes.  The reaction was stirred at 0 °C for 3 hours and monitored with TLC by quenching 
the aliquote of reaction mixture with a saturated ammonium chloride solution at 0 °C for 15 
minutes using 30/70 ethyl acetate/hexane.  The reaction mixture was filtered and the solid 
washed with ethyl acetate (20 mL).  Evaporation of the filtrate gave 0.54 g of the crude C3-α 
methyl secondary alcohol (80 % yield) obtained as a 9:1 mixture of diastereomers, which 
were separated with column chromatography using 0−40 % ethyl acetate/hexane and silica 
gel (230−400 mesh) as a stationary phase. 
Major 23 
Rf 0.6 (hexane/EtOAc 7/3); Yellow oil; [α]
20
D =+64.15 (c 0.26 in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 7.46−7.05 (m, 12H), 6.74 (s, 1H), 6.39 (s, 1H), 4.74 (s, 1H), 3.92−3.98 (m, 
1H), 3.91 (s, 3H), 3.84 (d, 1H), 3.73 (s, 3H), 3.48 (d, 1H), 2.95−2.76 (m, 3H), 2.34−2.15 (m, 
2H); 
13
C NMR (100 MHz, CDCl3): δ 147.8, 147.2, 144.1, 139.9, 129.0, 128.9, 128.4, 127.7, 
127.0, 126.6, 125.9, 112.3, 111.7, 69.7, 63.1, 57.2, 55.8, 55.8, 50.7, 31.9, 29.6, 29.3, 25.7, 
21.6; IR (neat): 2924, 2853, 1510, 1449, 1243, 1219, 1099, 1028, 749, 698 cm
-1
; HRESIMS 
m/z 404.2225 [M + 1H]
1+
 (calcd for C26H30NO3, 404.2226). 
Minor 23 
38 
Rf 0.65 (hexane/EtOAc 7/3); Yellow oil; [α]
20
D =+57.69 (c 0.28 in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 7.42−7.37 (m, 4H), 7.21−7.14 (s, 3H), 6.92 (d, 2H), 6.73 (s, 1H), 6.42 (s, 
1H), 4.86 (s, 1H), 4.0 (d, J=12.92 Hz, 1H), 3.92 (s, 3H), 3.91−3.82 (m, 2H), 3.75 (s, 3H), 
3.33 (d, J=12.88 Hz, 1H), 2.89−2.54 (m, 3H), 2.37−2.13 (m, 2H); 13C NMR (100 MHz, 
CDCl3): δ 148.0, 147.6, 143.3, 139.0, 129.4, 128.6, 127.3, 126.9, 125.2, 112.3, 111.6, 65.7, 
62.3, 57.9, 55.9, 55.8, 49.3, 24.5, 19.3; IR (neat): 2931, 2850, 1510, 1493, 1450, 1222, 1102, 
751, 699 cm
-1
; HRESIMS m/z 404.2220 [M + 1H]
1+
 (calcd for C26H30NO3, 404.2226). 
(S)-1-((1R,3S)-6,7-Dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)ethanol (24) 
A solution of benzyl protected TIQ sec alcohol 23 (300 mg, 0.7 mmol) in methanol (10 mL) 
was added to a suspension of 10 wt.- % Pd/C (0.2 g) in methanol (10 mL).  The reaction 
mixture was connected to a H2 source at atmospheric pressure and stirred at room 
temperature for 6 hours.  The Pd/C was filtered off on a celite pad and the filtrate was 
concentrated under reduced pressure to afford crude amino ester.  The products were purified 
with column chromatography using hexane/ethyl acetate as an eluent to yield a combined 
mass of 0.14 g (60 % yield) for major 24 and minor 24. 
Major 24 
Rf 0.3 (hexane/EtOAc 4/6); Brown oil; [α]
20
D =−11.11 (c 0.27 in CHCl3); 
1
H NMR (400 
MHz, CDCl3): δ 7.30−7.19 (m, 3H), 7.13−7.03 (m, 2H), 6.66 (s, 1H), 6.39 (s, 1H), 5.19 (s, 
1H), 3.86 (s, 3H), 3.73−3.65 (m, 4H), 2.83−2.74 (m, 1H), 2.92−2.85 (m, 1H), 2.67−2.59 (dd, 
J=4.20, 4.21 Hz, 1H), 1.12 (d, J=6.40 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ 147.9, 147.1, 
145.0, 128.5, 128.2, 127.7, 127.2, 127.1, 111.5, 110.8, 69.5, 59.6, 55.8, 51.5, 27.7, 18.2; IR 
(neat): 2930, 1589, 1520, 1454, 1346, 1226, 1124, 755, 702 cm
-1
; HRESIMS m/z 314.1761 
[M + 1H]
1+
 (calcd for C19H24NO3, 314.1756). 
Minor 24 
Rf 0.3 (hexane/EtOAc 4/6); Colorless oil; [α]
20
D =−10.71 (c 0.28 in CHCl3); 
1
H NMR (400 
MHz, CDCl3, 25°C): δ=7.40−7.15 (m, 5H), 6.66 (s, 1H), 6.40 (s, 1H), 5.50 (s, 1H), 3.88 (s, 
3H), 3.81−3.67 (m, 4H), 2.97−2.69 (m, 3H), 1.16 (d, J=5.72 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ 148.7, 147.9, 139.7, 129.3, 128.5, 125.0, 111.2, 110.5, 68.0, 57.9, 55.9, 55.8, 54.3, 
29.4, 19.5; IR (neat): 2933, 1694, 1513, 1451, 1243, 1089, 751 cm
-1
; HRESIMS m/z 
314.1756 [M + 1H]
1+
 (calcd for C19H24NO3, 314.1756). 
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ABSTRACT 
The use of the tetrahydroisoquinoline scaffold is well documented in biologically active 
compounds.  However, reports of the utilisation of tetrahydroisoquinoline compounds in 
asymmetric catalysis are limited.  The synthesis of novel diamine ligands possessing the 
tetrahydroisoquinoline (TIQ) backbone and evaluation of their activity in the asymmetric 
transfer hydrogenation of acetophenone are presented.  The diamine ligands in conjunction with 
i-PrOH as the hydrogen source and [RhCl2(Cp*)]2 as the metal precursor proved to be the most 
effective of the tetrahydroisoquinoline derivatives for this catalytic system.  Water was found to 
have a profound influence on the enantioselectivity of the reaction.  Optimisation of the amount 
water, i-PrOH and catalytic loading rendered the best result of 70% enantioselectivity for the 
(S)-1-phenylethanol isomer product. 
INTRODUCTION 
Since the isolation of naphthyridinomycin in 1974, the biological activity of 
tetrahydroisoquinoline carboxylic acid derivatives has been widely investigated.
1-3
  Previous 
reports on the use of tetrahydroisoquinoline derivatives as catalytic ligands have yielded limited 
success, with poor to moderate enantioselectivities in asymmetric catalysis such as allylic 
alkylation
4
 and borane-mediated hydrogenation reactions.
5-6
  However, in a related study the use 
42 
of different tetrahydroisoquinoline ligands for the addition of diethylzinc to benzaldehyde gave 
promising results.
7
  We have recently reported the use of tetrahydroisoquinoline amino alcohol 
derivatives to catalyse the asymmetric transfer hydrogenation of prochiral ketones with high 
reaction rates and moderate to good selectivities.
8
 
It has been shown in the literature that amine and diamine based ligands can be used for various 
asymmetric catalytic reactions.
9-13
  Noyori et al. reported a variety of simple amino alcohols and 
diamines with a ruthenium precursor, an i-PrOH source and KOH as a co-catalyst for the 
reduction of acetophenone (see Fig. 1).
14-15
  It was noted that a two carbon bridge between the 
donors formed the ideal chelater, and that unlike the amino alcohols, the diamines required one 
of the amines to be functionalised with an electron-withdrawing group.  Inherently the p-toluene 






Figure 1. Noyori’s diamine ligand 
Since this discovery there has been a surge of interest into asymmetric transfer hydrogenation, 
with the development of many successful catalysts.
16-20
  Other studies have attempted to 
optimise the performance of these catalysts, by varying steric, electronic and solubility 
properties.
21-22
  Development of the triethylamine: formic acid azeotrope (TEAF) and more 
recently formate salts in aqueous media have also broadened the scope for activity and 
selectivity.
20,23
  The aqueous systems show promise and in many cases enhanced overall 
performance has been observed in the presence of water.  A rigorous screening of these 























Figure 2. Diamine ligands studied for activity in asymmetric transfer hydrogenation 
Herein we report a systematic study of novel diamine ligands possessing tetrahydroisoquinoline 
as a rigid and tuneable chiral backbone in pre-catalysts for the asymmetric reduction of 
acetophenone. 
RESULTS AND DISCUSSION 
SYNTHESIS 
Ligands 2a–g (Scheme 1) were synthesised from commercially available tetrahydroisoquinoline 
amino acid 3.  Benzyl carbamate (Cbz) protection of 3 allowed for subsequent coupling of the 
respective amines to yield 5a–g.  Thereafter, removal of the Cbz group with palladium on 
carbon (Pd/C) and one atmosphere of hydrogen (H2) gas afforded the amides 6a–g.  The desired 






























Scheme 1. Synthetic route used to prepare 2a-g.  Reagents and conditions: (i) KHCO3, dioxane, 
water, Cbz-Cl; (ii) EDC.HCl, HOBt, R-NH2, DMAP, DMF; (iii) 10 % wt. Pd/C, H2, MeOH, 
THF; (iv) LiAlH4, THF. 
Ligand 2i (Scheme 2) was prepared as previously reported.
24-25
  Esterification of 3 via an in situ 
reaction to form the acyl chloride with thionyl chloride followed by condensation with methanol 
gave the methyl ester hydrochloride salt 7.  Conversion to the amide 8 was achieved by the 
treatment of this salt with a large excess of 25 % ammonium hydroxide with stirring for several 















Scheme 2. Synthetic route used to prepare 2h.  Reagents and conditions: (i) SOCl2, MeOH (ii) 
25 % NH4OH; (iii) LiAlH4, THF. 
Ligand 2i (Scheme 3) could not be prepared following the same approach as for 2a–g, due to 
racemisation, which was observed under LiAlH4 reduction conditions.  Therefore an alternate 
procedure employing a milder reduction condition was sought.  Cbz protection of the amino 
alcohol 9
8
 yielded 10 which was subsequently oxidised with pyridinium chlorochromate to 
45 
obtain compound 11.  Reductive amination on 11 using benzylamine and sodium 
cyanoborohydride afforded the desired product 12.  Selective deprotection of the N-Cbz group 




































Scheme 3. Synthetic route used to prepare 2i.  Reagents and conditions: (i) KHCO3, 
dioxane/water, Cbz-Cl; (ii) PCC, dry DCM; (iii) Benzylamine, NaBH3CN, MeOH/THF; (iv) 10 
% wt. Pd/C H2 1 atm, MeOH/THF. 
Ligand 2j (Scheme 4) was prepared from the amide 8, which was Cbz protected to form 13.  
Using NaBH4 with acetic acid in dioxane,
26
 the amide was reduced without cleavage of the Cbz 
group to yield 14.  Reaction of 14 with toluenesulfonyl chloride with base followed by removal 



















Scheme 4 Synthetic route used to prepare 2j. Reagents and conditions: (i) KHCO3, 
dioxane/water, Cbz-Cl; (ii) NaBH4, AcOH, dioxane, reflux; (iii) TsCl, DCM, TEA; (iv) 10 % 
wt. Pd/C H2 1 atm, MeOH/THF. 
STRUCTURAL MODIFICATIONS 
Given that the amines were designed to incorporate broad structural diversity to investigate the 
scope of tetrahydroisoquinoline-diamine ligands in asymmetric transfer hydrogenation, we 
proceeded to modify the backbone by changing the structural features of the substituent on the 
amine (see Fig. 1) and tested them for activity in asymmetric transfer hydrogenation of 
acetophenone (see Table 1).  The groups were chosen to cover both steric and electronic 
character.  Ligand 2a was the first of the diamine derivatives to be prepared and tested for its 
catalytic activity in asymmetric transfer hydrogenation, producing reasonable results (81% 
conv., 70% ee, entry 1).  Derivatives 2b and 2c (entries 2 and 3) possessing diphenyl or aniline 
groups, respectively, inherently make the amine more acidic.  Unfortunately 2b demonstrated 
very poor reactivity and little selectivity (22% conv., 11% ee, entry 2) while 2c showed no 
activity at all (entry 3).  When the pKa of the nitrogen was increased using derivatives 2d 
(methyl) and 2e (iso-propyl), 2d also showed no activity (entry 4).  However, 2e was found to 
possess moderate reactivity with fair selectivity (67% conv., 71% ee, entry 5).  It seemed 
apparent that the electronic effects of the substituents on the nitrogen were not the issue, but 
rather a steric effect dictating the selectivity.  To examine further, chiral amines possessing a 
benzyl and methyl group were employed.  These would have similar effects on the pKa as that 
of the benzyl group on 2a and offer less steric crowding than the diphenyl group on 2b.  
Promising results were obtained with the (R)-methylbenzylamine derivative 2f (24% conv., 77% 
ee, entry 6) yielding the (R)-1-phenylethanol enantiomers, which then led us to try the (S) 
isomer.  The (S)-methylbenzyamine derivative 2g showed lower reactivity and selectivity than 
the (R) enatiomer (5.5% conv., 51% ee, entry 7), but had preference for the expected (S)-1-
47 
phenylethanol enantiomer.  Compound 2h was prepared to determine whether the primary amine 
could also be used as a ligand in asymmetric transfer hydrogenation reaction, but it was found to 
have no activity in this reaction (entry 8).  Out of curiosity, and given our recent success with 
the amino alcohol derivative of the C
1
-substituted tetrahydroisoquinoline ligand, 2i was prepared 
(Scheme 3).  Disappointingly, this auxiliary showed no activity (entry 9).  Based on the 
significant increase in rate, an often selectivity observed, upon tosylation of one of the amine 
donors we investigated 2j for activity in asymmetric transfer hydrogenation of acetophenone.  


















Table 1. Asymmetric transfer hydrogenation of acetophenone by ligand 2a-j rhodium 





1 mol % (M/S), L*, H2O  
Entry Ligand Conv. (%) ee (%) Isomer 
1 2a 81 70 S 
2 2b 22 11 S 
3 2c - - - 
4 2d - - - 
5 2e 67 71 S 
6 2f 24 77 R 
7 2g 5.5 51 S 
8 2h - - - 
9 2i - - - 
10 2j - - - 
All reactions were carried out at 25 °C.  In the case where the hydrogen source is KCO2H the solvent used was 
water.    
i-PrOH was used as the solvent when employed as the HS along with t-BuOK as the base.  Testing was carried out 
using a S/C of 100. 
a
 Measured by GC with chiral capillary column β-DEX™ 120. 
EFFECT OF WATER 
As stated earlier it has been demonstrated in the literature that water has the potential to 
influence performance of a catalyst in asymmetric transfer hydrogenation reactions.
20-21,27-32
  
This prompted us to investigate how much water was necessary to obtain the highest 
enantiomeric excess using ligand 2a (Table 2).  Adding 1 equiv of water to the metal complex 
was found to increase activity (27 % ee, entry 1).  Progressively increasing the amount of water 
49 
from 2 to 400 equiv showed the selectivity to improve even more (entries 2–6).  Thereafter 
raising the amount of water to a 1000 and then further to 3000 equiv a maximum of 94 % 
conversion was reached with an optimum of 70% enantioselectivity (entries 7–9).  Extending the 
amount to 50:50 i-PrOH/water (many times excess) destroyed the reactivity completely (entry 
10).  Since reactivity dropped significantly at 3000, 1500 equiv was taken as the best 
compromise between reactivity and selectivity for subsequent testing. 
Table 2.  Results of the effect in varying the water content on the reaction of acetophenone by 





1 mol % (M/S), 2a, H2O  





1 1 64 27 
2 2 81 43 
3 10 88 45 
4 100 92 54 
5 200 88 62 
6 400 92 66 
7 1000 94 68 
8 1500 81 70 
9 3000 61 70 
10
b
 50:50 - - 
All reactions were carried out at 25 °C.  In the case where the hydrogen source is KCO2H the solvent used was 
water.   
i-PrOH was used as the solvent when employed as the hydrogen source along with t-BuOK as the base.  Testing 
was carried out using a S/C of 100. 
a Measured by GC with chiral capillary column β-DEX™ 120. 
b
 A 50/50 mixture of water and i-PrOH was used.   
50 
METAL AND DONOR STUDY 
Compound 2a was chosen as a representative of the di-secondary amine ligands for this study, 
the results of which are shown in Table 3.  Entries 1 and 4 show that very little activity is 
observed when the asymmetric transfer hydrogenation reaction is carried out in water using 
potassium formate as the hydrogen source (2 %, entry 1), and no activity with i-PrOH (entry 4) 
when [Ru(p-cymeme)Cl2]2 is employed as the metal precursor.  The same held for the formate 
hydrogen source with [IrCl2(Cp*)]2 (10 %, entry 2).  However a marked increase in activity was 
observed when the hydrogen source was changed to i-PrOH (40 %, entry 5).  Implementing a 
[RhCl2(Cp*)]2 precursor rendered significant activity with the formate (43 %, entry 3), but the 
greatest catalytic activity was seen when the i-PrOH was used instead (90 %, entry 6).  The 
results for the [RhCl2(Cp*)]2 prompted us to investigate whether using the TEAF hydrogen 
source could increase activity.  Unfortunately this proved unsuccessful (entry 7).  Changing 
from the [RhCl2(Cp*)]2 (arene) to the RhPPh3COH (hydride) did not improve on the 
[RhCl2(Cp*)]2 system (10 %, entry 8).  Therefore optimised conditions were found to be with 














Table 3. Asymmetric transfer hydrogenation of acetophenone by different hydrogen sources and 















1 [Ru(p-cymene)Cl2]2 HCO2K 2 10 R 
2 [IrCl2(Cp*)]2 HCO2K 10 25 R 
3 [RhCl2(Cp*)]2 HCO2K 43 50 R 
4 [Ru(p-cymene)Cl2]2 i-PrOH - - - 
5 [IrCl2(Cp*)]2 i-PrOH 40 - - 
6 [RhCl2(Cp*)]2 i-PrOH 90 - S 
7 [RhCl2(Cp*)]2 TEAF - - - 
8 RhPPh3COH i-PrOH 10 48 R 
All reactions were carried out at 25 °C.  In the case where the hydrogen source is KCO2H the solvent used was 
water.   
i-PrOH was used as the solvent when employed as the hydrogen source along with t-BuOK as the base.  Testing 
was carried out using a S/C of 100. 
a
 Measured by GC with chiral capillary column β-DEX™ 120. 
CONCLUSIONS 
We have prepared a series of diamine ligands possessing the tetrahydroisoquinoline backbone 
and tested them for activity in the asymmetric transfer hydrogenation of acetophenone.  The 
amine donors were all secondary ligands 2a–g and i, but 2h possessed both a primary and 
secondary amine.  It was found that when using [RhCl2(Cp*)]2 in conjunction with an i-PrOH, 
the best conversion achieved was 92 % in 1 h.  Furthermore, it was determined that no 
selectivity was obtained under anhydrous conditions, and that an optimum of 1500 equiv of 
water to rhodium gave the best selectivity of 77 % ee for ligand 2f.  However with regards to the 
best overall catalytic performance, ligands 2a and 2d bearing the benzyl and isopropyl 
52 
substituents, respectively, shared both good reactivity and selectivity for the asymmetric 
reduction of acetophenone.  We believe that these ligands could be successfully employed as 
catalysts for other asymmetric transformations. 
EXPERIMENTAL 
GENERAL 
All reagents and solvents were purchased from Aldrich, Merck and Fluka unless stated 
otherwise.  All NMR analysis was carried out on either a Bruker AVANCE III 400 or 600 MHz 
instrument.  Chemical shifts are expressed in parts per million (ppm) downfield from a TMS 
signal, and coupling constants are reported in Hertz.  NMR spectra were obtained at room 
temperature, except if stated differently.  Thin layer chromatography (TLC) was performed 
using Merck Kiesel gel 60 F254.  Crude compounds were purified via column chromatography 
using Silica Gel (60–200 mesh except if stated otherwise).  All solvents were dried using 
standard procedures, for example, Vogel.
26
  All IR spectra were recorded on a Perkin Elmer 
Spectrum 100 instrument with a universal ATR attachment.  Optical rotations were measured on 
a Perkin Elmer Polarimeter.  All melting points are uncorrected.  High resolution mass 
spectrometric data were obtained using a Bruker micrOTOF-Q II instrument, using a sample 
concentration of approximately 1 ppm.  All gas chromatography was carried out on an Agilent 
6820 instrument. 
General procedure for transfer hydrogenation of acetophenone 
i-PrOH hydrogen source 
To an oven-dried Schlenk tube was added metal precursor (3.0 mg) followed by the ligand (4 
mol equiv) and freshly distilled i-PrOH (5 mL) under a dry argon atmosphere.  The mixture was 
heated to 60 °C and stirred for 20 min, after which the solution was allowed to cool to ambient 
temperature.  The desired amount of acetophenone was then added (substrate/catalyst, S/C = 
100) followed by freshly prepared 0.1 M t-BuOK (2 equiv to metal) in i-PrOH.  To monitor the 
reactions, small aliquots were drawn, diluted with i-PrOH and then run through a small plug of 




i-PrOH hydrogen source in water 
The reaction was carried out as reported above with the exception that the water was added after 
complexation and just before the addition of acetophenone.  Monitoring of the progress of the 
reaction remained the same. 
Formate hydrogen source 
The metal precursor and ligand were complexed as describe above.  Water was then added (2 
mL), and the reaction mixture heated to 40 °C and stirred for 30 min.  The mixture was then 
cooled and the acetophenone (S/C = 100) was added followed by the potassium formate.  To 
monitor the reactions, small aliquots were drawn and extracted with hexane; the hexane extracts 
were then used for GC analysis. 
TEAF hydrogen source 
The TEAF was prepared as reported in the literature.
23
  The metal precursor and ligand were 
stirred in DCM for 30 min, followed by the addition of acetophenone (S/C = 100) and TEAF 
(0.9ml).  The reaction was monitored using a method similar to that used with the i-PrOH 
hydrogen source. 
(S)-2-(Benzyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 4 
To a suspension of 3 (5 g, 19.4 mmol) in dioxane (80 mL) and water (40 mL) was added 
NaHCO3 (77.8 mmol) at 0 °C following Schotten–Baumann conditions.  After addition of the 
base, Cbz-Cl was added and the reaction mixture was allowed to stir at 0 °C for 1.5 h and then at 
room temperature for a further 1.5 h.  The product was extracted twice with ethyl acetate, the 
organic layer dried with anhydrous magnesium sulfate and concentrated to dryness affording 4 
(5.56 g, 92% yield) that was carried forward without any purification. 
General procedure for the preparation of 5a–g 
(S)-2-(Benzyloxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 4 (1.5 g, 4.8 mmol) 
was dissolved in DMF (15 mL) followed by addition of EDC.HCl (1.1 g, 5.8 mmol), HOBt 
(0.81 g, 5.3 mmol), a catalytic amount of DMAP and the appropriate amine (5.3 mmol).  The 
reaction mixture was then stirred at room temperature until no more starting material could be 
detected by 
54 
TLC analysis (approximately 1 h).  The reaction mixture was poured into 30 volumes of chilled 
water; the mixture was then extracted twice with ethyl acetate.  The extracts were combined, 
washed with 10% HCl (aq) to remove latent EDC urea, dried over anhydrous magnesium sulfate 
and then concentrated to dryness affording the crude product which was purified by column 
chromatography. 
General procedure for the preparation of 6a–g 
The precursors 5a–g in 50/50 MeOH/THF with 0.5 eq. of 10 % palladium on carbon (Pd/C) was 
stirred under hydrogen (approximately 1 atm) for 2 h.  The reaction was limited for this period 
as side products were observed.  The crude product was obtained by filtering off the Pd/C 
through a plug of Celite, the filtrate was then concentrated to dryness and the residue purified by 
column chromatography. 
General procedure for the preparation of 2a–g 
The amino amides 6a–g were reduced with 4 equiv of LiAlH4 in refluxing dry THF under a 
nitrogen atmosphere for 3–4 days or alternatively the reductions could be carried out at 85 °C in 
a microwave reactor for 4–5 h.  The reactions were quenched by slow addition of saturated 
sodium sulfate solution and the white aluminium sulfate precipitate was then filtered off.  The 
filtrate was washed with water, dried over anhydrous magnesium sulfate and concentrated to 
dryness affording the crude product which was purified by column chromatography. 
(S)-benzyl 3-(benzylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5a 
The resultant product from reaction with benzylamine was purified by column chromatography 
(EtOAc/Hex = 50:50, Rf ~ 0.45) to afford the benzyl substituted TIQ derivative 5a (1.44 g, 75 
%) as a white powder.  [α]
20
D = – 8.333 (c = 0.12, CH2Cl2);  IR νmax: 695, 729, 1118, 1216, 
1302, 1322, 1400, 1650, 1680, 3029 and 3331.  Melting point: 105 – 107 °C.  HRMS calculated 
for C25H24N2O3 (M + H
+
) = 401.1867 m/z, Found 401.1860 m/z. (NMR spectra are reported for a 




H NMR (400 MHz, DMSO): δ 8.42 (m, 1H), 7.51 – 7.07 (m, 12H), 
6.91-6.76 (m, 2H), 5.27 – 5.07 (m, 2H), 4.87 – 4.42 (m, 3H), 4.28-4.05 (m, 2H), 3.26-3.06 (m, 
2H);  
13
C NMR (101 MHz, DMSO): δ 170.6, 139.2 – 126.1, 66.4, 54.5, 44.7, 41.8 and 31.8. 
(S)-N-benzyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6a 
Removal of Cbz and purification by column chromatography (DCM/MeOH/10% NH3 in CHCl3 
= 87:3:10, Rf ~ 0.4) gave the benzyl amide TIQ 6a (85%) as a white solid.  [α]
20
D = – 54.76 (c = 
55 
0.42, CH2Cl2).  IR νmax: 435, 467, 613, 694, 736, 797, 1029, 1222, 1453, 1546, 1643, 2925, 
3033, 3057, 3279 and 3330.  Melting point: 83 – 85 °C.  HRMS calculated for C17H18N2O (M + 
H
+
) = 267.1492 m/z, Found 267.1504 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.56 (s, 1H), 7.42 – 
7.12 (m, 9H), 4.48 (d, J = 5.6, 2H), 4.05 – 3.91 (d, J = 6.52 Hz, 2H), 3.61 (dd, J = 10.3, 5.2 Hz, 
1H), 3.28 (dd, J = 16.4, 5.2 Hz, 1H), 2.88 (dd, J = 16.4, 10.3 Hz, 1H), The NH proton was not 
observed.  
13
C NMR (101 MHz, CDCl3): δ 173.0, 138.3, 135.9, 134.4, 129.2, 128.7, 127.7, 
127.4, 126.6, 126.2, 125.5, 56.5, 47.5, 43.1 and 31.0. 
(S)-N-benzyl-1-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanamine 2a 
After reduction of 6a, the crude compound was purified by column chromatography 
(DCM/MeOH/Et2O/10% NH3 in CHCl3 = 66:4:20:10, Rf ~ 0.4) to afford the N-benzyl amine 
derivative 2a (31 %) as an off white/yellow solid.  [α]
20
D = – 70.93 (c = 0.43, CH2Cl2).  IR νmax: 
695, 729, 1118, 1216, 1302, 1322, 1400, 1650, 1680, 3029 and 3331 cm
–1
.  Melting point: 85 – 
87 °C.  HRMS calculated for C17H20N2 (M + H
+
) = 253.1699 m/z, found 253.1708 m/z.  
1
H 
NMR (400 MHz, CDCl3) δ 7.38 – 7.30 (m, 3H), 7.28 – 7.23 (m, 2H), 7.16 – 6.99 (m, 4H), 4.04 
(s, 2H), 3.84 (d, J = 2.8 Hz, 2H), 3.05 – 2.96 (m, 1H), 2.86 (dd, J = 11.9 and 3.8 Hz, 1H), 2.73 
(dd, J = 16.3 and 4.0 Hz, 1H), 2.64 (dd, J = 11.9 and 8.9 Hz, 1H), 2.59 – 2.51 (m, 1H), the two 
NH protons were not observed.  
13
C NMR (101 MHz, CDCl3): δ 140.3, 135.8, 134.4, 129.2, 
128.4, 128.1, 127.0, 126.1, 126.0, 125.7, 54.4, 54.1, 53.4, 48.2 and 33.3. 
(S)-benzyl 3-(benzhydrylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5b 
The resultant product from the reaction with diphenylmethanime was purified by column 
chromatography (EtOAc/Hex = 50:50, Rf ~ 0.4) to afford the diphenyl substituted TIQ 
derivative 5b (1.62 g, 71 %) light yellow oil. [α]
20
D = – 11.43 (c = 0.36, CH2Cl2).  IR νmax: 528, 
546, 604, 616, 639, 695, 738, 909, 1001, 1028, 1094, 1120, 1215, 1303, 1346, 1403, 1453, 1494, 




.  HRMS calculated for C31H28N2O3 (M + H
+
) = 
477.2137 m/z, found 477.2155 m/z. NMR spectra are reported for a mixture of two rotamers.  
1
H 
NMR (400 MHz, DMSO) δ = 8.95 – 8.69 (m, 1H), 7.64 – 6.88 (m, 19H), 6.11 – 5.85 (m, 1H), 
5.30 – 4.37 (m, 5H), 3.02 – 3.27 (m, 2H).  
13
C NMR (101 MHz, DMSO): δ 170.2, 155.3 – 125.9, 
86.6, 66.4, 54.8, 44.8 and 32.1. 
(S)-N-benzhydryl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6b 
Removal of Cbz and purification by column chromatography (DCM/MeOH/10% NH3 in CHCl3 
= 87:3:10, Rf =0.4) gave the diphenylmethamide tetrahydroisoquinoline 6b (80 %) as a light 
56 
brown solid.  [α]
20
D = – 105.7 (c = 0.35, CH2Cl2).  IR νmax: 402, 406, 619, 683, 734, 1159, 1219, 
1365, 1451, 1493, 1544, 1640, 2929, 2973 and 3292 cm
–1
.  HRMS calculated for C23H22N2O 
(M+H
+
) = 343.1795 m/z, found 343.1805 m/z. 
1
H NMR (400 MHz, CDCl3): δ 7.97 – 8.10 (m, 
1H), 7.42 – 6.95 (m, 14H), 7.09 – 7.02 (m, 1H), 4.08 – 3.95 (m, 2H), 3.58 – 3.40 (m, 1H), 3.31 – 
3.19 (m, 1H), 2.99 – 2.87 (m, 1H), the NH proton of the amine was not observed in the 
spectrum.  
13
C NMR (101 MHz, CDCl3): δ 172.0, 141.6, 141.5, 129.1–125.3, 56.4, 56.2, 47.1 
and 30.3. 
(S)-1,1-diphenyl-N-((1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)methanamine 2b 
After the reduction of 6b, the crude compound was purified by column chromatography 
(MeOH/Et2O = 5:95, Rf ~ 0.6) to afford the N-diphenylmethanamine amine derivative 2b (21 %) 
as a yellow solid.  [α]
20
D = – 55.77 (c = 0.52, CH2Cl2).  IR νmax: 430, 696, 706, 743, 800, 1027, 
1429, 1447, 1490, 1580, 1595, 2780, 2911, 3289 and 3324 cm
–1
.  Melting point: 89 – 91 °C.  
HRMS calculated for C23H24N2 (M + H
+
) = 329.2012 m/z, found 329.2004 m/z.  
1
H NMR (600 
MHz, CDCl3): δ 7.43 – 6.98 (m, 14H), 4.87 (s, 1H), 4.06 (s, 2H), 3.00 (m, 1H), 2.83 (dd, J = 
11.8 and 3.8 Hz, 1H), 2.73 (dd, J = 16.2 and 3.9 Hz, 1H), 2.64 (dd, J = 11.8 and 8.7 Hz, 1H), 
2.56 (dd, J = 16.2 and 10.8 Hz, 1H), the two NH protons were not observed.  
13
C NMR (151 
MHz, CDCl3): δ 144.2, 143.9, 135.9, 134.5, 129.2, 128.5, 127.3, 127.3, 127.04, 127.02, 126.1, 
126.0, 125.7, 67.7, 53.7, 53.6, 48.3 and 33.4. 
(S)-benzyl 3-(phenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5c 
The resultant product from reaction with aniline was purified by column chromatography 
purified (EtOAc/Hex = 40:60, Rf ~ 0.5) to afford the aniline substituted TIQ derivative 5c (1.54 
g, 83 %) light yellow oil.  [α]
20
D = – 38.10 (c = 0.42, CH2Cl2).  IR νmax: 487, 693, 736, 749, 960, 
1099, 1127, 1184, 1413, 1546, 1665, 1701, 3027 and 3301 cm
-1
.  Melting point: 137 – 139 °C.  
HRMS calculated for C24H22N2O3 (M + H
+
) = 387.1703 m/z, found 387.1689 m/z.  NMR spectra 
are reported for a mixture of two rotamers.  
1
H NMR (400 MHz, DMSO): δ 10.04 (d, J = 5.1 Hz, 
1H), 7.62 – 6.85 (m, 14H), 5.22 – 5.02 (m, 3H), 4.90 – 4.51 (m, 2H), 3.33 – 3.02 (m, 2H).  
13
C 
NMR (101 MHz, DMSO): δ 169.9, 155.3 – 119.2, 66.5, 54.9, 44.8 and 31.8. 
(S)-N-phenyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6c 
Removal of Cbz group the aniline amide TIQ 6c (88%) formed as a white solid, which required 
no further purification. [α]
20
D = – 144.7 (c = 0.38 , CH2Cl2).  IR νmax: 440, 551, 695, 736, 1060, 
1190, 1258, 1364, 1408, 1496, 1597, 1697, 2891, 2927, 2968, 3045 and 3299 cm
-1
.  Melting 
57 
point: 183 – 185 °C. HRMS calculated for C16H16N2O (M + H
+
) = 253.1317 m/z, found 
253.1335 m/z.  
1
H NMR (400 MHz, CDCl3): δ 9.39 (s, 1H), 7.60 (d, J = 7.8 Hz, 2H), 7.33 (t, J = 
7,8 Hz, 2H), 7.01 – 7.25 (m, 5H), 4.05 (d, J = 5.4 Hz, 2H), 3.73 (dd, J = 10.3 and 5.3 Hz, 1H), 
3.37 (dd, J = 16.4 and 5.2 Hz, 1H), 2.95 (dd, J = 16.3 and 10.3 Hz, 1H), the NH proton of the 
amine was not observed. 
13
C NMR (101 MHz, CDCl3): δ 171.1, 137.7, 135.8, 134.3, 129.2, 
129.1, 126.9, 126.4, 125.5, 124.1, 119.4, 56.7, 47.3 and 30.5. 
(S)-N-((1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)aniline 2c 
After reduction of 6c, the crude compound was purified by column chromatography (100 % 
diethyl ether, Rf ~ 0.5), yielding a white solid 2c (57 %). [α]
20
D = – 64.29 (c = 0.14, CH2Cl2).  IR 
νmax: 435, 488, 513, 585, 690, 743, 805, 1258, 1346, 1494, 1600, 2792, 2929, 3218 and 3301 cm
-
1
.  Melting point: 90 – 92 °C.  HRMS calculated for C16H18N2 (M + H
+
) = 239.1543 m/z, found 
239.1543 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.23 – 6.99 (m, 6H), 6.76 – 6.62 (m, 3H), 4.07 
(br s, 2H), 3.36 (d, J = 12.1 Hz, 1H), 3.26 – 3.17 (m, 1H), 3.14 – 3.06 (m, 1H), 2.85 (dd, J = 
16.3 and 4.1 Hz, 1H), 2.66 (dd, J = 16.3 and 10.5 Hz, 1H), the two NH protons were not 
observed.  
13
C NMR (101 MHz, CDCl3): δ 148.4, 135.7, 134.0, 129.3, 129.3, 126.2, 126.0, 
125.9, 117.5, 113.0, 53.0, 49.2, 48.1 and 33.1.  
(S)-benzyl 3-(methylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5d 
The resultant product from the reaction with methylamine was purified by column 
chromatography (EtOAc/Hex = 50:50, Rf ~ 0.4) to afford the methyl substituted TIQ derivative 
5d (1.06 g, 68 %) light yellow oil.  [α]
20
D = – 6.45 (c = 0.62, CH2Cl2).  IR νmax: 495, 616, 696, 
742, 908, 1011, 1120, 1215, 1302, 1323, 1406, 1536, 1655, 1695, 2939, 3031, 3065 and 3314 
cm
-1
.  HRMS calculated for C19H20N2O3 (M + H
+
) = 325.1547 m/z, found 325.1546 m/z.  NMR 
spectra are reported for a mixture of two rotamers.  
1
H NMR (400 MHz, DMSO): δ 7.85 (m, 
1H), 7.58 – 7.08 (m, 9H), 5.36 – 4.98 (m, 2H), 4.86 – 4.28 (m, 2H), 3.22 – 2.89 (m, 2H), 2.60 – 
2.52 (m, 1H), 2.47 (d, 4.66 Hz, 3H).  
13
C NMR (101 MHz, DMSO): δ 170.8, 136.7 - 125.9, 66.4, 
54.1, 44.4, 31.3 and 25.6. 
(S)-N-methyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6d 
Removal of Cbz and purification by column chromatography (DCM/MeOH/10 % NH3 in CHCl3 
= 87:3:10, Rf ~ 0.4) afforded methyl amide TIQ 6d (77 %) as a white solid.  [α]
20
D = – 222.5 (c 
= 0.20 , CH2Cl2).  IR νmax: 399, 435, 515, 609, 674, 738, 797, 963, 1129, 1225, 1413, 1562, 
1643, 2835, 2877, 2940 and 3302 cm
-1
.  Melting point: 84 – 86 °C.  HRMS calculated for 
58 
C11H14N2O (M + H
+
) = 191.1179 m/z, found 191.1183 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.24 
(br s, 1H), 7.19 – 7.11 (m, 3H), 7.03 (m, 1H), 3.99 (d, J = 3.6 Hz, 2H), 3.52 (dd, J = 10.8, 5.1 
Hz, 1H), 3.24 (dd, J = 16.5, 5.1 Hz, 1H), 2.85 (d, J = 5.0 Hz, 3H), 2.80 (dd, J = 16.5 and 10.8 
Hz, 1H), the NH proton of the amine was not observed.  
13
C NMR (101 MHz, CDCl3): δ 173.7, 
135.9, 134.4, 129.2, 126.6, 126.2, 125.5, 56.6, 47.6, 31.0 and 25.8.  
Synthesis of (S)-N-methyl-1-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanamine 2d 
After reduction the crude product 2d was purified by column chromatography (DCM/MeOH/10 
% NH3 in CHCl3 = 87:3:10, Rf ~ 0.4).  However this purification was not sufficient, therefore 
further refinement was achieved by precipitating the compound out as the dihydrochloride salt 
using a solution of HCl gas bubbled in ether, which generated a precipitate when added to the 
compound in DCM.  The precipitated salt was filtered and washed with a 90:10 mixture of 
ether:DCM affording 2d (15 %) a light brown solid.  [α]
20
D = – 1.30 (c = 0.1, MeOH).  IR νmax: 




.  HRMS calculated for C11H16N2 (M 
+ H
+
) = 177.1386 m/z, found 177.1389 m/z.  
1
H NMR (400 MHz, MeOD): δ 7.13 – 7.26 (m, 
4H), 4.42 (s, 2H), 3.98 – 3.89 (m, 1H), 3.46 (dd, J = 13.6, 6.5 Hz, 1H), 3.37 (dd, J = 13.7, 5.6 
Hz, 1H), 3.24 (d, J = 4.7 Hz, 1H), 3.03 (dd, J = 17.1, 11.0 Hz, 1H) and 2.76 (s, 3H), the two NH 
protons were not observed in the spectra.  
13
C NMR (101 MHz, MeOD): δ 130.9, 130.2, 129.5, 
128.7, 128.4, 127.7, 51.8, 51.2, 46.0, 34.4, 30.4. 
(S)-benzyl 3-(isopropylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5e 
The resultant product from the reaction with isopropyl amine was purified by column 
chromatography (EtOAc/Hex = 50:50, Rf ~ 0.45) to afford the 5e (1.43 g, 85 %) as a beige 
powder.  [α]
20
D = – 3.44 (c = 0.58, THF).  IR νmax: 695, 733, 749, 1124, 1212, 1311, 1408, 1546, 
1644, 1701, 2970 and 3299 cm
-1
.  Melting point: 95 – 97 °C.  HRMS calculated for C21H24N2O3 
(M + H
+
) = 353.1860 m/z, found 353.1860 m/z.  NMR spectra are reported for a mixture of two 
rotamers.  
1
H NMR (400 MHz, DMSO): δ 7.69 (m, 1H), 7.53 – 7.01 (m, 9H), 5.33 – 4.84 (m, 
2H), 4.78 – 4.35 (m, 3 H), 3.72 (m, 1 H), 3.21 – 2.81 (m, 2 H), 0.99 – 0.82 (m, 6 H).  
13
C NMR 
(101 MHz, DMSO): δ 169.6, 155.2 – 125.8, 67.0, 55.2, 44.6, 40.5, 31.8 and 22.1. 
(S)-N-isopropyl-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6e 
Removal of Cbz and purification by column chromatography (DCM/MeOH/10 % NH3 in CHCl3 
= 87:3:10, Rf ~ 0.5) afforded the isopropyl amide TIQ 6e (92 %) as a white solid.  [α]
20
D = – 






.  Melting point: 87 – 89 °C.  HRMS calculated for C13H18N2O 
(M + H
+
) = 219.1492 m/z, found 219.1501 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.12 – 7.19 (m, 
3H), 7.08 – 6.93 (m, 2H), 4.10 (m, 1H), 4.00 (d, J = 4.1 Hz, 2H), 3.50 (dd, J = 10.7 and 5.0 Hz, 
1H), 3.24 (dd, J = 16.5 and 5.0 Hz, 1H), 2.80 (dd, J = 16.5 and 10.7 Hz, 1H), 1.19 (d, J = 6.6 
Hz, 3H), 1.16 (d, J = 6.5 Hz, 3H), the NH proton of the amine was not observed.  
13
C NMR (101 
MHz, CDCl3): δ 172.1, 135.8, 134.4, 129.2, 126.6, 126.1, 125.5, 56.6, 47.7, 40.8, 31.1, 22.8, 
22.7. 
(S)-N-((1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)propan-2-amine 2e 
After reduction of 6e, the crude compound was purified by column chromatography 
(EtOAc:MeOH = 95:5, Rf ~ 0.5), yielding an off white solid 2e (46 %).  [α]
20
D = – 8.33 (c = 
0.12, CH2Cl2).  IR νmax: 695, 729, 1118, 1216, 1302, 1322, 1400, 1650, 1680, 3029 and 3331 
cm
-1
.  Melting point: 39 – 41 °C.  HRMS calculated for C13H20N2 (M + H
+
) = 205.1699 m/z, 
found 205.1708 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.15 – 6.99 (m, 4H), 4.05 (s, 2H), 3.02 – 
2.90 (m, 1H), 2.71 – 2.87 (m, 3H), 2.60 – 2.52 (m, 2H), 1.09 (overlapping-d, J = 6.5 Hz, 6H), 
the two NH protons were not observed.  
13
C NMR (101 MHz, CDCl3) δ = 136.0, 134.5, 129.2, 
126.0, 126.0, 25.7, 53.9, 52.9, 49.0, 48.3, 33.5, 23.1 and 23.0. 
(S)-benzyl 3-((R)-1-phenylethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5f 
The resultant product from the reaction with (R)-1-phenylethanamine was purified by column 
chromatography (EtOAc/Hex = 50:50, Rf ~ 0.4) to afford the (R)-1-phenylethanamine 
substituted TIQ derivative 5f (1.55 g, 78%) as a light yellow oil. [α]
20
D = + 10.68 (c = 1.03, 
CH2Cl2).  IR νmax: 491, 599, 696, 740, 905, 1001, 1093, 1119, 1214, 1302, 1322, 1347, 1400, 
1448, 1522, 1638, 1697, 2932, 3029, 3062 and 3315 cm
-1
.  HRMS calculated for C26H26N2O3 
(M + H
+
) = 415.2016 m/z, found 415.1998 m/z.  NMR spectra are reported for a mixture of two 
rotamers.  
1
H NMR = (400 MHz, DMSO): δ 8.24 (m, 1H), 7.53 – 6.91 (m, 14H), 5.32 – 4.96 (m, 
2H), 4.93 – 4.41 (m, 4H), 3.20 – 3.02 (m, 2H), 1.25 (d, J = 7.07 Hz, 3H).  
13
C NMR (101 MHz, 
DMSO): δ 170.1, 144.1 – 125.6, 66.4, 54.4, 47.5, 44.7, 32.0 and 22.0. 
(S)-N-((R)-1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6f 
Removal of Cbz and purification by column chromatography (Et2O:Acetone = 80:20, Rf ~ 0.5) 
gave the (R)-1-phenylethanamide TIQ 6f (72 %) as a white solid.  [α]
20
D = – 33.82 (c = 0.34, 
CH2Cl2).  IR νmax: 430, 583, 617, 695, 733, 748, 790, 803, 1180, 1221, 1446, 1492, 1544, 1643, 
2838, 2926 and 3284 cm
-1




) = 281.1648 m/z, found 281.1645 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.52 (d, J = 8.0 Hz, 
1H), 7.34 – 7.27 (m, 2H), 7.26 – 7.20 (m, 3H), 7.20 – 7.12 (m, 3H), 7.04 (m, 1H), 5.14 (m, 1H), 
3.99 (d, J = 11.82 Hz, 2H), 3.59 (dd, J = 10.2 and 5.2 Hz, 1H), 3.23 (dd, J = 16.4 and 5.2 Hz, 
1H), 2.82 (dd, J = 16.4 and 10.2 Hz, 1H), 1.51 (d, J = 6.9 Hz, 3H), the NH proton of the amine 
was not observed.  
13
C NMR (101 MHz, CDCl3): δ 172.2, 143.3, 135.9, 134.4, 129.2, 128.6, 
127.2, 126.6, 126.2, 126.0, 125.5, 56.4, 48.1, 47.6, 31.0 and 22.0. 
(R)-1-phenyl-N-(((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)ethanamine 2f 
After reduction of 6f, the crude compound was purified by column chromatography 
(DCM/MeOH/10 % NH3 in CHCl3 = 87:4:10, Rf ~ 0.5) to yield 2f (30%), a light yellow oil. 
[α]
20
D = – 43.55 (c = 0.93, CH2Cl2).  IR νmax: 431, 543, 695, 783, 1118, 1451, 1492, 2789, 2918, 
2960, 3026 and 3240.  HRMS calculated for C18H22N2 (M + H
+
) = 267.1856 m/z, found 
267.1846 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.33 – 7.29 (m, 4H), 7.21 (m, 1H), 7.10 – 7.05 
(m, 2H), 7.03 – 6.96 (m, 2H), 3.96 (d, J = 16.78 Hz, 2H), 3.74 (m, 1H), 2.82 (m, 1H), 2.66 – 
2.61 (m, 2H), 2.51 – 2.42 (m, 2H), 1.37 (d, J = 6.7, 3H), the two NH protons were not observed.  
13
C NMR (101 MHz, CDCl3): δ 145.6, 135.9, 134.5, 129.2, 128.4, 126.9, 126.5, 126.0, 126.0, 
125.6, 58.2, 53.7, 52.8, 48.3, 33.3 and 24.6. 
(S)-benzyl 3-((S)-1-phenylethylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 5g 
The resultant product from reaction with (S)-1-phenylethanamine was purified by column 
chromatography (EtOAc/Hex = 50:50, Rf ~ 0.4) to afford the (S)-1-phenylethanamine 
substituted TIQ derivative 5g (1.77 g, 89 %) light yellow oil.  [α]
20
D = – 21.43 (c = 0.70, 
CH2Cl2).  IR νmax: 696, 738, 1059, 1119, 1213, 1303, 1329, 1407, 1449, 1495, 1534, 1656, 1697, 
2972, 3029, 3062 and 3299 cm
-1
.  HRMS calculated for C26H26N2O3 (M + H
+
) = 415.2016 m/z, 
found 415.2009 m/z.  NMR spectra are reported for a mixture of two rotamers.  
1
H NMR (400 
MHz, DMSO): δ 8.29 (m, 1H), 7.49 – 6.91 (m, 14H), 5.22 – 4.99 (m, 2H), 4.86 – 4.41 (m, 4H), 
3.23 – 2.97 (m, 2H), 1.30 – 1.13 (m, 3H).  
13
C NMR (101 MHz, DMSO): δ 169.9, 154.9 – 125.5, 
66.3, 54.1, 47.5, 44.7, 31.8, 22.1. 
Synthesis of (S)-N-((S)-1-phenylethyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide 6g 
Removal of Cbz and purification by column chromatography (Et2O:Acetone = 80:20, Rf ~ 0.5) 
afforded the (S)-1-phenylethanamide TIQ 6g (76%) as a cream/beige solid. [α]
20
D = – 100.7 (c = 
0.36, CH2Cl2).  IR νmax: 428, 449, 525, 551, 609, 643, 697, 734, 750, 780, 1077, 1137, 1225, 
1248, 1493, 1533, 1646, 2926, 2966 and 3333 cm
-1
.  Melting point: 119 – 121 °C.  HRMS 
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calculated for C18H20N2O (M + H
+
) = 281.1648 m/z, found 281.1644 m/z.  
1
H NMR (400 MHz, 
CDCl3): δ 7.48 (m, 1H), 7.38 – 7.11 (m, 8H), 7.04 (m, 1H), 5.13(m, 1H), 3.99 (s, 2H), 3.53 (dd, 
J = 10.5, 5.1 Hz, 1H), 3.23 (dd, J = 16.5, 5.1 Hz, 1H), 2.85 (dd, J = 16.4, 10.5 Hz, 1H), 1.48 (d, 
J = 6.9 Hz, 3H), NH proton of the amine was not observed.  
13
C NMR (101 MHz, CDCl3): δ 
172.1, 143.3, 135.7, 134.3, 129.2, 128.7, 128.5, 127.3, 126.6, 126.2, 125.5, 56.5, 48.3, 47.5, 31.0 
and 22.0. 
(S)-1-phenyl-N-(((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)ethanamine 2g 
After reduction of 6g, the crude compound was purified by column chromatography 
(DCM/MeOH/10 % NH3 in CHCl3 = 87:4:10, Rf ~ 0.5) to yield 2g (35 %), a light yellow oil, 
which was then also stored as the dihydrochloride salt. [α]
20
D = – 43.55 (c = 0.93, CH2Cl2).  IR 
νmax: 431, 543, 695, 783, 1118, 1451, 1492, 2789, 2918, 2960, 3026 and 3240 cm
-1
.  HRMS 
calculated for C18H22N2 (M + H
+
) = 267.1856 m/z, found 267.1846 m/z.  
1
H NMR (400 MHz, 
MeOD): δ 7.58 – 7.10 (m, 9H), 4.52 – 4.31 (m, 3H), 3.87 (m, 1H), 3.49 (m, 1H), 3.19 – 3.01 (m, 
3H), 1.71 (d, J = 6.7, 3H).  
13
C NMR (101 MHz, MeOD): δ 137.1, 131.0, 130.6, 130.1, 129.4, 
129.0, 128.7, 128.6, 128.3, 127.7, 61.3, 52.5, 48.5, 46.0, 30.6 and 19.5. 
(1R,3S)-benzyl 3-(hydroxymethyl)-6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-
carboxylate 10 
Compound 9 (1 g, 3.3 mmol) was protected with a Cbz group, under the conditions described in 
the general procedure to afford 10 (1.31 g, 91 %), a light yellow oil after column 
chromatography (EtOAc/Hex = 60:40, Rf ~ 0.5).  [α]
20
D = + 40.38 (c = 0.26, CH2Cl2).  IR νmax: 
697, 1088, 1220, 1285, 1337, 1404, 1516, 1638, 1688, 2247, 3301 and 3553 cm
-1
.  HRMS 
calculated for C26H27NO5 (M + H
+
) = 434.1928 m/z, found 434.1962 m/z.  NMR spectra are 
reported for a mixture of two rotamers.  
1
H NMR (400 MHz, CDCl3): δ 7.43 – 6.92 (m, 10H), 
6.78 (s, 1H), 6.66 (s, 1H), 6.01 (s, 1H), 5.38 – 4.87 (m, 2H), 4.47 (m, 1H), 3.86 (s, 3H), 3.83 (s, 
3H), 3.63 (m, 1H), 3.34 (m, 1H), 3.02 – 2.89 (m, 2H).  
13
C NMR (101 MHz, CDCl3): δ 148.4 – 
125.3, 112.0, 110.7, 67.5, 64.4, 59.8, 56.1, 55.9, 54.7 and 29.4. 
(1R,3S)-benzyl 3-formyl-6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-2(1H)-
carboxylate 11 
Oxidation of 10 (0.8 g, 1.8 mmol) with PCC (3 equiv.) and anhydrous MgSO4 (3 equiv.) in dry 
DCM
34
 gave 11 (0.45 g, 57 %) as a yellow oil after treatment with wet diethylether and filtration 
through a small plug of silica gel to remove excess PCC and other metal species.  [α]
20
D = + 
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41.46 (c = 0.41, CH2Cl2).  IR νmax: 594, 697, 737, 994, 1028, 1092, 1221, 1264, 1339, 1397, 
1513, 1692, 2838 and 2924 cm
-1
.  HRMS calculated for C26H25NO5 (M + Na
+
) = 454.1625 m/z, 
found 454.1606 m/z.  NMR spectra are reported for a mixture of two rotamers.  
1
H NMR (400 
MHz, CDCl3): δ 9.38 (m, 1H), 7.65 – 7.02 (m, 10H), 6.96 – 5.90 (m, 3H), 5.38 – 4.84 (m, 2H), 
4.59 (m, 1H), 3.95 – 3.75 (m, 6H), 3.24 – 2.80 (m, 2H).  
13
C NMR (101 MHz, CDCl3): δ 148.5 – 
126.0, 110.7, 67.5, 60.6, 56.0, 55.9 and 29.7. 
(1R,3S)-benzyl 3-((benzylamino)methyl)-6,7-dimethoxy-1-phenyl-3,4-dihydroisoquinoline-
2(1H)-carboxylate 12 
To a 50 % mixture of dry THF in MeOH (6 mL) was added compound 11 (0.3 g, 0.6 mmol), 
followed by benzyl amine (0.23 g, 2.0 mmol) and the mixture was allowed to stir at room 
temperature for 3 h.  The reaction mixture was then cooled to 0 °C with an ice bath, followed by 
slow addition of NaCNBH3 (~ 0.3 g) and stirred for 30 minutes at 0 °C, and a further 30 minutes 
at RT.  Water was added to the reaction and the resultant mixture was extracted three times with 
DCM.  The crude product was purified by column chromatography (EtOAc/Hex = 70:30, Rf ~ 
0.7) to afford 12 (0.21 g, 60%) yellow oil.  [α]
20
D = + 27.27 (c = 0.44, CH2Cl2).  IR νmax: 593, 
697, 736, 999, 1028, 1092, 1219, 1338, 1397, 1452, 1514, 1689, 2931 and 3028 cm
-1
.  HRMS 
calculated for C33H34N2O4 (M + H
+
) = 523.2591 m/z, found 523.2579 m/z.  NMR spectra are 
reported for a mixture of two rotamers.  
1
H NMR (400 MHz, CDCl3): δ 7.41 – 7.10 (m, 15H), 
6.78 (s, 1H), 6.59 (s, 1H), 5.99 (s, 1H), 5.26 – 4.91 (m, 2H), 4.46 (m, 1H), 3.97 – 3.56 (m, 9H), 
3.08 – 2.68 (m, 3H), NH proton of the amine was not observed.  
13
C NMR (101 MHz, CDCl3): δ 
128.3 – 126.0, 112.2, 110.8, 77.3 – 77.0, 76.6, 67.5, 60.3, 56.1 – 55.9, 53.5, 30.1 and 29.6. 
N-benzyl-1-((1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-
yl)methanamine 2i 
Compound 12 (0.1 g, 0.19 mmol) was treated with palladium on carbon as mentioned in the 
general procedure, to remove the Cbz group.  The reaction was monitored carefully to avoid 
removal of the benzyl group.  Purification by column chromatography (DCM/MeOH/10% NH3 
in CHCl3 = 87:3:10, Rf ~ 0.5) yielded 2i (0.038 g, 52%) as a white oil.  [α]
20
D = – 26.83 (c = 
0.41, CH2Cl2).  IR νmax: 573, 699, 753, 819, 1057, 1127, 1224, 1293, 1449, 1519, 1609, 2832, 
2920, 2994 and 3060 cm
-1
.  HRMS calculated for C25H28N2O2 (M + H
+
) = 389.2224 m/z, found 
389.2224 m/z.  
1
H NMR (400 MHz, CDCl3): δ 7.38 – 7.13 (m, 10H), 6.63 (s, 1H), 6.41 (s, 1H), 
5.10 (s, 1H), 3.86 (s, 3H), 3.70 (s, 3H), 3.50 (s, 2H), 3.02 (m, 1H), 2.74 – 2.67 (m, 2H), 2.59 – 
2.47 (m, 2H), the two NH protons were not observed.  
13
C NMR (101 MHz, CDCl3): δ 147.8, 
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147.1, 145.3, 140.3, 128.5, 128.34, 128.33, 128.32, 128.1, 128.10, 126.9, 126.8, 111.4, 111.0, 
59.3, 55.89, 55.83, 53.8, 53.4, 46.2 and 33.1. 
(S)-benzyl 3-carbamoyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 13 
Compound 8 (0.4 g, 2.2 mmol) was protected with a Cbz group, under the conditions described 
in the general procedure to afford 13 (0.63 g, 89%), a colourless oil after column 
chromatography (EtOAc/Hex = 20:80, Rf ~ 0.5).  [α]
20
D = – 2.26 (c = 0.59, CH2Cl2).  IR νmax: 
427, 593, 675, 697, 740, 908, 983, 1027, 1038, 1091, 1119, 1216, 1348, 1403, 1496, 1605, 1661, 
2158, 2586, 2882 and 3179 cm
-1
.  HRMS calculated for C18H18N2O3 (M + Na
+
) = 333.1210 m/z, 
found 333.1211 m/z. (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR (400 
MHz, CDCl3): δ 7.50 – 7.00 (m, 9H), 5.29 – 4.86 (m, 3H), 4.84 – 4.50 (m, 2H), 3.37 – 3.02 (m, 
2H), the amide protons were not observed.  
13
C NMR (101 MHz, CDCl3): δ 156.1, 136.6, 132.5, 
129.0, 128.5, 128.5, 128.0, 127.9, 126.7, 126.3, 126.0, 67.3, 52.5, 43.3, 43.1 and 30.7. 
(S)-benzyl 3-(aminomethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 14 
To a solution of 13 (0.5 g, 1.5 mmol) in dioxane (3 mL) was added NaBH4 (0.17 g, 4.5 mmol).  
The mixture was then cooled to 0 °C and acetic acid (0.18 g, 4.5 mmol) was added dropwise, 
after addition the reaction was set to reflux for 48 hours to yield 14 as yellow oil.
35
  Due to 
problems with stability problems, the crude product 14 (0.07 g, 15 % in ~ 90 % purity) was 
carried forward without further purification.  [α]
20
D = – 15.0 (c = 0.16, CH2Cl2).  IR νmax: 426, 
495, 548, 565, 658, 705, 746, 810, 850, 880, 1071, 1093, 1154, 1314, 1450, 1494, 1598, 1722, 
2853, 2922, 3031 and 3288 cm
-1
.  HRMS calculated for C18H20N2O2 (M + H
+
) = 297.1595 m/z, 
found 297.1598 m/z. (NMR spectra are reported for a mixture of two rotamers). 
1
H NMR (400 
MHz, CDCl3): δ 7.46 – 7.24 (m, 5H), 7.23 – 6.98 (m, 4H), 5.26 – 5.10 (m, 2H), 4.89 (m, 1H), 
4.59 – 4.25 (m, 2H), 3.06 (m, 1H), 2.77 (m, 1H), 2.70 (dd, J = 13.24, 7.94 Hz, 1H), 2.59 (m, 
1H).  
13
C NMR (101 MHz, CDCl3): δ 156.1, 136.6, 132.5, 129.0, 128.5, 128.5, 128.0, 127.9, 
126.7, 126.3, 126.0, 67.3, 52.5, 43.3, 43.1 and 30.7. 
(S)-4-methyl-N-((1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)benzenesulfonamide 2j 
Compound 14 (0.06 g, 0.2 mmol) was first treated with TsCl (0.042 g, 0.2 mmol) and TEA 
(0.045 g, 0.45 mmol) in CH2Cl2 (1.5 mL) for 12 hours at room temperature.  Water was then 
added, and the organic layer washed with diluted HCl and then saturated sodium carbonate.  The 
resulting oil was dried and the deprotection of the Cbz group was carried out as described in the 
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general procedure.  The crude oil was purified by column chromatography (EtOH:Toluene, 
20:80 Rf ~ 0.7) to yield 2j (0.038 g, 60%) as a pale yellow oil:  [α]
20
D = – 13.82 (c = 0.17, 
CH2Cl2).  HRMS calculated for C17H20N2O2S (M + H
+
) = 317.1339 m/z, found 317.1318 m/z.  
IR νmax: 430, 457, 594, 696, 735, 808, 912, 1020, 1095, 1117, 1217, 1249, 1320, 1418, 1495, 




H NMR (400 MHz, CDCl3): δ 7.76 (d, J = 8.13 Hz, 2H), 7.30 
(d, J = 8.75 Hz, 2H), 7.14 – 6.96 (m, 4H), 3.94 (d, J = 4.66 Hz, 2H), 3.19 (dd, J = 3.86, 12.66 
Hz, 1H), 3.00 (m, 1H), 2.84 (dd, J = 8.99, 12.65 Hz, 1H), 2.71 (dd, J = 4.43, 16.27 Hz, 1H), 2.49 
(dd, J = 10.86, 16.83 Hz, 1H), 2.41 (s, 3H), The NH protons were not observed.  
13
C NMR (101 
MHz, CDCl3): δ 143.4, 136.8, 135.1, 133.3, 129.8, 129.2, 127.2, 126.4, 126.1, 125.1, 68.3, 52.7, 
47.4, 32.2 and 21.5. 
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ABSTRACT 
A novel family of tetrahydroisoquinoline (TIQ) phosphine-oxazoline ligands and four 
corresponding iridium complexes have been developed and applied to the asymmetric 
hydrogenation of unfunctionalised olefins.  The results showed that the best conversion rates 
were observed up to 99 % with an enantioselectivity of 91 %.  
INTRODUCTION 
The enantioselective hydrogenation of olefins represents an important process for obtaining 
optically pure biologically active compounds.
1-3
  The discovery of the Wilkinson catalyst 
(RhCl[P(C6H5)3]3) possessing chiral phosphine ligands for the hydrogenation of olefins sparked 
the development of other chiral ligands in this field.
4-6
  Early ligands were coordinated with 
ruthenium- and rhodium metals and applied to the asymmetric hydrogenation of olefins.
6
  There 
have been many reports more recently describing the use of chiral N,P ligands and Ir-catalyzed 
hydrogenations of olefins.
7-8
  The first chiral mimic of the Crabtree complex
9
 was reported by 
Pfaltz and co-workers,
10
 and was successfully used in asymmetric hydrogenation of olefins.  
Amongst the nitrogen donor ligands, oxazoline has become one of the most popular moieties in 
asymmetric catalysis (Figure 1).
7,11-14
  Andersson et al. have developed chiral iridium catalysts 
for a wide range of substrates.
15-16
  In particular, derivatives of the bicyclic phosphene-
oxazoline 1 are among the most successful and have produced excellent results in the 
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 and vinyl boronates.
19
  
The asymmetric hydrogenation of unfunctionalised olefins remains a challenge due to substrate 
dependence, and the development of new catalysts targeting this class of substrate is 
imperative.
20 
Recently, we have reported on the synthesis and evaluation of several novel classes of chiral 
tetrahydroisoquinoline (TIQ) ligands.
21-23
  Their metal complexes have been employed for 
asymmetric transfer hydrogenation
21-22
 and Henry type reactions.  Previous reports described 
the application of N,P derived TIQ oxazoline ligands for asymmetric C–C bond forming 
reactions.
24-26
  In this paper, we report a new class of iridium phosphine-oxazoline catalysts for 









1 2 3  
Figure 1. Previously reported P,N oxazoline ligands 
RESULTS AND DISCUSSIONS 
The first alternate route to that employed by Blanc et al. for the synthesis of the TIQ phosphine-
oxazoline ligands is described in this report, whereby the diphenyl phosphine is introduced after 
the formation of the oxazoline (Scheme 1).  The TIQ carboxylic acid is easily available from a 
Pictet-Spengler reaction of L-phenyl alanine.
27
  The amine was protected with benzyl 
chloroformate (Cbz) to give TIQ-Cbz acid 4
27
 followed by amide coupling with the appropriate 
L- and D-amino alcohols leading to hydroxylamides 5-8.
17
  The compounds were subsequently 
converted into five membered oxazoline rings 9-12 with triphenyl phosphine and diethyl 
azodicarboxylate (DEAD) by the Mitsunobu reaction in good yields.
28
  The cleavage of the Cbz 
group was accomplished by hydrogenolysis using palladium on carbon as a catalyst to yield the 
amines 13-16.  The ligands 17-20 were obtained by treating these amines with 
diphenylphosphine chloride in the presence of diisopropylethylamine.
17
  Due to compound 
instability upon addition of the phosphine onto the sp
3
 nitrogen of the TIQ oxazolines, the 




H NMR spectroscopy.  Iridium 
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complexes 21-24 were prepared by refluxing the appropriate phosphine-oxazoline ligands and 
[Ir(COD)Cl]2 in CH2Cl2 followed by counter-ion exchange with sodium tetrakis[(3,5-
trifluoromethyl)phenyl]borate (NaBArF) in a CH2Cl2/H2O mixture with vigorous stirring.  The 
crude complexes were purified by column chromatography on silica gel deactivated by 





















5 R1 = Ph, R2 = H
6 R1 = H, R2 = Ph
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21 R1 = Ph, R2 = H
22 R1 = H, R2 = Ph
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Scheme 1. Reagents for the synthesis of iridium complexes 21-24 (i) EDC.HCl, HOBt, 
Triethylamine, amino alcohol, THF, H2O, rt, 16 hrs; (ii) PPh3, DEAD, dichloromethane, 0 °C-rt, 
3 hrs; (iii) 10 % Pd/C wt. H2 (1 atm), MeOH, rt, 1 hr; (iv) PPh2Cl, DIPEA, dichloromethane, rt, 
16 hrs; (v) [Ir(COD)Cl]2, dichloromethane, reflux 1 hr then H2O, NaBArF.3H2O, rt, 2 hrs; 
69 
LIGAND ACTIVITY 
In the first set of experiments, we used the Ir-catalyzed hydrogenation of (3,3-dimethylbut-1-en-
2-yl) benzene 25 as the benchmark reaction for the catalysts 21-24.  The reaction was performed 
in dichloromethane with a catalyst loading of 0.5 mol % under a pressure of 50 bar of hydrogen 
gas.  Good conversion rates were observed up to >99 % using the catalysts 21-24 for the 
benchmark reaction with variable enantioselectivities (table 1).  The best enantioselectivity was 
obtained for catalysts 22 and 23 with 88 % for the (S) isomer and 91 % for the (R) isomer 
respectively (entries 2 and 3, table 1).  The enantioselectivity of the reaction was observed to be 
dependent on the chirality of the oxazoline ring. 













1 21 99 79 (R) 
2 22 99 88 (S) 
3 23 99 91 (R) 
4 24 99 72 (S) 
aAll reactions were carried out at 50 bar H2 in DCM at RT for 2 hours with 0.5 mol % S/C loading. 
bConversions 




Enantiomeric excess was determined using HPLC with a chiral column and by GC 
using a β-dex chiral capillary column. 
The results obtained from the Ir-complexes 22 and 23, encouraged us to screen a wider range of 
olefins.  Most substrates were hydrogenated with high conversions and moderate selectivities 
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27  
99 40 (S) 99 67 (R) 
3 
28  
99 63 (S) 99 48 (R) 
4 
29  
99 41 (S) 99 71 (R) 
5 
30  
99 46 (S) 99 73 (R) 
6 
31  




99 6 (S) 99 48 (R) 
8 
33  
99 16 (S) 99 51 (R) 
9 
34  





27 47 (S) 41 racemic 
a
All reactions were carried out at 50 bar H2 in DCM at RT for 2 hours with 0.5 mol % S/C loading. 
b
Conversions 




Enantiomeric excess was determined using HPLC with a chiral column and by GC 
using a β-dex chiral capillary column. 
Considerable differences were observed for hydrogenations of the cyclic and acyclic olefins.  No 
activity was observed for the propene substrate (table 2, entry 1) but >99 % conversion for the 
butene and pentene analogs was achieved (table 2, entries 2-5).  An increase in bulk did not 
result in a difference in conversion but did give higher enantioselectivities.  This effect was 
more profound for the butene derivatives and presumably this can be attributed to the increased 
steric crowding closer to the pro-chiral center.  The exocyclic olefins (table 2, entries 6 and 7) 
and an internal cyclic olefin (table 2, entry 8) gave quantitative conversions but essentially 
racemic mixtures.  Poor conversions and selectivities were observed for activated branched 
olefins (table 2, entries 9 and 10). 
CONCLUSION 
We have developed TIQ phosphine-oxazoline iridium complexes for asymmetric hydrogenation 
of olefins.  The best results obtained in this study were with 99 % conversions and 
enantioselectivities of up to 91 % in 2 hours with 0.5 mol % catalyst loading.  The variation in 
72 
results clearly supports other reports of the substrate dependence for this important class of 
olefins and encourages further investigations. 
EXPERIMENTAL 
GENERAL 
Reagents and solvents were purchased from Aldrich, Merck and Fluka.  All NMR spectra were 
recorded on Bruker AVANCE III 400 MHz or 600 MHz instruments at room temperature.  
Chemical shifts are expressed in ppm downfield from TMS as an internal standard, and coupling 
constants are reported in Hz.  Thin layer chromatography (TLC) was performed using Merck 
Kieselgel 60 F254.  Crude compounds were purified with column chromatography using Silica 
gel (60–200 mesh except if stated differently).  All solvents were dried using standard 
procedures. All IR spectra were recorded on a Perkin Elmer spectrum 100 instrument with a 
universal ATR attachment.  Optical rotations were recorded on a Perkin-Elmer Polarimeter 
(Model 341).  All melting points are uncorrected.  High resolution mass spectrometric data was 
obtained using a Bruker micrOTOF-Q II instrument operating at ambient temperatures, and a 
sample concentration of approximately 1 ppm. 
General procedure for preparation hydroxylamides 5, 6, 7 and 8 
This method was adapted from literature.
14
  To a round bottom flask was added Cbz-protected 
TIQ acid 4 (2.0 g, 0.04 mol), the amino alcohol (1.1 equiv.) and HOBt (2.0 equiv.) in THF (60 
mL).  The mixture was cooled to 0 ºC followed by the addition of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (2.0 equiv.) and triethylamine (3.0 equiv.) and allowed to 
react at ambient temperature for 16 hours.  Completion of the reaction was monitored by TLC 
using dichloromethane/methanol (98:2, Rf = 0.4).  The solvent was evaporated, and the residue 
was dissolved in ethyl acetate (50 mL). The organic layer was washed with 10 % HCl (10 mL) 
followed by saturated NaHCO3 (10 mL).  The organic phase was dried over anhydrous MgSO4 
and evaporated to give crude hydroxylamide, which was purified by column chromatography 
using 0-2% MeOH/CH2Cl2 as the eluent to yield pure compounds 5, 6, 7 and 8. 
General procedure for preparation of protected oxazolines 9, 10, 11 and 12 
This method was adapted from literature.
28
  To a stirred solution of Cbz-protected TIQ-
hydroxylamide (1.0 g) in dry dichloromethane (60 mL) was added triphenylphosphine (2.0 
equiv.) at room temperature under N2 atm.  The reaction mixture was cooled to 0 °C and to this 
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was added a solution of diethyl azodicarboxylate (2.2 equiv.) in dry dichloromethane (20 mL) 
drop-wise over a period of 20 min and the resulting mixture was stirred for 4 h under a N2 
atmosphere.  After completion of the reaction, the mixture was diluted with dichloromethane (10 
mL), washed with water (2 × 10 mL), dried over anhydrous MgSO4 and concentrated under 
reduced pressure to yield the crude product, which was purified by column chromatography 
using (EtOAc/hexane, 50:50) as the eluent to yield pure compounds 9, 10, 11 and 12. 
General deprotection procedure for preparation of TIQ-oxazolines 13, 14, 15 and 16 
This method was adapted from literature.
14
  A solution of Cbz-protected TIQ–oxazoline (1.0 g) 
in methanol (30 mL) was added to a suspension of 10 wt.-% Pd/C (0.5 g) in methanol (10 mL).  
The reaction mixture was connected to a hydrogen source at one atm. and stirred at room 
temperature for 2 h.  Completion of the reaction was monitored by TLC using hexane/ethyl 
acetate (50:50, Rf = 0.5).  The Pd/C was filtered off on a Celite pad, and the filtrate was 
concentrated under reduced pressure to afford the crude TIQ-oxazoline ligand.  The crude 
compounds were purified on a deactivated silica gel column.  The deactivation was done as 
follows: the column was packed with a suspension of silica gel in 20 % Et3N/CH2Cl2 and the 
silica was washed with 1 % Et3N/CH2Cl2.  The chromatography was performed using 0–2 % 
MeOH : 1 % Et3N : 99–97 % CH2Cl2 as the eluent to afford pure oxazoline compounds 13, 14, 
15 and 16. 
General procedures for preparation of ligands 17, 18, 19 and 20 
This method was adapted from literature.
20
  The TIQ-oxazoline was co-evaporated with dry 
toluene (3 × 20 mL) and dissolved in dry THF (6 mL) under a N2 atmosphere.  Freshly distilled 
di-isopropylethylamine was added and the solution was cooled to 0 ºC in an ice-bath.  Freshly 
distilled chlorodiphenylphosphene was added dropwise and the reaction was kept at 4 ºC 
(fridge) overnight.  The reaction was quenched with saturated NaHCO3 (20 mL) under a N2 
atmosphere at room temperature, the aqueous phase was extracted with CH2Cl2 (3 × 15 mL) and 
the combined organic layers were dried over anhydrous Na2SO4 and the crude product was 
purified by column chromatography using deactivated silica gel with Et3N: CH2Cl2: pentane as 
the eluent to afford ligands 17, 18, 19 and 20. 
General procedure for preparation of iridium complexes 21-24 
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The ligand and [Ir(COD)Cl]2 (0.5 equiv.) was dissolved in CH2Cl2 (2 mL) under a N2 
atmosphere and the mixture was refluxed for 1 h.  After the solution was allowed to cool to 
room temperature, distilled water was added and whilst vigorously stirring, NaBArF.3H2O was 
added to the reaction mixture in one portion and reacted for 1 h at ambient temperature.  The 
complex was extracted with CH2Cl2 (2 × 10 mL) and the combined organic phases were dried 
over anhydrous Na2SO4.  Evaporation of the solvent produced the crude complex and 
purification by column chromatography on silica gel with CH2Cl2: pentane (1:1) as the eluent 
afforded the metal complexes 21-24. 
General procedure for iridium-catalyzed asymmetric hydrogenation of olefins  
A vial was charged with substrate and the iridium complex in dry CH2Cl2 (2 mL).  The reaction 
vessel was placed in a high-pressure hydrogenation apparatus and flushed with hydrogen gas 
three times before the pressure was adjusted to 50 bar.  The mixture was stirred for 2 h, the 
pressure released and the solvent removed under vacuum.  Conversion was determined by 
1
H 
NMR analysis of the crude product.  The residue was filtered through a short pad of silica gel 
with pentane: diethyl ether (1:1) as the eluent.  After the solvent was removed, the enantiomeric 






















Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2);  Off white solid (2.2 g, yield 80 %);  m.p: 133−135 ºC 
(CH2Cl2);  [α]D
20
 = –26.19 (c 0.42 in CH2Cl2);  (NMR spectra are reported for a mixture of two 
rotamers). 
1
H NMR (400 MHz, CDCl3): δ 7.50 − 6.89 (m, 13H), 6.40 (m, 1H), 5.31 − 5.08 (m, 
2H), 4.99 − 4.50 (m, 4H), 3.72 − 3.27 (m, 3H), 3.11 (m, 1H);  13C NMR (100 MHz, CDCl3): δ 
128.7, 128.6, 128.3, 128.0, 127.7, 127.2, 126.4, 126.0, 67.9, 65.9, 55.6, 45.2; IR νmax/cm
-1
 (neat): 
3230, 3063, 1702, 1647, 1336, 1308, 1231, 740, 691, 534;  HR ESI MS: m/z = 431.1940 [M+ H] 
+




Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2);  Off white solid (2.0 g, yield 74 %);  m.p: 120−122 ºC;  [α]D
20
 
= +10.71 (c 0.70 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).
1
H 
NMR (400 MHz, CDCl3): δ 7.54 − 7.02 (m, 11H), 6.85 − 6.32 (m, 3H), 5.40 − 5.06 (m, 2H), 
5.04 − 4.43 (m, 4H), 3.89 − 3.03 (m, 4H);  13C NMR (100 MHz, CDCl3): δ 136.1, 133.6, 133.3, 
128.6, 128.5, 128.4, 128.2, 127.3, 126.0, 67.9, 65.5, 56.5, 55.9, 54.7, 45.3, 31.5; IR νmax/cm
-1
 
(neat): 3438, 3309, 2912, 1656, 1672, 1412, 1354, 1205, 1132, 749, 730, 691; HR ESI MS: m/z 
= 431.1985[M+ H] 
+
 (calcd. for C26H27N2O4 431.1965). 
(S)-benzyl 3-((R)-1-hydroxy-3-methylbutan-2-ylcarbamoyl)-3,4-dihydroisoquino-line-
2(1H)-carboxylate (7) 
Rf = 0.5 (CH2Cl2/MeOH, 9.8:0.2);  Off white solid (2.2 g, yield 86 %);  m.p: 110−112 ºC 
(CH2Cl2);  [α]D
20
 = +4.37 (c 0.80 in CH2Cl2);  (NMR spectra are reported for a mixture of two 
rotamers); 
1
H NMR (400 MHz, CDCl3): δ 7.45 − 7.05 (m, 9H), 5.29 − 5.13 (m, 2H), 4.84 − 4.44 
(m, 3H), 3.61 − 3.02 (m, 5H), 1.76 (m, 1H), 0.96 − 0.47 (m, 6H);  13C NMR (100 MHz, CDCl3): 
δ 171.8, 128.8, 128.6, 128.3, 128.2, 128.0, 128.0, 126.9, 67.9, 63.3, 57.0, 56.6, 45.3, 32.6, 31.3, 
28.5, 19.2, 18.5; IR νmax/cm
-1
 (neat): 3479, 3306, 2946, 1678, 1647, 1554, 1421, 1346, 1225, 
1136, 1047, 756, 728, 692;  HR ESI MS: m/z = 419.1941[M+ Na] 
+




Rf = 0.5 (CH2Cl2/MeOH, 9.8:0.2);  White solid (2.2 g, yield 86 %);  m.p: 110−112 ºC (CH2Cl2);  
[α]D
20
 = − 23.08 (c 1.17 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers); 
1
H NMR (400 MHz, CDCl3): δ 7.54 − 7.07 (m, 9H), 5.86 (m, 1H), 5.41 − 4.99 (m, 2H), 4.89 − 
4.40 (m, 3H), 3.64 − 2.99 (m, 5H), 0.79 − 0.22 (m, 6H);  13C NMR (100 MHz, CDCl3): δ 136.0, 
128.6, 128.4, 127.9, 126.9, 126.1, 125.9, 67.9, 63.5, 56.7, 45.4, 28.6, 19.3, 17.8;  IR νmax/cm
-1
 
(neat): 3407, 3333, 2955, 1678, 1662, 1538, 1411, 1347, 1228, 1124, 1094, 736;  HR ESI MS: 
m/z = 419.1941[M+ Na] 
+
 (calcd. for C23H28N2NaO4 419.1941). 
(S)-benzyl 3-((R)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxy-
late (9) 
Rf = 0.6 (hexane/EtOAc, 65:35);  Off white solid (0.86 g, yield 90 %);  m.p: 96−98 ºC (CH2Cl2);  
[α]D
20




NMR (400 MHz, CDCl3): δ 7.49 − 7.03 (m, 12H), 6.65 − 6.43 (m, 2H), 5.54 − 5.13 (m, 3H), 
5.04 (m, 1H), 4.89 − 4.67 (m, 2H), 4.52 (m, 1H), 3.89 (m, 1H), 3.39 − 3.15 (m, 2H);  13C NMR 
(100 MHz, CDCl3): δ 166.4, 156.0, 142.1, 133.4, 132.9, 131.6, 128.9, 128.4, 128.0, 127.9, 
127.2, 126.8, 126.6, 126.2, 69.5, 67.6, 67.4, 49.1, 48.9, 44.7, 32.1;  IR νmax/cm
-1
 (neat): 3324, 
1702, 1665, 1411, 1326, 1304, 1184, 1114, 997, 744, 697;  HR ESI MS: m/z = 413.1895 [M+ H] 
+
 (calcd. for C26H25N2O3 413.1860).  
(S)-benzyl 3-((S)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-carb-
oxylate (10) 
Rf = 0.6 (hexane/EtOAc, 65:35);  Off white solid (0.85 g, yield 89 %);  m.p: 60−62 ºC (CH2Cl2);  
[α]D
20
 = +12.20 (c 0.41 in CH2Cl2);  (NMR spectra are reported for a mixture of two 
rotamers).
1
H NMR (400 MHz, CDCl3): δ 7.48 − 7.04 (m, 12H), 6.77 (m, 2H), 5.55 − 4.99 (m, 
4H), 4.97 − 4.38 (m, 3H), 3.94 (m, 1H), 3.44 − 3.05 (m, 2H);  13C NMR (100 MHz, CDCl3): δ 
167.2, 156.3, 142.3, 136.4, 133.8, 132.2, 129.4, 129.0, 127.3, 127.0, 75.8, 68.0, 48.8, 44.8, 31.5; 
IR νmax/cm
-1
 (neat): 3313, 3031, 2925, 1662, 1407, 1216, 1119, 744, 696;  HR ESI MS: m/z = 
413.1861[M+ H] 
+
 (calcd. for C26H25N2O3 413.1860). 
(S)-benzyl 3-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-3,4-dihydroisoquinoline-2(1H)-
carboxylate (11) 
Rf = 0.6 (hexane/EtOAc, 60:40);  Colorless oil (0.85 g, yield 89 %);  [α]D
20
 = +3.37 (c 0.89 in 
CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers); 
1
H NMR (400 MHz, 
CDCl3): δ 7.54 − 6.94 (m, 9H), 5.42 − 5.10 (m, 3H), 4.90 − 4.55 (m, 2H), 4.36 − 3.96 (m, 4H), 
3.93 − 3.74 (m, 2H), 3.25 − 3.03 (m, 2H), 1.47 (m, 1H), 0.67 − 0.34 (m, 6H); 13C NMR (100 
MHz, CDCl3): δ 164.5, 155.8, 136.5, 132.6, 128.3, 127.8, 127.6, 127.0, 126.7, 126.2, 71.6, 70.0, 
67.4, 64.1, 62.5, 62.2, 48.5, 44.4, 31.8, 17.9, 17.1, 14.3; IR νmax/cm
-1
 (neat): 3301, 2958, 1679, 
1647, 1256, 1225, 1049, 756, 729; HR ESI MS: m/z = 379.2016[M+ H] 
+




Rf = 0.6 (hexane/EtOAc, 60:40); Colorless oil (0.85 g, yield 89 %); [α]D
20
 = −9.72 (c 0.72 in 
CH2Cl2); (NMR spectra are reported for a mixture of two rotamers). 
1
H NMR (400 MHz, 
CDCl3): δ 7.52 − 7.07 (m, 9H), 6.65 (m, 1H), 5.39 − 5.07 (m, 2H), 4.91 − 4.44 (m, 3H), 3.64 − 
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3.01 (m, 4H), 1.90 (m, 1H), 0.91 − 0.24 (m, 6H); 13C NMR (100 MHz, CDCl3): δ 171.2, 132.1, 
131.9, 128.6, 128.5, 128.3, 127.1, 126.5, 126.0, 67.7, 63.4, 62.2, 45.2, 28.4, 19.3, 17.9; IR 
νmax/cm
-1
 (neat): 3334, 2956, 1662, 1679, 1412, 1220, 1121, 1095, 737, 694; HR ESI MS: m/z = 
379.2016[M+ H] 
+
 (calcd. for C23H27N2O3 379.2016). 
(R)-4-phenyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazole (13) 
Rf = 0.3 (CH2Cl2/MeOH, 98:2); White solid (0.41 g, yield 59 %); m.p: 129−131 ºC (CH2Cl2); 
[α]D
20
 = +46.15 (c 0.26 in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.37 − 7.23 (m, 3H), 7.23 − 
7.10 (m, 5H), 7.08 − 7.02 (m, 1H), 5.23 (t, J = 18.21 Hz, 1H), 4.68 (q, J = 10.10, 3.46 Hz, 1H), 
4.16 (m, 3H), 3.92 (m, 1H), 3.19 − 3.06 (m, 2H), 1.93 (brs, 1H); 13C NMR (100 MHz, CDCl3): δ 
168.9, 142.0, 135.0, 133.3, 129.2, 128.7, 127.6, 126.5, 126.2, 126.1, 126.0, 75.0, 69.4, 51.5, 
47.6, 32.4. IR νmax/cm
-1
 (neat): 3225, 1663, 1493, 1454, 1366, 957, 916, 740, 697; HR ESI MS: 
m/z = 279.1500 [M+ H] 
+
 (calcd. for C18H19N2O 279.1492).   
(S)-4-phenyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazole (14) 
Rf = 0.3 (CH2Cl2/MeOH, 98:2); Yellow oil (0.45, yield 65 %); [α]D
20
 = −7.40 (c 1.85 in 
CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.41 − 7.01 (m, 9H), 5.23 (t, J = 18.33 Hz, 1H), 4.68 
(q, J = 10.04, 8.56 Hz, 1H), 4.20 − 4.13 (m, 3H), 3.92 (t, J = 5.84 Hz, 1H), 3.13 (d, J = 9.08 Hz, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 168.9, 142.1, 135.0, 133.4, 129.4, 129.0, 127.8, 126.8, 
126.4, 126.2, 75.2, 69.5, 51.6, 47.7, 32.5; IR νmax/cm
-1
 (neat): 3227, 1663, 1493, 1109, 957, 916, 
907, 749, 697; HR ESI MS: m/z = 279.1492[M+ H] 
+
 (calcd. for C18H19N2O 279.1492).  
 (R)-4-isopropyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazole (15) 
Rf = 0.3 (CH2Cl2/MeOH, 9.8:0.2); Pale yellow oil (0.35 g, 54 %); [α]D
20
 = −12.73 (c 0.55 in 
CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.18 − 7.07 (m, 3H), 7.03 (m, 1H), 4.28 (q, J = 9.32, 
8.12 Hz, 1H), 4.12 (s, 2H), 4.05 − 3.92 (m, 2H), 3.81 − 3.75 (m, 1H), 3.09 − 2.94 (m, 2H), 1.78 
(m, 1H), 1.27 (t, J = 7.18 Hz, 1H), 0.96 (d, J = 6.88 Hz, 3H), 0.87 (t, J = 6.88 Hz, 3H); 
13
C NMR 
(100 MHz, CDCl3): δ 167.6, 135.2, 133.6, 129.1, 126.2, 126.06, 126.04, 72.1, 70.4, 51.8, 48.0, 
32.6, 18.9, 18.1; IR νmax/cm
-1
 (neat): 3298, 2960, 1717, 1642, 1525, 1222, 1065, 741, 615; HR 
ESI MS: m/z = 245.1468[M+ H] 
+
 (calcd. for C15H21N2O 245.1462). 
(S)-4-isopropyl-2-((S)-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazole (16) 
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Rf = 0.3 (CH2Cl2/MeOH, 9.8:0.2); Pale yellow oil (0.38 g, yield 59 %); [α]D
20
 = −10.87 (c 0.69 
in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.19 − 7.08 (m, 3H), 7.02 (m, 1H), 4.33 − 4.14 (m, 
2H), 4.11 (s, 2H), 4.05 − 3.91 (m, 2H), 3.79 (m, 1H), 3.02 (d, J = 7.58 Hz, 2H), 1.77 (m, 1H), 
1.25 (t, J = 14.3 Hz, 1H), 0.96 (d, J = 6.79 Hz, 3H), 0.87 (d, J = 6.79 Hz, 3H); 
13
C NMR (100 
MHz, CDCl3): δ 167.5, 135.1, 133.6, 129.4, 126.4, 126.2, 72.1, 70.4, 51.7, 47.8, 32.6, 32.5, 
18.9, 18.1; IR νmax/cm
-1
 (neat): 3279, 2957, 1744, 1644, 1559, 1225, 1069, 880, 736; HR ESI 
MS: m/z = 245.1468[M+ H] 
+





H NMR (400 MHz, C6D6): δ 7.85 (t, 2H), 7.54 (t, 2H), 7.21 − 6.84 (m, 13H), 
6.71 − 6.61 (m, 2H), 4.82 − 4.56 (m, 3H), 4.20 (dd, J = 9.34, 2.99 Hz, 1H), 3.84 (m, 1H), 3.56 
(m, 1H), 3.31 (m, 1H), 3.18 (m, 1H); 
31





H NMR (400 MHz, C6D6): δ 7.83 − 7.45 (m, 4H), 7.23 − 6.90 (m, 13H), 6.78 − 
6.58 (m, 3H), 4.82 − 4.58 (m, 3H), 4.20 (d, J = 8.64 Hz, 1H), 3.88 (m, 1H), 3.56 (m, 1H), 3.31 
(m, 1H), 3.08 (m, 1H); 
31





H NMR (400 MHz, C6D6): δ 7.78 (m, 2H), 7.45 (m, 2H), 7.25 − 6.76 (m, 9H), 
6.56 (m, 1H), 4.68 − 3.80 (m, 5H), 3.66 − 2.89 (m, 3H), 1.23 (m, 1H), 0.57 (d, J = 6.7 Hz, 3H), 
0.50 (d, J = 6.7 Hz, 3H); 
31





H NMR (400 MHz, C6D6): δ 7.76 (m, 2H), 7.44 (m, 2H), 7.21 − 6.79 (m, 9H), 
6.57 (m, 1H), 4.63 (m, 1H), 4.41 (d, 16.4 Hz, 1H), 4.10 (d, 16.1 Hz, 1H), 3.64 − 3.01 (m, 6H), 
1.27 (m, 1H), 0.64 (d, J = 6.8 Hz, 3H), 0.54 (d, J = 6.8 Hz, 3H); 
31




Yield: 64 %; [α]D
20
 = −3.12 (c 0.32 in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.81 − 7.58 (m, 
10H), 7.56 − 7.41 (m, 7H), 7.40 − 7.11 (m, 11H), 6.82 (m, 2H), 6.71 (m, 1H), 5.21 − 4.72 (m, 
2H), 4.38 (m, 1H), 4.11 (m, 2H), 3.76 (m, 2H), 3.36 − 3.18 (m, 3H), 2.76 (m, 1H), 2.31 − 2.06 
(m, 2H), 1.98 − 1.78 (m, 8H); 13C NMR (100 MHz, CDCl3): δ 174.1, 163.1 − 160.7, 138.9, 
135.0, 133.0 − 131.4 (m), 130.5 − 127.4 (m), 126.31, 125.6, 125.2, 123.8, 122.0, 117.6 (d, J = 
3.89 Hz), 42.4, 36.2, 29.2, 20.1, 8.7; 
31
P NMR (162 MHz, CDCl3): δ 66.13; IR νmax/cm
-1
 (neat): 
2928, 2034, 1610, 1353, 1273, 1115, 885, 838, 744, 711; HR ESI MS: m/z = 763.2418 [M − 
BArF]
+
 (calcd. for C38H39IrN2OP 763.2424). 
Complex 22: 
Yield: 62 %; [α]D
20
 = +40.87 (c 1.15 in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 8.02 − 6.82 (m, 
30H), 6.67 (m, 1H), 5.16 − 4.77 (m, 2H), 4.62 (m, 1H), 4.55 − 4.28 (m, 4H), 3.66 (m, 1H), 3.44 
− 3.28 (m, 2H), 3.10 − 2.88 (m, 2H), 2.51 − 1.85 (m, 8H); 13C NMR (100 MHz, CDCl3): δ 
174.7, 162.2 (q), 138.3, 135.2, 133.6 − 131.9 (m), 130.6 − 127.6 (m), 126.5, 126.4, 123.6, 120.9, 
117.9 (t), 94.7, 69.1, 65.9, 63.9, 57.6, 53.9, 52.3, 36.5, 34.6, 30.1, 27.5, 22.8, 14.5; 
31
P NMR 
(162 MHz, CDCl3): δ 65.83; IR νmax/cm
-1
 (neat): 2924, 2024, 1610, 1353, 1272, 1114, 885, 734, 
711, 681; HR ESI MS: m/z = 763.2424 [M − BArF]
+
 (calcd. for C38H39IrN2OP 763.2424). 
Complex 23: 
Yield: 68 %; [α]D
20
 = +1.56 (c 0.64 in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.94 − 7.83 (m, 
3H), 7.78 − 7.45 (m, 15H ), 7.43 − 7.07 (m, 7H), 6.63 (d, 1H), 5.02 − 4.66 (m, 5H), 3.48 − 3.01 
(m, 4H), 2.74 (m, 1H), 2.44 − 1.16 (m, 8H), 0.94 − 0.73 (m, 6H), 0.32 (d, J = 6.79 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ 173.4, 162.1 (q, J = 96.43, 44.72 Hz), 135.0 − 131.9 (m), 129.9 − 
129.0 (m), 127.7 − 125.7 (m), 123.4, 120.7, 117.6, 94.7 (d), 92.8 (d), 73.3, 65.6 (t), 57.2, 53.6, 
51.8, 42.4, 36.1, 35.4, 32.5, 29.1, 26.5; 
31
P NMR (162 MHz, CDCl3): δ 65.5;IR νmax/cm
-1
 (neat): 
2924, 2036, 1610, 1353, 1272, 1114, 885, 744; HR ESI MS: m/z = 729.2580 [M − BArF]
+
 
(calcd. for C35H41IrN2OP 729.2580). 
Complex 24: 
Yield: 65 %; [α]D
20
 = +30.23 (c 0.86 in CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ 7.89 − 7.64 (m, 
5H), 7.64 − 7.47 (m, 9H), 7.40 − 7.09 (m, 9H), 6.87 − 6.77 (m, 2H), 6.67 (d, J = 7.6 Hz, 1H), 
80 
5.04 − 4.62 (m, 5H), 3.46 − 3.19 (m, 4H), 2.80 (m, 1H), 2.01 − 1.62 (m, 8H), 1.61 − 1.41 (m, 
3H), 0.78 (d, J = 6.7 Hz, 3H), 0.17 (d, J = 6.7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3): δ 172.9 
(m), 162.1 (q, J = 99.58, 49.81 Hz), 135.3, 133.0 − 132.6 (m, 132.3 (m), 130.3 − 127.6 (m), 
126.0 (m), 125.4, 124.1, 122.3, 117.9, 95.4, 70.1, 65.8, 64.1, 57.1, 52.4, 36.7, 36.0, 32.7, 32.4, 
30.2, 29.2, 26.8, 18.8, 14.6, 13.5; 
31
P NMR (162 MHz, CDCl3): δ 65.94; IR νmax/cm
-1
 (neat): 
2990, 2791, 2029, 1641, 1353, 1272, 1114, 885, 744; HR ESI MS: m/z = 729.2580 [M − BArF]
+
 
(calcd. for C35H41IrN2OP 729.2580). 
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ABSTRACT 
A novel family of eleven new tetrahydroisoquinoline (TIQ)-oxazoline intermediates and five 
corresponding copper(II) catalysts has been developed and applied to the catalytic asymmetric 
Henry reaction of various aldehydes with nitromethane to provide β-hydroxy nitroalkanes in 
high conversion (>99 %).  This paper describes the synthesis of the TIQ compounds from L- 
dihydroxyphenylalanine (L-DOPA) as the starting material.  The chiral ligands were complexed 
in situ with various transition metals such as Cu, Sc, Co, Zn, Ni, Mn and tested as a chiral 
catalysts for the Henry reaction.  The reaction was optimized in terms of the metal, counter ion, 
solvent, temperature and over a range of substrates.  The corresponding catalyst with copper(II) 
acetate and 2-propanol as the solvent provide the best enantioselectivities (up to 77 % ee) for 
the formation of the corresponding nitroalcohol from 4-chlorobenzaldehyde.  
INTRODUCTION 
Chiral ligands containing nitrogen donor atoms are widely used as catalysts for asymmetric 
carbon-carbon bond formation reactions.
1
  In particular, the Henry reaction is one of the classic 
methods for carbon-carbon bond formation in organic synthesis
2
 and has received much 
attention after the pioneering work of Shibasaki and co-workers.
3-25
  Moreover, compounds 
containing a chiral-oxazoline ring are amongst the most frequently used ligands in asymmetric 
83 
catalysis.  Specific structural features of oxazoline rings have been used with great success in 
asymmetric reactions due to their modular nature and applicability to a wide range of metal-
catalyzed transformations.
26
  The majority of these ligands are synthesized from readily 
available chiral amino alcohols through amidation, followed by chlorination and base-induced 
cyclisation to obtain the oxazoline.
27
  Evans et al. reported a novel Cu-bis(oxazoline) catalyst 
which could efficiently catalyse the asymmetric nitroaldol reaction with a variety of aldehydes 
in excellent yield and 96 % ee.
28
  





nitrogen systems have been reported.
11-12
  It has been reported that the TIQ class of molecules 





, and 5HT1A receptor antagonism.
31
  It is also a common key intermediate in 
many biosynthetic pathways
32 
contributing further to the level of interest conferred upon it.  
Previous reports on the use of TIQ derivatives as ligands have yielded limited success, with poor 





 and the addition of diethylzinc to benzaldehyde.
36
  We are investigating the 
use this class of scaffold as chiral ligands and have recently reported the use of TIQ amino 
alcohols for the asymmetric transfer hydrogenation of prochiral ketones.
37
  Herein we report the 
synthesis of a new class of oxazoline ligands built on the TIQ scaffold and a preliminary 
investigation of their efficiency for the asymmetric Henry reaction of aldehydes with 


































Figure 1. Novel chiral TIQ-oxazoline ligands used in this study  
RESULTS AND DISCUSSION 
SYNTHESIS OF THE TIQ-OXAZOLINE LIGANDS 
The synthesis of the each ligand was achieved from commercially available L-3,4-
dihydroxyphenylalanine (L-DOPA) 4 as the starting material.  Compound 7 was synthesized as 
reported previously
37
 and upon hydrolysis with lithium hydroxide, yielded the N-Cbz protected 
amino acid 8.  This molecule served as the key intermediate for the synthesis of all the ligands.  
The amide bond coupling to the appropriate amino alcohols was facilitated by 1-[3- 
(dimethylamino)propyl]-3-ethylcarbodiimide (EDC) and 1-hydroxybenzotriazole (HOBt) to 
yield the hydroxyl amides 9–11b.  Attempts to form the oxazoline ring via chlorination and base 
mediated cyclisation
27
 were inefficient with our system and low yields of product were obtained.  
This was possibly due to harsh reaction conditions such as high temperatures and the use of 
SOCl2 as the chlorination agent.  However, the Mitsunobu reaction
38-42
 for the preparation of 
oxazoline derivatives, under mild and neutral conditions, was found to be successful for our 
ligand synthesis.  The Mitsunobu protocol was used to convert the hydroxyl amides 9–11b to the 
corresponding oxazolines 12–14b.  Removal of the Cbz protecting group was facilitated with 
Pd/C under a hydrogen atmosphere to yield ligands 1–3b.  The sequence of reactions is 



















































10b R1 = i-Pr, R2 = H
11a R1 = H, R2 = Ph
11b R1 = Ph, R2 = H
12 R1 = H, R2 = H






14a R1 = H, R2 = Ph
14b R1 = Ph, R2 = H
1 R1 = H, R2 = H
2a R1 = H, R2 = i-Pr






3b R1 = Ph, R2 = H
i, ii, iii
 
Scheme 1. Reagents for the synthesis of ligands 1-3b (i) Benzaldehyde, K2CO3, EtOH/H2O, 1.5 
hrs; (ii) CbzCl, KHCO3, dioxane/H2O, 0 ºC-rt, 3 hrs; (iii) Me2SO4, KHCO3, acetone, reflux, 24 
hrs; (iv) LiOH, THF, MeOH, H2O, rt, 22 hrs; (v) EDC, HOBt, NMM, DMF, rt, 18 hrs; (vi) 
DEAD, PPh3, DCM, 0 ºC-rt, 2 hrs; (vii) Pd/C, H2 (1atm), MeOH, rt, 1.5 hrs 
METAL SCREENING AND REACTION OPTIMIZATION 
The metal catalyzed Henry reaction between p-nitrobenzaldehyde and nitromethane was used as 
a benchmark reaction to evaluate the enantioselectivity of the TIQ-oxazoline ligands 1–3b 
(Table 1).  All the reactions were complete in 24 hours with just 1 mol % of the ligands 1–3b 
using Cu(OAc)2.H2O as the metal source in the presence of 2-propanol at room temperature.  
86 
The procedure used to execute the reaction was similar to those reported before.
25,28
  Ligand 1 
gave 28 % ee with the model reaction (Table 1), which is comparable to the selectivity obtained 
with ligand 2a, derived from (R)-valinol.  Whereas ligand 2b, derived from (S)-valinol, gave 52 
% ee for the same reaction.  The (S)-phenylglycinol-derived TIQ-oxazoline ligand 3a was found 
to be the most selective with 62 % ee.  From these results, it is deduced that the presence and 
orientation of the substituent on the oxazoline ring is crucial for enantioselectivity.  Furthermore, 
ligand 3a was identified as the most effective among the chiral catalytic series, and it was 
selected for further optimization. 
Table 1 The enantioselective Henry reaction of p-nitrobenzaldehyde with nitromethane in the 

















All the reactions were carried out with 0.33 mmol of 4-nitrobenzaldehyde, 3.3 mmol of nitromethane and 0.05 
mmol of catalyst in 2 mL of 2-propanol. bDetermined by HPLC. cThe enantiomeric excess was determined by 
HPLC using a Chiralcel IB-H column. Reported values are the average of two runs.  
The benchmark reaction was investigated using ligand 3a and Cu(OAc)2.H2O at different 
substrate/catalyst molar ratios as well as at different temperatures, and the results are 
summarized (Table 2).  Loading of the ligands and the reaction temperature had a significant 
influence on the efficiency of the reaction with regards to selectivity and reactivity.  The 
reaction with ligand 1 was repeated with 1 mol % of the ligand, the reaction was completed in 
24 hours at room temperature and the nitroaldol adduct was obtained in 62 % ee with 99 % 
conversion (Table 2).  A lower loading (0.5 mol %) resulted in a reduction in enantioselectivity 





1 1 99 28 
2 2a 95 27 
3 2b 97 52 
4 3a 99 62 
5 3b 99 42 
87 
to 49 % ee (Table 2, entry 2).  No significant advantage was realized with an increased amount 
of the ligand (2 mol % and 5.0 mol %).  Decreased reaction temperatures led to slightly higher 
enantioselectivities but with significant declines in the reactivity.  On the basis of these 
observations, it became clear that 1 mol % of ligand is the optimal quantity for the reaction at 
room temperature as well as at lower temperatures.
 
Table 2 The effect of the loading of ligand 3a–Cu(OAc)2·H2O and temperature on the 




All the reactions were carried out with 0.33 mmol of 4-nitrobenzaldehyde, 3.3 mmol of nitromethane and 0.05 




The enantiomeric excess was determined by 
HPLC using a Chiralcel IB-H column. Reported values are the average of two runs. 
It was found that the type of solvent had a significant effect on both the conversion and 
enantioselectivity of the Henry products with the best catalyst system [3a–Cu(OAc)2·H2O, see 
Table 3].  2-propanol was found to be the best solvent for this catalytic system (Table 3, entry 
5).  The use of different protic and aprotic solvents such as THF, ethanol, methanol, n-butanol, 









1 1 rt 24 99 62 
2 0.5 rt 24 95 49 
3 2 rt 24 99 59 
4 5 rt 24 99 46 
5 1 0 90 83 70 
6 2 0 90 89 69 
7 1 -15 90 45 68 
88 
Table 3 Effect of various solvents on the enantioselective Henry reaction of p-




All the reactions were carried out with 0.33 mmol of 4-nitrobenzaldehyde, 3.3 mmol of nitromethane and 0.05 
mmol of catalyst in 2 mL of appropriate solvent. 
b
Determined by HPLC. 
c 
The enantiomeric excess was determined 
by HPLC using a Chiralcel IB-H column. Reported values are the average of two runs. 
The effect of other transition metals as Lewis acids was investigated by forming catalytic 
complexes with the TIQ-oxazoline ligand 3a (Table 4).  Different counter ions were also 
investigated for the best catalytic system.  The acetate counter ion was found to be crucial for 














1 THF 97 33 
2 ethanol 89 47 
3 methanol 89 36 
4 2-propanol 99 62 
5 acetonitrile 4 16 
6 dichloromethane 75 39 
89 
Table 4 Effect of Lewis acid on the enantioselective Henry reaction of p-nitrobenzaldehyde with 




All the reactions were carried out with 0.33 mmol of 4-nitrobenzaldehyde, 3.3 mmol of 
nitromethane and 0.05 mmol of catalyst in 2 mL of 2-propanol. 
b
Reaction was performed in 
absence of metal.
 c
Determined by HPLC. 
d
The enantiomeric excess was determined by HPLC 
using a Chiralcel IB-H column. Reported values are the average of two runs. 
As shown in Table 5, the scope of the catalytic enantioselective Henry reaction was 
demonstrated by treatment of various aromatic aldehydes with nitromethane in the presence of 1 
mol % TIQ-oxazoline 3a-Cu(OAc)2.H2O complex in 2-propanol.  In all cases, the reactions 
proceeded with moderate to good enantioselectivities.  In general, the reactions performed at 
room temperature exhibit moderate enantioselectivity (40–64 % ee, Table 5, entries 1, 4, 7 and 
10–12).  Higher enantiomeric excesses (72–77 % ee, Table 5, entries 2, 3, 5 and 8) are observed 
at 0 °C for aromatic aldehydes bearing either electron-withdrawing (4-fluorobenzaldehyde, 4-
chlorobenzaldehyde) or electron-donating (4-methylbenzaldehyde) groups.  It became clear that 
the electronic nature and steric hindrance of the substituent at the aromatic rings does not have 
much of an effect on the enantioselectivity for our system. (Table 5, entries 3, 5 and 8). 
 







 － 10 rac 
2 CuCl2 3 rac 
3 Cu(OTf)2 5 10 
4 Cu(OAc)2.H2O  99 62 
5 Co(ClO)4 12 rac 
6 Sc(OTf)2 2 rac 
7 Zn(II) (OAc)2.H2O  97 12 
8 Ni(II) (OAc)2.2H2O 99 25 
9 Mn(II) (OAc)2.2H2O 99 rac 
90 



















1 4-chlorobenzaldehyde 1 r.t. 24 97  62(S) 
2 4-chlorobenzaldehyde 1 0 90 22  76(S) 
3 4-chlorobenzaldehyde 2 0 90 50  77(S) 
4 4-fluorobenzaldehyde 1 r.t. 24 25 52(S) 
5 4-fluorobenzaldehyde 1 0 90 3 72(S) 
6 4-fluorobenzaldehyde 2 0 90 10 67(S) 
7 4-methylbenzaldehyde 1 r.t. 24 84 60(S) 
8 4-methylbenzaldehyde 1 0 90 16 72(S) 
9 4-methylbenzaldehyde 2 0 90 24 63(S) 
10 3, 5-dimethoxybenzaldehyde 1 r.t. 24 76 40(S) 
11 Piperonal 1 r.t. 24 87 53(S) 
12 Naphthaldehyde 1 r.t. 24 96 64(S) 
a
All the reactions were carried out with 0.33 mmol of corresponding benzaldehyde, 3.3 mmol of 
nitromethane and 0.05 mmol in 2 mL of 2-propanol. 
b
Determined by HPLC. 
c
The enantiomeric 
excess was determined by HPLC using a Chiralcel IB-H column. Reported values are the 
average of two runs. 
d
The absolute configurations were established by comparison with 
literature data.
25  
Despite high enantioselectivities obtained by other groups for this reaction, some limitations are 
still encountered such as high catalyst loading, a low required temperature and the use of 
additives for optimal enantioselectivity.  In most instances, a high catalyst loading is the 
essential parameter to obtain high enantioselectivities.  Christensen et al. used 20 mol % of the 
Cu
II




Maheswaran et al. also used 20 mol % of dichloro[(–)-
sparteine-N,N']copper(II) complex for the Henry reaction with nitromethane and obtained a 97 
% ee.
14
  You and Ma have reported the use of 10 mol% for a series of new chiral bis-
imidazoline ligands and their application to the copper(II)-catalyzed Henry reaction with a best 
enantioselectivity of 98 % ee.
43





highly enantioselective Henry reactions (99 % ee) catalyzed by copper(II) complexes with 
diamino ligands using 5 mol % and 12 mol % of ligand, respectively.  Feng and co-workers have 
described the use of 10 mol % of copper(I) complexes with N,N’-dioxide
16
 and tetrahydrosalen 
ligands with 96 % ee.
18
  Finally, Evans et al. reported the 1 mol % copper acetate/bisoxazoline 
catalyzed addition of nitromethane to aldehydes on large-scale reactions with an excellent 94 % 
enantiomeric excess after 56 h.
28
  The low catalyst loading required by our TIQ based 
compounds could make them a promising new catalyst.  A computational chemistry 
investigation of chiral steric hindrance induced by the Ligand may be required to improve the 
enantioselectivity of the reaction.   
CONCLUSION 
In conclusion, we have explored a new class of chiral TIQ-oxazoline-Cu(OAc)2.H2O catalysts 
for the asymmetric Henry reaction.  To the best of our knowledge, this is the first report of the 
use of the TIQ-backbone in combination with an oxazoline ring with sp
2
 and of sp
3
 nitrogen 
systems for the asymmetric Henry reaction.  This effective TIQ ligand is readily prepared by 
using the Mitsunobu protocol to form the external oxazoline ring under mild conditions.  More 
importantly, the catalysts 3a-Cu(OAc)2. H2O gave 62 % ee at minimal catalyst loading (1 mol 
%) at room temperature and affording 77 % ee at lower temperature.  Efforts are underway to 
elucidate the mechanistic details and other significant applications of this catalytic system. 
EXPERIMENTAL  
GENERAL 
Reagents and solvents were purchased from Aldrich, Merck and Fluka.  All NMR spectra were 
recorded on Bruker AVANCE III 400 MHz or 600 MHz instruments at room temperature.  
Chemical shifts are expressed in ppm downfield from CDCl3 as an internal standard, and 
coupling constants are reported in Hz.  Thin layer chromatography (TLC) was performed using 
Merck Kieselgel 60 F254.  Crude compounds were purified with column chromatography using 
92 
Silica gel (60–200 mesh except if stated different).  All solvents were dried using standard 
procedures.  All IR spectra were recorded on a Perkin Elmer spectrum 100 instrument with a 
universal ATR attachment.  Optical rotations were recorded on a Perkin-Elmer Polarimeter 
(Model 341).  All melting points are uncorrected.  All testing reactions were carried out under 
dry UHP Argon (99.999 % purity).  High resolution mass spectrometric data was obtained using 
a Bruker micrOTOF-Q II instrument operating at ambient temperatures, and a sample 
concentration of approximately 1 ppm. 
General procedure for the enantioselective Henry reaction 
After a study of the methods used in literature for this reaction, it was decided to use a 
modification of the method reported by Ginotra et al.
25
 
A solution of ligand 3a (1.3 mg, 0.031 mmol) and Cu(OAc)·H2O (0.7 mg, 0.03 mmol, 10 mol 
%) in anhydrous 2-propanol (2 mL) was stirred for 4 hrs at room temperature under Ar.  To the 
resulting green solution, nitromethane (0.18 ml, 3.3 mmol), and p-nitrobenzaldehyde (50 mg, 
0.33 mmol) were added at room temperature.  The reaction mixture was stirred for the 
appropriate time and the progress of the reaction monitored by TLC (EtOAc:hexane, 15:85, Rf = 
0.12).  After completion of the reaction, the volatile components were removed under reduced 
pressure and the residue was purified by column chromatography on silica gel (EtOAc/hexane, 
15:85 and increased to 20:80) to afford the nitro aldol product.  It was obtained in a maximum of 
62 % ee.  Enantiomeric excess was determined by HPLC with a Chiralcel IB-H column 
(hexane/2-propanol 85:15, λ = 254 nm); flow rate 0.8 mL/min; tR = 16.5 min (R), 18.8 min (S); 
[α]D
20
 = +21 (c 1, CH2Cl2).  The reaction was repeated three times and the average value is 
reported. 






carboxylic acid (8)  
The experimental procedure used for this reaction was taken from literature.
44
  To a round 
bottom flask was added 7 (6.0 g, 0.01 mmol), LiOH.H2O (4.6 g, 0.19 mmol), THF (142 mL), 
MeOH (9.5 mL) and H2O (4.7 mL).  The reaction mixture was stirred for three days until TLC 
93 
indicated that all starting material had been consumed (Rf = 0.4, EtOAc/hexane, 30:70).  The 
organic solvents were removed under reduced pressure; the aqueous layer was acidified to pH 1 
using 10% HCl and filtered off white solid, washed with 10 mL of water and dried under 
vacuum to yield 8 as white solid (5.6 g, 96 %); m.p: 86–88 °C; [α]20D  = 23.08 (c 0.13 in CH2Cl2); 




H NMR (400 MHz, DMSO-d6): δ 
7.45–7.11 (m, 10H), 6.91 (d, J = 6.96 Hz, 1H), 6.75 (d, J = 6.84 Hz, 1H), 6.09 (d, J = 10.68 Hz, 
1H), 5.14–4.94 (m, 3H), 3.79–3.64 (m, 6H), 3.18–3.01 (m, 2H); 
13
C NMR (100 MHz, DMSO): δ 
172.9, 172.6, 155.4, 147.6, 145.0, 143.9, 136.5, 129.4, 128.2, 128.1, 128.0, 127.7, 127.6, 127.4, 
127.0, 126.8, 126.3, 125.8, 125.6, 123.3, 123.0, 111.5, 111.2, 66.4, 66.2, 59.0, 58.7, 55.6, 55.4, 
55.0, 54.9; IR νmax/cm
-1
 (neat): 3603, 3498, 2938, 1686, 1606, 1515, 1404, 1224, 1090, 990, 696.  
HR ESI MS: m/z = 470.1574 [M+ Na] + (calcd. for C26H25NNaO6 470.1556).  
General procedure for the formation of amino alcohols (9-11b) 
This method was adapted from literature.
45
  To a round bottom flask was added acid 8 (2.0 g, 
0.04 mol) together with the amino alcohol (1.1 equiv.), HOBt (1.3 equiv.) and DMF (40 mL).  
The mixture was allowed to stir in an ice bath until its temperature reached 0 ºC.  To the stirred 
mixture was added EDC.HCl (1.2 equiv.) and N-methylmorpholine (3.0 equiv.) and the reaction 
was allowed to proceed for 16 hours at ambient temperature.  The mixture was acidified with 
10% HCl until a milky precipitate formed.  Ethyl acetate (20 mL) was added to the reaction 
flask and allowed to stir for 15 minutes.  The organic layer was separated and washed with H2O 
(2 x 20 mL) and a saturated solution of NaHCO3 (2 × 20 mL).  The organic layer was dried over 
anhydrous MgSO4 and concentrated under reduced pressure affording the crude amino alcohol, 
which was purified by column chromatography using (MeOH:DCM 2.5:97.5) as the eluent to 
yield pure compounds 9-11b.  
General procedure for oxazoline formation (12-14b) 
This method was adapted from literature.
42
  To a stirred solution of Cbz-protected TIQ-
oxazoline amino alcohol (1.0 g) in dry dichloromethane (80 mL) triphenyl phosphine (2.0 
equiv.) was added at room temperature and under N2 atmosphere.  The reaction mixture was 
cooled to 0 °C and to this was added a solution of diethylazodicarboxylate (2.2 equiv.) in dry 
dichloromethane (20 mL) in a dropwise manner over period of 20 min.  The resulting reaction 
mixture was stirred at the same temperature for 4 h under N2 atmosphere.  After completion of 
the reaction, the reaction mixture was diluted with dichloromethane (10 mL), washed with water 
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(2 × 10 mL), dried over anhydrous MgSO4 and concentrated under reduced pressure to yield 
crude product, which was purified by column chromatography using (EtOAc/hexane, 35:65) as 
the eluent to yield pure compounds 12-14b.  
General procedure for nitrogen deprotection (1-3b) 
This method was adapted from literature.
45
  A solution of Cbz-protected TIQ–oxazoline (0.8 g) 
in methanol (30 mL) was added to a suspension of 10 wt.-% Pd/C (0.4 g) in methanol (10 mL).  
The reaction mixture was connected to a hydrogen source at atmospheric pressure and stirred at 
room temperature for 6 h.  The Pd/C was filtered off on a Celite pad, and the filtrate was 
concentrated under reduced pressure to afford the crude TIQ-oxazoline ligand.  The crude 
compounds were purified on a deactivated silica gel column.  The deactivation was done as 
follows: the column was packed with a suspension of silica gel in 20 % Et3N/CH2Cl2 and the 
silica was washed with 1 % Et3N/CH2Cl2.  The chromatography was performed using 0–2 
%MeOH/1% Et3N/CH2Cl2 as the eluent to afford pure oxazoline compounds 1-3b. 
(1R,3S)-benzyl 3-(2-hydroxyethylcarbamoyl)-6,7-dimethoxy-1-phenyl-3,4-dihydroisoquino-
line-2(1H)-carboxylate (9) 
Rf = 0.3 (EtOAc/hexane, 6:4). Pale yellow solid (1.8 g, yield 82 %); m.p: 154–156 °C (CH2Cl2);  
[α]D
20
= 44.00 (c 0.5 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers.) 
1
H 
NMR (400 MHz, CDCl3): δ 7.96 (s, 1H), 7.40–6.98 (m, 10H), 6.88 (m, 1H), 6.62 (s, 1H), 6.22 
(m, 1H), 5.37–5.00 (m, 2H), 4.83 (m, 1H), 3.86 (s, 3H), 3.79 (s, 3H), 3.51–2.98 (m, 6H);  
13
C 
NMR (100 MHz, CDCl3): δ 173.1, 162.5, 148.8, 148.0, 128.5, 128.2, 127.4, 127.4, 125.8, 125.6, 
125.3, 111.7, 110.9, 110.7, 67.9, 61.9, 61.4, 57.6, 56.2, 56.0, 41.9;  IR νmax/cm
-1
  (neat): 3312, 
2933, 1705, 1665, 1514, 1398, 1239, 1219, 1126, 700.48;  HR ESI MS: m/z = 513.1996 [M+ 
Na] + (calcd. for C28H30N2NaO6 513.1984). 
(1R,3S)-benzyl 3-((R)-1-hydroxy-3-methylbutan-2-ylcarbamoyl)-6,7-dimethoxy-1-phenyl-
3,4-dihydroisoquinoline-2(1H)-carboxylate (10a) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Off white solid (2.0 g, yield 84 %);  m.p: 185–187 °C 
(CH2Cl2);  [α]D
20
 = 36.36 (c 0.11 in CH2Cl2); (NMR spectra are reported for a mixture of two 
rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.42–7.01 (m, 10H), 6.90–6.60 (m, 3H), 6.61–6.31 
(m, 4H), 6.30–6.07 (m, 1H), 5.51–5.14 (m, 2H), 5.13–4.81 (m, 2H), 4.62–4.26 (m, 1H), 3.98–
3.76 (m, 7H), 3.46–3.03 (m, 2H), 1.78–1.68 (m, 2H);  
13
C NMR (100 MHz, CDCl3): δ 171.5, 
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156.3, 148.1, 140.5, 135.9, 128.6, 128.5, 128.4, 128.3, 127.1, 125.7, 125.5, 112.0, 111.0, 68.1, 
63.3, 59.5, 58.9, 58.2, 57.9, 56.5, 56.4, 55.9, 31.3, 28.4, 19.2, 17.5 ;  IR νmax/cm
-1
 (neat): 3549, 
2958, 1697, 1662, 1515, 1405, 1238, 1220, 1127, 1090, 697;  HR ESI MS: m/z = 533.2646 [M+ 
H] + (calcd. for C31H37N2O6 533.2642). 
(1R,3S)-benzyl 3-((S)-1-hydroxy-3-methylbutan-2-ylcarbamoyl)-6,7-dimethox-y-1-phenyl-
3,4-dihydroisoquinoline-2(1H)-carboxylate (10b) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Pale yellow solid (2.1 g, yield 88 %);  m.p: 136–138 °C 
(CH2Cl2);  [α]D
20
 = 31.82 (c 0.11 in CH2Cl2);  (NMR spectra are reported for a mixture of two 
rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.47–7.05 (m, 10H), 6.98–6.86 (m, 1H), 6.37–6.12 
(m, 1H), 5.57–5.35 (m, 1H), 5.31–5.06 (m, 2H), 4.92–4.81 (m, 1H), 3.95–3.74 (m, 6H), 3.62–
2.88 (m, 5H), 1.52–1.37 (m, 1H), 0.67–0.48 (m, 3H), 0.41–0.23 (m, 3H);  
13
C NMR (100 MHz, 
CDCl3): δ 171.5, 156.3, 148.1, 140.5, 135.9, 128.6, 128.5, 128.4, 128.3, 127.1, 125.7, 125.5, 
112.0, 111.0, 68.1, 63.3, 59.5, 58.9, 58.2, 57.9, 56.5, 56.4, 55.9, 31.3, 28.4, 19.2, 17.5;  IR 
νmax/cm
-1
 (neat): 3549, 2958, 1697, 1662, 1515, 1405, 1238, 1220, 1127, 1090, 697.  HR ESI 
MS: m/z = 533.2646 [M+ H] + (calcd. for C31H37N2O6 533.2627). 
(1R,3S)-benzyl 3-((R)-2-hydroxy-1-phenylethylcarbamoyl)-6,7-dimethoxy-1-phenyl-3,4-
dihydroisoquinoline-2(1H)-carboxylate (11a) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Off white solid (2.1 g, yield 83 %);  m.p: 86–88 ºC;  [α]D
20
 = 
23.08 (c 0.13 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR 
(400 MHz, DMSO): δ 7.42-6.61 (m, 15H), 6.39–5.76 (m, 2H), 5.31–5.04 (m, 2H), 5.0–4.52 (m, 
2H), 3.98–3.77 (m, 6H), 3.70–3.25 (m, 2H), 3.16–2.96 (m, 2H);  
13
C NMR (100 MHz, CDCl3): 
δ 172.7, 156.1, 149.1, 148.2, 140.5,138.3, 135.8, 128.7, 128.5, 128.2, 127.9, 127.6, 127.2, 126.3, 
125.8, 125.5, 125.1, 111.8, 111.2, 110.8, 68.1, 66.4, 66.0, 58.8, 58.0, 57.5, 56.4, 56.4, 56.2, 56.1, 
55.8;  IR νmax/cm
-1
 (neat): 3313, 2936, 1662, 1513, 1401, 1339, 1238, 1221, 1092, 697.  HR ESI 
MS: m/z = 567.2474 [M+ H] + (calcd. for C34H35N2O6 567.2474). 
(1R,3S)-benzyl 3-((S)-2-hydroxy-1-phenylethylcarbamoyl)-6,7-dimethoxy-1-phenyl-3,4-
dihydroisoquinoline-2(1H)-carboxylate (11b) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Yellow oil (2.05, yield 81 %);  [α]D
20
 = + 39.13 (c 0.23 in 
CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR (400 MHz, 
CDCl3): δ 7.50–7.04 (m, 12H), 6.94 (s, 1H), 6.63–6.16 (m, 4H), 5.40–5.12 (m, 2H), 5.03–4.72 
(m, 2H), 3.98–3.66 (m, 7H), 3.63–3.27 (m, 2H), 3.11–2.80 (m, 4H);  
13
C NMR (100 MHz, 
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CDCl3): δ 172.0, 162.5, 156.2, 149.0, 141.2, 128.6, 128.3, 128.1, 127.4, 127.1, 126.0, 125.4, 
111.9, 110.7, 68.0, 65.64, 59.6, 58.9, 58.1, 57.9, 56.1, 55.8, 54.3, 54.1, 36.4, 31.4, 30.9;  IR 
νmax/cm
-1
 (neat): 3323, 2933, 1696, 1661, 1514, 1402, 1222, 1128, 1092, 696.  HR ESI MS: m/z 
= 567.2490 [M+ H] + (calcd. for C34H35N2O6 567.2479). 
(1R,3S)-benzyl 3-(4,5-dihydrooxazol-2-yl)-6,7-dimethoxy-1-phenyl-3,4-
dihydroisoquinoline-2(1H)-carboxylate (12) 
Rf = 0.3 (EtOAc/hexane, 7:3).  Off white solid (0.72 g, yield 73 %);  m.p: 68–70 °C (hexane/ 
EtOAc);  [α]D
20
 = –3.22 (c 0.62 in CH2Cl2);  (NMR spectra are reported for a mixture of two 
rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.43–6.40 (m, 12H), 6.11 (m, 1H), 5.39–4.77 (m, 
2H), 4.24–3.44 (m, 9H), 3.34–2.89 (m, 2H), 1.25 (m, 2H);  
13
C NMR (100 MHz, CDCl3): δ 
156.4, 148.1, 132.2, 129.5, 128.7, 128.6, 128.2, 127.9, 127.1, 126.9, 126.1, 111.7, 110.9, 68.3, 
68.2, 67.6, 60.2, 59.6, 56.4, 56.2, 54.5, 51.2, 31.3;  IR νmax/cm
-1
 (neat): 2934, 1698, 1513, 1398, 




Rf = 0.6 (EtOAc/hexane, 5:5).  Pale yellow solid (0.81 g, yield 83 %);  m.p: 128–130 °C 
(hexane/ethylacetate);  [α]D
20
 = 3.22 (c 0.31 in CH2Cl2);  (NMR spectra are reported for a 
mixture of two rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.41–6.84 (m, 10H), 6.76 (m, 1H), 
6.55 (m, 1H), 6.11 (m, 1H), 5.35–4.92 (m, 3H), 4.18–3.57 (m, 9H), 3.34–2.90 (m, 2H), 1.67 (m, 
2H), 1.42 (m, 1H), 0.66–0.35 (m, 6H);  
13
C NMR (100 MHz, CDCl3): δ 156.2, 148.0, 129.8, 
128.4, 128.1, 127.8, 127.6, 126.7, 126.9, 123.7, 123.3, 111.8, 111.0, 71.4, 69.9, 67.3, 60.1, 59.6, 
56.0, 51.0, 18.2, 17.8;  IR νmax/cm
-1
 (neat): 3337, 2961, 1695, 1684, 1513, 1399, 1222, 1126, 




Rf = 0.6 (EtOAc/hexane, 5:5).  Off white solid (0.71 g, yield 73 %);  m.p: 80–82 °C (CH2Cl2);  
[α]D
20
 = 17.65 (c 0.17 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.48–6.85 (m, 11H), 6.41–6.12 (m, 1H), 5.68–5.08 (m, 3H), 4.84 
(d, J = 8.36 Hz), 3.96–3.75 (m, 7H), 3.48–2.89 (m, 6H), 1.89–1.44 (m, 6H), 0.87–0.51 (m, 6H);  
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13
C NMR (100 MHz, CDCl3): δ 156.4, 148.4, 130.0, 128.3, 128.0, 127.8, 126.8, 126.7, 126.1, 
111.9, 111.1, 71.8, 70.1, 60.1, 56.2, 51.2, 18.4, 17.1;  IR νmax/cm
-1
 (neat): 3337, 2961, 1695, 
1684, 1513, 1399, 1222, 1126, 1093, 1028, 737, 698.  HR ESI MS: m/z = 537.2360 [M+ Na] + 
(calcd. for C31H34N2NaO5 537.2365).  
(1R,3S)-benzyl 6,7-dimethoxy-1-phenyl-3-((R)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-
dihydroisoquinoline-2(1H)-carboxylate (14a) 
Rf = 0.6 (EtOAc/hexane, 5:5).  Colorless oil (0.85 g, yield 88 %);  [α]D
20
 = –14.29 (c 0.28 in 
CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR (400 MHz, 
CDCl3): δ 7.24–7.02 (m, 10H), 6.95–6.64 (m, 3H), 6.58–6.33 (m, 3H), 6.31–6.06 (m, 1H), 5.53–
5.15 (m, 2H), 5.14–4.81 (m, 2H), 4.63–4.26 (m, 1H), 3.98–3.76 (m, 7H), 3.45–3.05 (m, 2H), 
1.78–1.62 (m, 2H);  
13
C NMR (100 MHz, CDCl3): δ 167.1, 156.7, 156.3, 156.1, 148.3, 144.6, 
143.2, 142.2, 136.0, 130.1, 128.4, 127.9, 127.3, 126.9, 126.7, 126.5, 126.2, 125.9, 123.1, 111.7, 
111.4, 111.0, 110.6, 76.0, 75.7, 69.2, 67.5, 67.4, 62.2, 60.1, 59.6, 56.0, 55.0, 51.2; IR (neat): 
3028, 2935, 1697, 1514, 1397, 1224, 1093, 993, 698;  HR ESI MS: m/z = 549.2384 [M+ H] + 
(calcd. for C34H33N2O5 549.2379). 
(1R,3S)-benzyl 6,7-dimethoxy-1-phenyl-3-((S)-4-phenyl-4,5-dihydrooxazol-2-yl)-3,4-
dihydr-oisoquinoline-2(1H)-carboxylate (14b) 
Rf = 0.6 (EtOAc/hexane, 5:5).  Yellow oil (0.81 g, yield 84 %);  [α]D
20
 = –39.29 (c 0.28 in 
CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers).  
1
H NMR (400 MHz, 
CDCl3): δ 7.43–7.09 (m, 11H), 6.98–6.58 (m, 5H), 6.19–5.97 (m, 1H), 5.56–5.31 (m, 1H), 5.30–
4.83 (m, 3H), 4.45–4.05 (m, 2H), 3.96–3.69 (m, 8H), 3.41–3.10 (m, 2H);  
13
C NMR (100 MHz, 
CDCl3): δ 167.1, 156.7, 156.3, 156.1, 148.3, 144.6, 143.2, 142.2, 136.0, 130.1, 128.4, 128.3, 
128.1, 127.9, 127.6, 126.9, 126.5, 126.2, 125.9, 123.1, 111.7, 111.4, 110.6, 76.0, 75.7, 69.2, 
67.5, 67.4, 62.2, 60.1, 59.6, 56.0, 55.0, 51.2;  IR νmax/cm
-1
 (neat): 3028, 2935, 1697, 1514, 1397, 
1224, 1093, 993, 698. HR ESI MS: m/z = 549.2384 [M+ H] + (calcd. for C34H33N2O5 549.2385). 
2-((1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-4,5-dihydrooxazole 
(1) 
Rf = 0.3 (CH2Cl2/MeOH, 8:2).  Pale yellow oil (0.21 g, yield 40 %);  [α]D
20
 = – 39.47 (c 0.19 in 
CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 7.35–7.15 (m, 5H), 6.68 (s, 1H), 6.34 (s, 1H), 5.34 (s, 
1H), 3.95–3.75 (m, 6H), 3.65 (m, 3H), 3.02–2.75 (m, 2H), 1.50 (m, 2H);  
13
C NMR (100 MHz, 
CDCl3): δ 162.9, 148.9, 148.0, 140.6, 136.2, 130.0, 128.7, 126.2, 125.9, 117.1, 114.9, 111.0, 
98 
55.7, 36.6, 31.6;  IR νmax/cm
-1
 (neat): 2946, 1685, 1610, 1542, 1232, 1112, 1058, 672;  HR ESI 
MS: m/z = 339.1703 [M+ H] + (calcd. for C20H23N2O3 339.1708). 
(R)-2-((1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-isopropyl-4,5-
dihydrooxazole (2a) 
Rf = 0.3 (EtOAc/hexane, 5:5).  Off white solid (0.35 g, yield 59 %);  m.p: 126–128 °C (CH2Cl2);  
[α] D
20
 = –63.64 (c 0.22 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 7.31–7.18 (m, 3H), 7.19–
7.18 (m, 2H), 6.62 (s, 1H), 6.32 (s, 1H), 5.26 (s, 1H), 3.96–3.76 (m, 6H), 3.65 (s, 3H), 3.06 (dd, 
J = 4.88 Hz, 1H), 2.95 (dd, J = 9.08 Hz, 1H), 2.50 (q, J = 7.48, 14.29 Hz, 1H), 1.70 (m, 1H), 
0.87 (d, J = 6.68 Hz, 3H), 0.79 (d, J = 6.80 Hz, 3H);  
13
C NMR (100 MHz, CDCl3): δ 167.7, 
147.8, 147.3, 144.7, 128.7, 128.3, 128.0, 127.2, 126.0, 111.1, 110.8, 71.7, 69.9, 62.2, 58.9, 
55.88, 55.82, 46.4, 46.1, 32.3, 31.9, 18.6, 17.7, 14.4;  IR νmax/cm
-1
 (neat): 3243, 2951, 1646, 
1623, 1516, 1240, 1224, 1112, 1062, 696, 539.  HR ESI MS: m/z = 381.2173 [M+ H] + (calcd. 
for C23H29N2O3 381.2192). 
(S)-2-((1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-isopropyl-4,5-
dihydrooxazole (2b) 
Rf = 0.3 (EtOAc/hexane, 5:5).  Pale Yellow solid (0.3 g, yield 50 %);  m.p: 106–108 °C 
(CH2Cl2);  [α]D
20
 = –42.11 (c 0.38 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 7.31–7.19 (m, 
3H), 7.18–7.13 (m, 2H), 6.63 (s, 1H), 6.31 (s, 1H), 5.19 (s, 1H), 3.96–3.82 (m, 6H), 3.65 (s, 3H), 
3.06–3.0 (m, 2H), 1.73–1.63 (m, 1H), 0.87 (d, J = 6.80 Hz, 3H), 0.78 (d, J = 6.76 Hz, 3H);  
13
C 
NMR (100 MHz, CDCl3): δ 167.4, 147.8, 147.2, 144.6, 132.1, 132.0, 131.96, 131.94, 128.7, 
128.5, 128.4, 128.3, 127.9, 127.2, 126.1, 111.1, 110.8, 71.9, 70.1, 62.2, 59.0, 55.85, 55.81, 46.6, 
46.1, 32.3, 31.8, 18.6, 17.8, 14.4;  IR νmax/cm
-1
 (neat): 3243, 2951, 1646, 1623, 1516, 1240, 




Rf = 0.3 (EtOAc/hexane, 5:5).  White solid (0.38 g, yield 63 %);  m.p: 70–72 °C (CH2Cl2);  
[α]D
20
 = –46.43 (c 0.14 in CH2Cl2);  (NMR spectra are reported for a mixture of two rotamers.)  
1
H NMR (400 MHz, CDCl3): δ 7.33–7.18 (m, 8H), 7.13–7.08 (m, 2H), 6.68 (s, 1H), 6.37 (s, 
1H), 5.33 (s, 1H), 5.16 (t, J = 17.9 Hz,1H), 4.59 (q, J = 10.08, 8.48 Hz, 1H), 4.08 (t, J = 16.08, 
1H), 4.01–3.95 (m, 1H), 3.88 (s, 3H), 3.70 (s, 3H), 3.21 (dd, J = 5.00, 5.00 Hz, 1H), 3.11 (dd, J 
99 
= 8.28 Hz, 1H);  
13
C NMR (100 MHz, CDCl3): δ 169.2, 147.9, 147.4, 144.8, 142.1, 129.2, 128.7, 
128.6, 128.3, 128.2, 127.5, 127.2, 126.5, 125.8, 111.2, 110.9, 74.9, 69.4, 58.9, 55.8, 46.9, 46.2, 
32.0;  IR νmax/cm
-1
 (neat): 2931, 1652, 1511, 1450, 1246, 1220, 1113, 1027, 838, 756, 698.  HR 
ESI MS: m/z = 415.2016 [M+ H] + (calcd. for C26H27N2O3 415.1979). 
(S)-2-((1R,3S)-6,7-dimethoxy-1-phenyl-1,2,3,4-tetrahydroisoquinolin-3-yl)-4-phenyl-4,5-
dihydrooxazole (3b) 
Rf = 0.3 (EtOAc/hexane, 5:5).  Off white solid (0.32 g, yield 53 %);  m.p: 70–72 °C (CH2Cl2);  
[α]D
20
 = –57.14 (c 0.28 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 7.32–7.16 (m, 8H), 7.11–
7.06 (m, 2H), 6.67 (s, 1H), 6.34 (s, 1H), 5.24 (s, 1H), 5.17 (t, 1H), 4.59 (q, J = 10.08, 8.48 Hz, 
1H), 4.07(t, J = 8.12 Hz, 1H), 4.04–3.98 (t, J = 6.46 Hz, 1H), 3.85 (s, 3H), 3.68 (s, 3H), 3.16 (d, 
J = 6.48 Hz, 2H);  
13
C NMR (100 MHz, CDCl3): δ 168.9, 147.9, 147.3, 144.6, 142.1, 128.7, 
128.6, 128.4, 128.1, 127.5, 127.3, 126.5, 126.0, 111.2, 110.8, 74.9, 69.4, 59.0, 55.89, 55.82, 
47.1, 31.8;  IR νmax/cm
-1
 (neat): 2907, 1738, 1658, 1511, 1451, 1351, 1244, 1220, 1115, 1027, 
757, 699.  HR ESI MS: m/z = 415.2016 [M+ H] + (calcd. for C26H27N2O3 415.1996). 
ACKNOWLEDGEMENTS 
This work was supported by the UKZN productivity research grant, a SA/Swedish Research 
Links Programme grant and Aspen Pharmacare, SA. The NRF (South Africa) is thanked for the 
support. 
REFERENCES 
1. Fache, F.; Schulz, E.; Tommasino, M. L.; Lemaire, M. Chem. Rev. 2000, 100, 2159-
2231. 
2. Boruwa, J.; Gogoi, N.; Saikia, P. P.; Barua, N. C. Tetrahedron-Asymmetry 2006, 17, 
3315-3326. 
3. Sasai, H.; Suzuki, T.; Arai, S.; Arai, T.; Shibasaki, M. J. Am. Chem. Soc. 1992, 114, 
4418-4420. 
4. Sasai, H.; Suzuki, T.; Itoh, N.; Tanaka, K.; Date, T.; Okamura, K.; Shibasaki, M. J. Am. 
Chem. Soc. 1993, 115, 10372-10373. 
5. Arai, T.; Yamada, Y. M. A.; Yamamoto, N.; Sasai, H.; Shibasaki, M. Chem. Eur. J. 
1996, 2, 1368-1372. 
6. Trost, B. M.; Yeh, V. S. C. Angew. Chem., Int. Ed. 2002, 41, 861-863. 
7. Palomo, C.; Oiarbide, M.; Laso, A. Angew. Chem., Int. Ed. 2005, 44, 3881-3884. 
8. Liu, S. L.; Wolf, C. Org. Lett. 2008, 10, 1831-1834. 
9. Kogami, Y.; Nakajima, T.; Ashizawa, T.; Kezuka, S.; Ikeno, T.; Yamada, T. Chem. Lett. 
2004, 33, 614-615. 
10. Christensen, C.; Juhl, K.; Jorgensen, K. A. Chem. Commun. 2001, 2222-2223. 
11. Du, D. M.; Lu, S. F.; Fang, T.; Xu, J. X. J. Org. Chem. 2005, 70, 3712-3715. 
100 
12. Lu, S. F.; Du, D. M.; Zhang, S. W.; Xu, J. X. Tetrahedron-Asymmetry 2004, 15, 3433-
3441. 
13. Gan, C. S.; Lai, G. Y.; Zhang, Z. H.; Wang, Z. Y.; Zhou, M. M. Tetrahedron-Asymmetry 
2006, 17, 725-728. 
14. Maheswaran, H.; Prasanth, K. L.; Krishna, G. G.; Ravikumar, K.; Sridhar, B.; Kantam, 
M. L. Chem. Commun. 2006, 4066-4068. 
15. Bandini, M.; Piccinelli, F.; Tommasi, S.; Umani-Ronchi, A.; Ventrici, C. Chem. 
Commun. 2007, 616-618. 
16. Qin, B.; Xiao, X.; Liu, X. H.; Huang, J. L.; Wen, Y. H.; Feng, X. M. J. Org. Chem. 2007, 
72, 9323-9328. 
17. Bandini, M.; Benaglia, M.; Sinisi, R.; Tommasi, S.; Umani-Ronchi, A. Org. Lett. 2007, 
9, 2151-2153. 
18. Xiong, Y.; Wang, F.; Huang, X.; Wen, Y. H.; Feng, X. M. Chem. Eur. J. 2007, 13, 829-
833. 
19. Colak, M.; Aral, T.; Hosgoren, H.; Demirel, N. Tetrahedron-Asymmetry 2007, 18, 1129-
1133. 
20. Blay, G.; Climent, E.; Fernandez, I.; Hernandez-Olmos, V.; Pedro, J. R. Tetrahedron-
Asymmetry 2007, 18, 1603-1612. 
21. Arai, T.; Yokoyama, N.; Yanagisawa, A. Chem. Eur. J. 2008, 14, 2052-2059. 
22. Choudary, B. M.; Ranganath, K. V. S.; Pal, U.; Kantam, M. L.; Sreedhar, B. J. Am. 
Chem. Soc. 2005, 127, 13167-13171. 
23. Kowalczyk, R.; Sidorowicz, L.; Skarzewski, J. Tetrahedron-Asymmetry 2007, 18, 2581-
2586. 
24. Selvakumar, S.; Sivasankaran, D.; Singh, V. K. Org. Biomol. Chem. 2009, 7, 3156-3162. 
25. Ginotra, S. K.; Singh, V. K. Org. Biomol. Chem. 2007, 5, 3932-3937. 
26. Hargaden, G. C.; Guiry, P. J. Chem. Rev. 2009, 109, 2505-2550. 
27. McManus, H. A.; Guiry, P. J. J. Org. Chem. 2002, 67, 8566-8573. 
28. Evans, D. A.; Seidel, D.; Rueping, M.; Lam, H. W.; Shaw, J. T.; Downey, C. W. J. Am. 
Chem. Soc. 2003, 125, 12692-12693. 
29. Parmee, E. R.; Brockunier, L. L.; He, J. F.; Singh, S. B.; Candelore, M. R.; Cascieri, M. 
A.; Deng, L. P.; Liu, Y.; Tota, L.; Wyvratt, M. J.; Fisher, M. H.; Weber, A. E. Bioorg. 
Med. Chem. Lett. 2000, 10, 2283-2286. 
30. Labarre, M.; Butterworth, J.; St-Onge, S.; Payza, K.; Schmidhammer, H.; Salvadori, S.; 
Balboni, G.; Guerrini, R.; Bryant, S. D.; Lazarus, L. H. Eur. J. Pharm. 2000, 406, R1-
R3. 
31. Mokrosz, M. J.; Duszynska, B.; Wesolowska, A.; Borycz, J.; Chojnacka-Wojcik, E.; 
Karolak-Wojciechowska, J. Med. Chem. Res. 2000, 10, 58-68. 
32. Cheng, S. L.; Zhang, X. Y.; Wang, W.; Zhao, M.; Zheng, M. Q.; Chang, H. W.; Wu, J. 
H.; Peng, S. Q. Eur. J. Med. Chem. 2009, 44, 4904-4919. 
33. Blanc, C.; Hannedouche, J.; Agbossou-Niedercorn, F. Tetrahedron Lett. 2003, 44, 6469-
6473. 
34. Stingl, K.; Martens, J.; Wallbaum, S. Tetrahedron-Asymmetry 1992, 3, 223-226. 
35. Jones, G. B.; Heaton, S. B.; Chapman, B. J.; Guzel, M. Tetrahedron-Asymmetry 1997, 8, 
3625-3636. 
36. Hari, Y.; Sakuma, M.; Miyakawa, A.; Hatano, K.; Aoyama, T. Heterocycles 2008, 76, 
305-311. 
37. Chakka, S. K.; Andersson, P. G.; Maguire, G. E. M.; Kruger, H. G.; Govender, T. Eur. J. 
Org. Chem., 972-980, S972/1-S972/40. 
38. Roush, D. M.; Patel, M. M. Synth. Commun. 1985, 15, 675-679. 
39. Wipf, P.; Miller, C. P. Tetrahedron Lett. 1992, 33, 6267-6270. 
101 
40. Galeotti, N.; Montagne, C.; Poncet, J.; Jouin, P. Tetrahedron Lett. 1992, 33, 2807-2810. 
41. Wang, F. J.; Hauske, J. R. Tetrahedron Lett. 1997, 38, 6529-6532. 
42. Jiao, P.; Xu, J. X.; Zhang, Q. H.; Choi, M. C. K.; Chan, A. S. C. Tetrahedron-Asymmetry 
2001, 12, 3081-3088. 
43. Ma, K. Y.; You, J. S. Chem. Eur. J. 2007, 13, 1863-1871. 
44. Eustache, J.; Van de Weghe, P.; Le Nouen, D.; Uyehara, H.; Kabuto, C.; Yamamoto, Y. 
J. Org. Chem. 2005, 70, 4043-4053. 







ASYMMETRIC CONJUGATE ADDITION OF 
THIOGLYCOLATE TO CHALCONE USING 






 Pher G. Andersson,
a,c
 Hendrik G. Kruger,
a*
 Glenn E. M. 
Maguire
a




School of Chemistry, University of KwaZulu-Natal, Durban, South Africa. 
b
School of Pharmacy and Pharmacology, University of KwaZulu-Natal, Durban, South 
Africa.  
c
Department of Biochemistry and Organic chemistry, Uppsala University, 
Uppsala, Sweden.  
*
Corresponding Author: email: govenderthav@ukzn.ac.za 
ABSTRACT 
A series of novel TIQ based N,N'-dioxide ligands were synthesised and screened for their 
catalytic activity in the enantioselective conjugate addition of a sulphur-containing nucleophile 
on a range of α,β-unsaturated ketones.  Bulkier groups on the side chain of the TIQ backbone 
provided the highest enantioselectivity up to 81 % with a 10 mol % catalytic loading.  It was 
also observed that these reactions proceeded optimally in the presence of dichloromethane as a 
solvent.  Screening of various metals revealed La(OTf)3 as the ideal pre-catalyst for this 
particular reaction.  Further catalytic testing on α,β-unsaturated substrates yielded novel 
sulphur-containing molecules.  To the best of our knowledge, this is the second report for the 
conjugate addition of thioglycolates to chalcones.  
INTRODUCTION 
The drive to synthesise optically pure compounds accounts for the huge interest in the field of 
asymmetric catalysis.
1-3
  Reactions involving C-C bond formations provide methods by which 
larger molecules can be synthesised.
4-7






 and Michael additions
12-13
 play a significant role in 
organic chemistry as well as in asymmetric catalysis.  
The Michael addition is ubiquitous in organic chemistry and has been utilized to produce a 
diverse array of compounds for applications in various fields.
12-15
  Furthermore, the use of the 
Michael reaction for applications other than C-C bond formation opens up avenues by which 
molecules that possess unique properties can be realized.  One such deviation is the addition of 
sulphur as a nucleophile to α,β-unsaturated ketones.  These types of conjugate addition have 
been widely reported
16-19
 and applications in total synthesis have already been realized.
20-21
 
The use of N-oxide containing ligands in asymmetric catalysis are well documented with 
numerous examples of catalytic systems possessing this chemical moiety.
22
  Some examples of 
these molecules are shown in Figure 1.  Applications of N-oxide ligands include allylation of 
aldehydes,
23-24
 asymmetric aldol reactions,
25-26































Figure 1. Examples of N-oxide ligands utilized in asymmetric catalysis. 
The use of the TIQ scaffold in asymmetric catalysis is an ongoing interest in our research group.  
Applications include catalytic asymmetric transfer hydrogen (ATH),
31-32
 high pressure 
hydrogenation of unsymmetrical olefins,
33
 Henry type C-C bond formations
34
 and as an 
organocatalyst in the Diels-Alder reaction.
35
  In this paper, we extended the utilization of the 
TIQ backbone in the construction of a catalyst for carbon-sulphur bond formation via conjugate 
addition.  The backbone was modified to include the N,N’-dioxide moiety.  Furthermore, the use 
104 
of uncommon molecules in the analysis of the substrate scope afforded novel sulphur-containing 
compounds. 
RESULTS AND DISCUSSIONS 
The ligands were synthesized as illustrated in Scheme 1.  The benzyl chloroformate (Cbz) 
protected TIQ acid
36
 underwent amide coupling, facilitated by active ester formation with ethyl 
chloroformate, with various substituted amines to afford the intermediates 5-9.
37
  The cleavage 
of the Cbz group was accomplished with 10 % wt. Pd/C under a hydrogen atmosphere (1 atm) to 
afford the free amines 10-14.  Bridging of these free secondary amines 10-14 was accomplished 
with K2CO3 and 1,3-dibromopropane in acetonitrile to yield the products 15-19.  Finally, 
intermediates 15-19 were oxidized with m-chloroperbenzoic acid (m-CPBA) and K2CO3 in 






































5. R = Phenyl
6. R = 2-methyl phenyl
7. R = 2,6-dimethyl phenyl
8. R = 2,6-diisopropyl phenyl
9. R = Benzyl
10. R = Phenyl
11. R = 2-methyl phenyl
12. R = 2,6-dimethyl phenyl
13. R = 2,6-diisopropyl phenyl
14. R = Benzyl
15. R = Phenyl
16. R = 2-methyl phenyl
17. R = 2,6-dimethyl phenyl
18. R = 2,6-diisopropyl phenyl
19. R = Benzyl
20. R = Phenyl
21. R = 2-methyl phenyl
22. R = 2,6-dimethyl phenyl
23. R = 2,6-diisopropyl phenyl





Scheme 1. Reagents for the synthesis of TIQ N-oxide ligands 20-24: (i) Ethyl chloroformate, 
triethyl amine, amines, DCM, 0 °C – rt, 18 h; (ii) 10 % wt. Pd/C, H2 (1 atm), MeOH/THF, rt, 3 
h; (iii) 1,3-dibromopropane, anhydrous K2CO3, ACN, microwave, 90 °C, 12 h; (iv) m-CPBA (70 
%), anhydrous K2CO3, DCM, –78 °C – rt 8 h; 
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The activities of the synthesized ligands 20-24 were determined with the conjugate addition of 
methyl thioglycolate to chalcone (Table 1).  The reaction conditions chosen were adopted from 
literature.
37,30,38
  Ligand 20, possessing the phenyl substitution, provided poor selectivity across 
a range of catalytic loading (Table 1, entries 1-3).  Replacement of the phenyl group with groups 
possessing substitution on aromatic side chain resulted in a marked increase in the selectivity of 
the ligands.  Substitution of a 2-methyl phenyl group on the side chain of the TIQ backbone 
resulted in a selectivity of 50 % (Table 1, entry 6) whilst substitution with 2,6-dimethyl phenyl 
group afforded a selectivity of 71 % (Table 1, entry 9).  Replacing the 2-methylphenyl group 
with 2,6-diisopropyl phenyl groups resulted in the highest enantioselectivity of 81 % (Table 1, 
entry 12).  Reactions at lower temperatures did not affect the enantioselectivity (Table 1, entry 
13).  The use of the benzyl amide 24 group resulted in a complete loss of selectivity (Table 1, 
entries 14-16). 
Table 1 Asymmetric conjugate addition of thioglycolate to chalcone catalysed by various 
ligands with La(OTf)3  
Ph
O




1,2 Dichloroethane, rt  





1 20 1 75 rac 
2 20 5 82 2 
3 20 10 90 6 
4 21 1 65 11 
5 21 5 85 33 
6 21 10 92 50 
7 22 1 69 28 
8 22 5 85 43 
9 22 10 93 71 
106 
10 23 1 78 32 
11 23 5 89 53 
12 23 10 95 81 
13
d
 23 10 45 80 
14 24 1 69 rac 
15 24 5 78 rac 
16 24 10 93 rac 
a
All reactions were performed at 0 °C to room temperature.  
b
Crude products were purified 
through column chromatography.  
c
Determined by Chiral HPLC column (IB-H).  
d
Performed the 
reaction at 0 °C for 18 h. 
Ligand 23, showing the best activity at a loading of 10 mol % was then used to screen a range of 
solvents under these specific reaction conditions (Table 2).  DCM provided the best selectivity 
whilst other chlorinated solvents such as DCE and CHCl3 provided moderate to low selectivities 
(Table 2, entries 1-3).  Non-chlorinated solvents such as THF and acetonitrile showed poor 
selectivity and provided racemic mixtures respectively (Table 2, entries 4-5). 
Table 2 Asymmetric conjugate addition of thioglycolate to chalcone using La(OTf)3 with ligand 
23 in different solvents 





1 ClCH2CH2Cl 92 76 
2 CH2Cl2 95 81 
3 CHCl3 65 17 
4 THF 45 9 
5 CH3CN 35 rac 
a
All reactions were performed at 0 °C to room temperature.  
b
Crude products were purified 
through column chromatography.  
c
Determined by Chiral HPLC column (IB-H) 
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After the identification of appropriate solvent, various other lanthanide group metals were 
screened to determine the best pre-catalyst for this system (Table 3).  The metal chosen earlier in 
the study was seen to be the best choice as all other metals showed lower selectivity with good 
yields (Table 3, entries 2-5).  This observation is in agreement with that made by Feng et. al.
37
 
Table 3 Asymmetric conjugate addition of thioglycolate to chalcone catalysed by different 
metals with ligand 23 





1 La(OTf)3 10 95 81 
2 Yb(OTf)3 10 56 2 
3 Y(OTf)3 10 35 4 
4 In(OTf)3 10 43 1 
5 Sc(OTf)3 10 65 6 
a
All reactions were performed at 0 °C to room temperature. 
b
Crude products were purified 
through column chromatography. 
c
Determined by Chiral HPLC column (IB-H) 
To study the scope of applications of these N,N’-dioxide ligands, it was decided to screen the 
activity and selectivity of the catalytic system on a unique range of substrates using the 
optimized conditions (Table 4).  Considering the importance of hetero aromatic and aliphatic 
groups in medicinal chemistry, we selected a variety of aromatic and non-aromatic substituted 
chalcones for asymmetric conjugate addition.  An enormous fall in selectivity was observed for 
the substrates having a pyridyl group (Table 4, entries 1-2).  Replacement of the pyridyl with a 
five membered furfuryl group on the chalcone increased the rate of reaction with lower 
selectivity (Table 4, entry 3).  This effect was more profound when substituting an aliphatic side 
chain on the chalcone which resulted in racemic product poor conversion rates (Table 4, entry 
4).  From the literature we found that cyclohexenone, a well known substrate for Michael type 
additions and diethyl zinc reactions, afforded poor conversion rates with racemic product for this 
thioglycolate conversion (Table 4, entry 5).  
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Table 4 Asymmetric conjugative addition of thioglycolate to various chalcones catalysed by 
metal La(OTf)3 with Ligand 23 in DCM 
























All reactions were performed at 0 °C to room temperature.
 b
Crude products were purified 
through column chromatography. 
c
Determined by Chiral HPLC column (IB-H) 
CONCLUSION 
A series of novel TIQ based N-oxide ligands have been synthesised and evaluated in the 
conjugate addition of thioglycolate to a diverse array of α,β-unsaturated carbonyl substrates.  
Complexation of these novel ligands with various metals highlighted lanthanum as the optimum 
choice for this particular reaction.  These results show that bulkier amide substituents afforded 
the higher enantioselectivity.  The choice of solvent played an important role in the selectivity of 
the reaction with chlorinated solvents, particularly dichloromethane, being realised as the 
optimum solvent for the reaction.  This conjugate addition is heavily dependent upon catalytic 
loading as high enantioselectivities were only achieved with loadings of 10 mol %.  Further 
investigation into this new class of ligands is ongoing. 
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EXPERIMENTAL SECTION 
Reagents and solvents were purchased from Aldrich, Merck and Fluka.  All NMR spectra were 
recorded on Bruker AVANCE III 400 MHz or 600 MHz instruments.  Chemical shifts are 
expressed in ppm downfield from TMS as an internal standard, and coupling constants are 
reported in Hz.  Thin layer chromatography (TLC) was performed using Merck Kieselgel 60 
F254.  Crude compounds were purified with column chromatography using Silica gel (60–200 
mesh except if stated different).  All solvents were dried using standard procedures.  All IR 
spectra were recorded on a Perkin Elmer spectrum 100 instrument with a universal ATR 
attachment.  Optical rotations were recorded on a Perkin-Elmer Polarimeter (Model 341).  All 
melting points are uncorrected.  High resolution mass spectrometric data was obtained using a 
Bruker micrOTOF-Q II instrument operating at ambient temperatures, and a sample 
concentration of approximately 1 ppm. 
Typical procedure for enantioselective conjugate addition of thioglycolate to chalcones 
A solution of ligand 23 (7.44 mg, 0.001 mmol), La(OTf)3 (5.86 mg, 0.001 mmol) and chalcone 
(20.8 mg, 0.1 mmol) in anhydrous dichloromethane (2 mL) was stirred under microwave 
irradiation at 35 °C for 30 min.  The reaction mixture was cooled to 0 °C and the thioglycolate 
(15.92 mg, 0.15 mmol) was added, the reaction mixture was stirred at 0 °C for 2 h followed by 
16 h at room temperature.  Solvents were evaporated under reduced pressure and the residue was 
purified through column chromatography using (hexane/ethyl acetate, 80:20) to afford pure 
addition product.  The enantioselectivity was determined by chiral HPLC using the IB-H column 
(hexane/2-propanol 90:10, λ = 254 nm); flow rate 0.8 mL/min. 
General procedure for synthesis of amides 2-6 
This method was adapted from the literature.
37
  To a stirred solution of TIQ Cbz acid 4 (2.0 g, 
6.3 mmol) in dichloromethane (20 mL), triethylamine (0.71 g, 7.0 mmol) and ethyl 
chloroformate (0.76 g, 7.0 mmol) was added at 0 
o
C.  After 1 h, the amine (1.1 eq) was added 
and the mixture stirred at ambient temperature for 18 h.  Completion of the reaction was 
monitored by thin layer chromatography.  The reaction mixture was washed with saturated 
sodium hydrogen carbonate (20 mL) followed by brine (10 mL).  The organic layer was 
separated, dried over anhydrous magnesium sulfate and purified through column 
chromatography using hexane/ethyl acetate as the mobile phase and silica gel as the stationary 
phase. 
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General procedure for removal of Cbz group 7-11 
A solution of the Cbz-amide (1.0 g) in THF (20 mL) was added to a suspension of activated 
Pd/C (500 mg, 10 wt.-%) in methanol under an inert atmosphere.  The reaction mixture was 
connected to a H2 source at 1 atm and stirred at room temperature for 3 h.  Completion of the 
reaction was monitored by TLC using hexane/ethyl acetate (7:3).  The Pd/C was filtered off on a 
pad of celite and washed with ethyl acetate (10 mL) followed by dichloromethane (5 mL).  The 
filtrate was concentrated under reduced pressure affording the crude amide, which was purified 
by column chromatography using hexane/ethyl acetate as the mobile phase and silica gel as the 
stationary phase. 
General Procedure to form bridged compounds 12-16 
This method was adapted from the literature.
37
  To a solution of deprotected amine (0.20 g) in 
acetonitrile (10 mL), anhydrous K2CO3 (5.0 eq) followed by 1,3-dibromopropane (1.1 eq) was 
added and the mixture stirred in the microwave reactor at 100 °C for 12 h.  Completion of the 
reaction was monitored by TLC using hexane/ethyl acetate.  The solvent was evaporated and the 
crude product taken up in ethyl acetate (20 mL), washed with water (2 x 10 mL) followed by 
brine (10 mL).  The organic layer was separated, dried over anhydrous magnesium sulfate and 
concentrated under reduced pressure affording the crude bridged compound, which was purified 
by column chromatography using hexane/ethyl acetate as the eluent to get the pure bridged 
amide. 
General procedure to form the N-oxide 17-21 
To a solution of the bridge amide (0.2 g) in dichloromethane (10 mL) was added anhydrous 
K2CO3 (5.0 eq) and the reaction mixture was cooled to –78 °C.  m-CPBA (2.2 eq) was added in 
one portion and the temperature maintained for 3 h.  The reaction mixture was allowed to warm 
to room temperature and stirred for 2 h whilst the completion of the reaction was monitored by 
TLC.  The reaction mixture was diluted with dichloromethane (5 mL), filtered through a pad of 
celite and concentrated under reduced pressure to afford the crude N,N'-dioxide.  The pure N,N'-





 (S)-benzyl 3-(o-tolylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate (6) 
111 
Rf = 0.4 (Hexane/ethyl acetate, 7:3).  Off white solid (1.7 g, yield 68 %);  m.p: 108 – 110 °C 
(hexane/ethyl acetate);  [α]D
20
 = –19.23 (c 0.78 in CHCl3); (NMR spectra are reported for a 
mixture of two rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.74 – 6.86 (m, 13H), 5.41 – 4.40 (m, 
5H), 3.55 – 2.99 (m, 2H), 2.05 – 1.50 (m, 3H);  
13
C NMR (100 MHz, CDCl3):δ 133.5, 130.3, 
128.6, 128.4, 128.1, 127.7, 127.3, 126.8, 126.5, 126.3, 125.4, 123.4, 68.1, 57.1, 49.5, 45.2, 32.1, 
16.8;  IR νmax/cm
-1
 (neat): 3259, 1701, 1661, 1533, 1412, 1202, 760, 698;  HR ESI MS: m/z = 
401.1864 [M+ H]
+
 (calcd. for C25H25N2O3 401.1860). 
(S)-benzyl 3-(2,6-dimethylphenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(7) 
Rf = 0.5 (Hexane/ethyl acetate, 7:3).  Off white solid (1.6 g, yield 48 %);  m.p: 143 – 145 °C 
(hexane/ethyl acetate);  [α]D
20
 = –32.00 (c 0.50 in CHCl3);  (NMR spectra are reported for a 
mixture of two rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.59 – 6.82 (m, 12H), 5.43 – 4.91 (m, 
3H), 4.91 – 4.41 (m, 2H), 3.49 (m, 1H), 3.16 (m, 1H), 1.93 – 1.53 (m, 6H);  
13
C NMR (100 
MHz, CDCl3): δ 169.7, 135.4, 133.8, 133.0, 128.8, 128.6, 128.1, 127.4, 126.6, 126.4, 68.3, 56.7, 
45.9, 32.5, 17.8;  IR νmax/cm
-1
 (neat): 3275, 1697, 1650, 1526, 1417, 1207, 1123, 1093, 739;  HR 
ESI MS: m/z = 415.2016 [M+ H]
+
 (calcd. for C26H27N2O3 415.2016). 
(S)-benzyl 3-(2,6-diisopropylphenylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
(8) 
Rf = 0.4 (Hexane/ethyl acetate, 70:30).  Off white solid (1.5 g, yield 51 %);  m.p: 60 – 62 °C 
(hexane/ethyl acetate);  [α]D
20
 = –11.32 (c 0.53 in CHCl3);  (NMR spectra are reported for a 
mixture of two rotamers).  
1
H NMR (400 MHz, CDCl3): δ 7.52 – 6.93 (m, 12H), 5.58 – 5.00 (m, 
3H), 4.93 – 4.52 (m, 2H), 3.53 (m, 1H), 3.12 (m, 1H), 1.22 (m, 2H), 0.88 (m, 12H);  
13
C NMR 
(100 MHz, CDCl3): δ 170.6, 146.1, 132.6, 128.7, 128.4, 127.9, 123.2, 68.2, 56.6, 45.9, 32.2, 
28.2, 23.6;  IR νmax/cm
-1
 (neat): 3280, 1643, 1547, 1453, 1222, 1029, 963, 755, 694;  HR ESI 
MS: m/z = 471.2639 [M+ H]
+








Rf = 0.3 (Hexane/ethyl acetate, 7:3).  Off white solid (0.6 g, yield 90 %);  m.p: 124 – 126 °C 
(hexane/ethyl acetate);  [α]D
20
 = –60.00 (c 0.50 in CHCl3);  
1
H NMR (400 MHz, CDCl3): δ 9.40 
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(s, 1H), 8.08 (d, J = 7.96 Hz, 2H), 7.25 – 7.15 (m, 3H), 7.09 (m, 1H), 7.04 (m, 1H), 4.06 (d, J = 
9.96 Hz, 2H), 3.74 (q, J = 9.98, 5.58 Hz, 1H), 3.35 (dd, J = 16.28, 5.56 Hz, 1H), 2.94 (dd, J = 
16.28, 10.22 Hz, 1H), 2.27 (s, 3H);  
13
C NMR (100 MHz, CDCl3): δ 171.4, 136.4, 135.9, 134.6, 
130.4, 129.2, 127.8, 127.0, 126.9, 126.5, 125.6, 124.5, 121.4, 57.0, 47.4, 30.8, 17.8;  IR νmax/cm
-
1
 (neat): 3280, 2905, 1659, 1587, 1531, 1455, 1125, 1042, 807, 724, 715;  HR ESI MS: m/z = 
267.1491 [M+ H]
+
 (calcd. for C17H19N2O 267.1492). 
(S)-N-(2,6-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) 
Rf = 0.4 (Hexane/ethyl acetate, 7:3).  Off white solid (0.61 g, yield 91 %);  m.p: 195 – 197 °C 
(hexane/ethyl acetate);  [α]D
20
 = –78.79 (c 0.33 in CHCl3);  
1
H NMR (400 MHz, CDCl3): δ 8.76 
(s, 1H), 7.24 – 7.16 (m, 3H), 7.13 – 7.03 (m, 4H), 4.09 (d, J = 10.48 Hz, 2H), 3.80 (q, J = 9.38, 
5.62 Hz, 1H), 3.33 (dd, J = 16.14, 5.58 Hz, 1H), 3.01 (dd, J = 16.08, 9.40 Hz, 1H), 2.17 (s, 6H);  
13
C NMR (100 MHz, CDCl3): δ 171.8, 136.3, 135.1, 134.6, 133.9, 129.1, 128.2, 127.1, 127.0, 
126.5, 125.7, 56.5, 47.3, 31.3, 18.5;  IR νmax/cm
-1
 (neat): 3250, 2928, 1670, 1594, 1525, 1466, 
1220, 761, 742, 713;  HR ESI MS: m/z = 281.1648 [M+ H]
+
 (calcd. for C18H21N2O 281.1649). 
(S)-N-(2,6-diisopropylphenyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (13) 
Rf = 0.4 (Hexane/ethyl acetate, 7:3).  Off white solid (0.66 g, yield 93 %);  m.p: 142 – 144 °C 
(hexane/ethyl acetate);  [α]D
20
 = –58.33 (c 0.48 in CHCl3);  
1
H NMR (400 MHz, CDCl3): δ 8.76 
(s, 1H), 7.29 – 7.06 (m, 7H), 4.09 (d, J = 15.72 Hz, 2H), 3.85 (q, J = 8.84, 5.76 Hz, 1H), 3.31 
(dd, J = 16.0, 5.72 Hz, 1H), 3.05 (dd, J = 15.98, 8.90 Hz, 1H), 2.88 (m, 2H), 1.15 (d, J = 6.88 
Hz, 12H);  
13
C NMR (100 MHz, CDCl3): δ 172.9, 145.9, 136.4, 134.8, 131.3, 129.0, 128.1, 
127.0, 126.5, 125.7, 123.4, 56.3, 47.2, 31.2, 28.9, 23.7;  IR νmax/cm
-1
 (neat): 3234, 2958, 1671, 
1494, 1454, 1471, 799, 742;  HR ESI MS: m/z = 337.2274 [M+ H]
+







Rf = 0.5 (Hexane/ethyl acetate, 1:1).  Colourless oil (0.16 g, yield 68 %);  [α]D
20
 = –28.57 (c 0.35 
in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 9.11 (s, 2H), 7.43 (d, J = 7.84 Hz, 4H), 7.26 (t, J = 
7.44 Hz, 4H), 7.22 – 7.12 (m, 6H), 7.11 – 7.01 (m, 4H), 3.92 (d, J = 15.00 Hz, 2H), 3.72 (d, J = 




C NMR (100 MHz, CDCl3): δ 171.4, 137.6, 134.5, 134.2, 129.1, 128.2, 127.4, 126.6, 
126.4, 124.2, 119.3, 63.3, 52.0, 28.3, 26.5;  IR νmax/cm
-1
 (neat): 3281, 2955, 2926, 1684, 1599, 
1517, 1440, 1287, 1123, 1075, 743, 692;  HR ESI MS: m/z = 545.2917 [M+ H]
+




Rf = 0.4 (Hexane/ethyl acetate, 1:1).  Yellow oil (0.16 g, yield 69 %);  [α]D
20
 = –15.15 (c 0.33 in 
CHCl3);  
1
H NMR (400 MHz, CDCl3): δ 9.14 (s, 2H), 7.92 (d, J = 7.96 Hz, 2H), 7.22 – 7.12 (m, 
8H), 7.11 – 7.04 (m, 4H), 7.03 – 6.96 (m, 2H), 3.92 (d, J = 14.12 Hz, 2H), 3.71 (d, J = 14.12 Hz, 
2H), 3.53 (t, J = 6.12 Hz, 2H), 3.13 (d, J = 6.12 Hz, 4H), 2.80 – 2.62 (m, 4H), 1.95 – 1.85 (m, 
8H);  
13
C NMR (100 MHz, CDCl3): δ 171.5, 135.8, 135.2, 134.4, 130.4, 128.1, 127.6, 126.9, 
126.7, 126.2, 124.5, 121.3, 63.5, 54.0, 51.9, 29.4, 26.7, 17.5;  IR νmax/cm
-1
 (neat): 3287, 2955, 
2926, 1724, 1686, 1586, 1518, 1454, 1289, 1120, 745;  HR ESI MS: m/z = 573.3228 [M+ H]
+
 
(calcd. for C37H41N4O2 573.3224). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(N-(2,6-dimethylphenyl)-1,2,3,4-tetrahydroisoquinoline-
3-carboxamide) (17) 
Rf = 0.4 (Hexane/ethyl acetate, 1:1).  Pale yellow oil (.15 g, yield 65 %);  [α]D
20
 = –35.71 (c 0.14 
in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 8.7 (s, 2H), 7.24 – 7.11 (m, 8H), 7.08 – 6.89 (m, 
6H), 3.98 (d, J = 13.12 Hz, 2H), 3.71 (d, J = 13.08 Hz, 2H), 3.60 (q, J = 7.16, 3.44 Hz, 2H), 3.26 
(dd, J = 15.28, 3.44 Hz, 2H), 3.13 (dd, J = 15.16, 7.24 Hz, 2H), 2.91 – 2.75 (m, 4H), 2.04 (m, 
2H), 1.90 (s, 12H);  
13
C NMR (100 MHz, CDCl3): δ 171.7, 135.6, 134.7, 133.7, 128.2, 128.0, 
127.7, 127.1, 126.8, 126.1, 63.1, 54.7, 52.1, 30.4, 26.5, 18.4 ;  IR νmax/cm
-1
 (neat): 3205, 2955, 
1725, 1646, 1520, 1263, 1135, 764, 728;  HR ESI MS: m/z = 601.3538 [M+ H]
+




Rf = 0.4 (Hexane/ethyl acetate, 7:3);  Colourless oil (0.17 g, yield 75 %);  [α]D
20
 = –12.50 (c 0.16 
in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 8.73 (s, 2H), 7.31 – 7.14 (m, 9H), 7.11 – 6.98 (m, 
5H), 4.00 (d, J = 13.12 Hz, 2H), 3.69 (d, J = 13.12 Hz, 2H), 3.62 (q, J = 7.14, 2.42 Hz, 2H), 3.31 
(dd, J = 15.05, 3.10 Hz, 2H), 3.1 (dd, J = 15.14, 7.22 Hz, 2H), 2.99 – 2.77 (m, 4H), 2.14 – 2.04 
(m, 2H), 1.64 (m, 4H), 1.03 (m, 24H);  
13
C NMR (100 MHz, CDCl3): δ 173.1, 145.7, 136.0, 
114 
135.0, 131.2, 128.1, 127.87, 127.80, 126.8, 126.1, 123.4, 63.3, 55.4, 51.9, 30.6, 28.6, 26.8, 23.8, 
23.7;  IR νmax/cm
-1
 (neat): 3269, 2958, 2925, 1664, 1486, 1472, 1256, 1129, 1098, 797, 738, 
510;  HR ESI MS: m/z = 713.4794 [M+ H]
+
 (calcd. for C47H61N4O2 713.4789). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(N-benzyl-1,2,3,4-tetrahydroisoquinoline-3-
carboxamide) (19) 
Rf = 0.4 (Hexane/ethyl acetate, 3:2).  Yellow oil (0.16 g, yield 69 %); [α]D
20
 = –5.88 (c 0.17 in 
CH2Cl3); 
1
H NMR (400 MHz, CDCl3): δ 7.50 (m, 2H), 7.25 – 7.15 (m, 13H), 7.05 (d, J = 6.52 
Hz, 2H), 6.92 (m, 3H), 4.45 (dd, J = 15.04, 6.88 Hz, 2H), 4.18 (dd, J = 15.04, 5.28 Hz, 2H), 3.77 
(d, J = 14.32 Hz, 2H), 3.54 (d, J = 14.53 Hz, 2H), 3.38 (t, J = 6.33 Hz, 2H), 3.11 (dd, J = 15.99, 
6.08 Hz, 2H), 3.03 (dd, J = 15.82, 6.60 Hz, 2H), 2.48 (t, J = 7.26 Hz, 4H), 1.64 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3): δ 173.2, 138.3, 135.1, 134.4, 128.5, 128.0, 127.2, 126.4, 126.2, 62.6, 
53.1, 52.0, 42.8, 29.3, 26.1;  IR νmax/cm
-1
 (neat): 3298, 2928, 1650, 1517, 1496, 1453, 1257, 
1029, 742, 698;  HR ESI MS: m/z = 573.3227 [M+ H]
+
 (calcd. for C37H41N4O2 573.3224). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(3-(phenylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline 2-
oxide) (20) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  White solid (0.15 g, yield 71 %);  m.p: 100 – 102 °C 
(DCM/MeOH);  [α]D
20
 = –27.27 (c 0.11 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 12.62 (s, 
2H), 7.67 – 7.46 (m, 4H), 7.36 – 6.92 (m, 14H), 4.82 – 4.37 (m, 4H), 4.35 – 4.01 (m, 2H), 3.99 – 
3.47 (m, 4H), 3.48 – 3.11 (m, 4H), 2.78 – 2.25 (m, 2H);  
13
C NMR (100 MHz, CDCl3): δ 165.0, 
137.9, 129.9, 129.7, 129.0, 128.9, 128.5, 128.4, 128.2, 127.8, 127.6, 127.3, 126.7, 126.3, 124.5, 
120.1, 73.0, 68.0, 66.1, 29.6, 29.3, 29.0, 25.7, 17.3;  IR νmax/cm
-1
 (neat): 2958, 1726, 1683, 1597, 
1552, 1497, 1290, 1077, 906, 753, 692;  HR ESI MS: m/z = 577.2808 [M+ H]
+




Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  White solid (0.14 g, yield 66 %);  m.p: 112 – 114 °C 
(DCM/MeOH);  [α]D
20
 = – 20.0 (c 0.1 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 12.63 (s, 
2H), 8.05 (d, J = 8.04 Hz, 2H), 7.34 – 6.93 (m, 14H), 4.67 (d, J = 15.16 Hz, 2H), 4.48 (d, J = 
15.16 Hz, 2H), 3.95 (dd, J = 17.16, 8.56 Hz, 2H), 3.78 – 3.62 (m, 4H), 3.24 (dd, J = 16.90, 4.58 
Hz, 2H), 2.99 – 2.86 (m, 2H), 2.28 – 2.15 (m, 8H);  
13
C NMR (100 MHz, CDCl3): δ 165.0, 
136.1, 130.4, 129.9, 128.9, 128.4, 128.3, 128.2, 128.0, 127.5, 127.4, 127.2, 126.7, 126.5, 124.4, 
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120.9, 72.7, 66.2, 66.0, 50.6, 29.7, 29.4, 29.0, 18.3, 17.3;  IR νmax/cm
-1
 (neat): 2918, 1677, 1588, 
1547, 1458, 1290, 753;  HR ESI MS: m/z = 605.3118 [M+ H]
+
 (calcd. for C37H41N4O4 
605.3122). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(3-(2,6-dimethylphenylcarbamoyl)-1,2,3,4-
tetrahydroisoquinoline 2-oxide) (22) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Off white solid (0.13 g, yield 62 %);  m.p: 106 – 108 °C 
(DCM/MeOH);  [α]D
20
 = –26.67 (c 0.15 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 11.82 (s, 
2H), 7.34 – 7.19 (m, 5H), 7.14 – 6.95 (m, 9H), 4.82 (d, J = 15.20 Hz, 2H), 4.54 (d, J = 15.24 Hz, 
2H), 4.03 (dd, J = 17.10, 8.30 Hz, 2H), 3.95 – 3.68 (m, 4H), 3.31 (dd, J = 17.08, 4.88 Hz, 2H), 
3.00 (m, 2H), 2.21 (s, 12H), 2.30 – 2.12 (m, 2H);  
13
C NMR (100 MHz, CDCl3): δ165.1, 134.1, 
133.5, 130.9, 129.8, 128.8, 128.3, 128.2, 128.1, 127.4, 127.2, 27.1, 126.9, 126.6, 72.9, 66.0, 
65.6, 29.9, 19.0, 18.4;  IR νmax/cm
-1
 (neat): 2958, 2926, 1728, 1682, 1522, 1470, 1377, 1285, 
1123, 1073, 767, 741;  HR ESI MS: m/z = 633.3435 [M+ H]
+
 (calcd. for C39H45N4O4 633.3435). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(3-(2,6-diisopropylphenylcarbamoyl)-1,2,3,4-
tetrahydroisoquinoline 2-oxide) (23) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Off white solid (0.16 g, yield 77 %);  m.p: 78 – 80 °C 
(DCM/MeOH);  [α]D
20
 = – 38.46 (c 0.13 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 11.96 (s, 
2H), 7.33 – 7.13 (m, 9H), 7.04 (m, 5H), 4.81 (d, J = 15.40 Hz, 2H), 4.56 (d, J = 15.40 Hz, 2H), 
4.18 – 4.02 (m, 2H), 3.90 (m, 2H), 3.65 (m, 2H), 3.46 (m, 2H), 3.31 (dd, J = 17.06, 4.74 Hz, 
2H), 3.19 – 3.02 (m, 4H), 2.31 (m, 2H), 1.31 – 1.11 (m, 24H);  
13
C NMR (100 MHz, CDCl3): δ 
169.6, 166.5, 164.7, 145.9, 145.2, 136.0, 133.0, 131.0, 129.9, 128.9, 128.3, 128.0, 127.4, 126.5, 
123.5, 72.6, 66.5, 60.7, 45.3, 31.8, 29.8, 29.1, 23.8, 23.6, 22.5;  IR νmax/cm
-1
 (neat): 3248, 2960, 
2927, 2868, 1724, 1681, 1500, 1458, 1383, 1272, 1122, 797, 740;  HR ESI MS: m/z = 745.4686 
[M+ H]
+
 (calcd. for C47H61N4O4 745.4686). 
(3S,3'S)-2,2'-(propane-1,3-diyl)bis(3-(benzylcarbamoyl)-1,2,3,4-tetrahydroisoquinoline 2-
oxide) (24) 
Rf = 0.4 (CH2Cl2/MeOH, 9.8:0.2).  Off white solid (0.17 g, yield 81 %);  m.p: 72 – 74 °C 
(DCM/MeOH);  [α]D
20
 = – 22.22 (c 0.18 in CH2Cl2);  
1
H NMR (400 MHz, CDCl3): δ 10.46 (s, 
2H), 7.83 – 6.68 (m, 18H), 4.80 – 4.14 (m, 8H), 3.68 – 2.84 (m, 6H), 2.80 – 1.93 (m, 6H);  
13
C 
NMR (100 MHz, CDCl3): δ 167.2, 138.2, 130.9, 130.1, 128.7, 128.6, 128.4, 128.2, 128.0, 127.9, 
127.6, 127.4, 127.1, 126.5, 72.8, 66.1, 65.2, 43.0, 29.6, 16.5;  IR νmax/cm
-1
 (neat): 3230, 2927, 
116 
1727, 1670, 1542, 1497, 1454, 1271, 1120, 1029, 919, 740, 699;  HR ESI MS: m/z = 605.3129 
[M+ H]
+
 (calcd. for C37H41N4O4 605.3122). 
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The research outlined in this thesis involves the development of novel tetrahydroisoquinoline 
(TIQ) ligands for enantioselective reactions with the research carried out having relevance in 
both the academic and pharmaceutical fields.  The newly synthesized TIQ amino alcohols 
exhibited remarkable reactivity with significantly higher than enantioselectivities for the 
asymmetric transfer hydrogenation (ATH) reactions.  With results obtained from these 
experiments, and with the support of computations from the Jaguar interphase program, it was 
observed that it is critical to have a phenyl group at the C
1
 position, in the trans form, for greater 
enantioselectivity.  The highest selectivity obtained in the ATH reaction, with acetophenone as a 
substrate, was >99 % with higher conversion rates observed at lower temperatures (Paper I).  In 
addition to the amino alcohols, a series of novel N,N TIQ ligands were synthesized and 
evaluated for their activities in the ATH reaction.  Water played an important role in enhancing 
the selectivity in the ATH reaction when using [RhCp*Cl2]2 as a pre-catalyst.  An 
enantioselectivity of 70 % was obtained with higher conversion rates at ambient temperature 
(Paper II). 
Novel derivatives of P,N TIQ oxazoline ligands were synthesised and coordinated to iridium 
BArF.  These iridium catalysts were stable at room temperature and screened for the asymmetric 
high-pressure hydrogenation of terminal, functionalized and non-functionalized alkenes.  The 
best enantioselectivity obtained was >92 % ee.  All reactions were carried out at room 
temperature using dichloromethane (DCM) as a solvent (Paper III). 
In the literature thus far, very few TIQ ligands have been designed and tested for C-C bond 
formation reactions.  We extended the scope of the TIQ backbone in the field of asymmetric 
catalysis by designing a series of TIQ ligands for use in this particular application.  A novel 
class of C
1
 substituted TIQ oxazoline ligands were synthesized, coordinated with various metals 
(Cu, Sc, Co, Zn, Ni and Mn) and screened in the Henry (nitroaldol) reaction.  The best 
enantioselectivity obtained was >77 % ee when Cu(OAc)2 was employed as a pre-catalyst and 
iso-propanol as a solvent at ambient temperature (Paper IV). 
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In the final chapter, the scope of the TIQ backbone in the construction of N-oxide ligands was 
investigated.  Utilization of C-hetero bond forming reactions is essential in the pharmaceutical 
industry.  Novel N-oxide ligands were synthesised with the TIQ backbone and screened for the 
conjugate addition of thioglycolate to alpha-beta unsaturated carbonyl substrates.  The highest 
enantioselectivity (>81 % ee) obtained was only possible with a loading of 10 mol % and with 
bulky groups on the terminal chain. This is only the second report describing the conjugate 
addition of thioglycolate conjugation to an alpha-beta unsaturated carbonyl system (Paper V). 
The catalysts designed and synthesised in this thesis have great potential in the field of 
asymmetric catalysis.  With the array of synthetic approaches outlined, a novel class of 
promising TIQ ligands has been realised.  However, there is still unlimited scope for these 
ligands in other applications.  All ligands were characterized using analytical techniques 
including infrared spectroscopy (IR), nuclear magnetic resonance spectroscopy (NMR), 
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